MDxHealth (MDXH) 20-F 30 Apr 24 2023 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2023 shares
Document Information Line Items
Entity Registrant Name	MDXHEALTH SA
Trading Symbol	MDXH
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	27,288,093
Amendment Flag	false
Entity Central Index Key	0001872529
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-40996
Entity Address, Country	BE
Entity Address, Address Line One	Zone Industrielle des Hauts-Sarts
Entity Address, Postal Zip Code	4040
Entity Address, City or Town	Herstal
Entity Incorporation, State or Country Code	C9
Title of 12(b) Security	Ordinary shares, no par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	International Financial Reporting Standards
Auditor Name	BDO Réviseurs d’Entreprises SRL
Auditor Location	Zaventem, Belgium
Auditor Firm ID	1432
Business Contact
Document Information Line Items
Entity Address, Country	CA
Entity Address, Address Line One	15279 Alton Parkway
Entity Address, Postal Zip Code	92618
Entity Address, City or Town	Irvine
Contact Personnel Name	Michael McGarrity
Entity Address, Address Line Two	Suite 100
City Area Code	+1 949
Local Phone Number	812-6979

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [abstract]
Services	$ 69,965	$ 36,965	$ 21,937
Royalties and other revenues	228	89	302
Revenues	70,193	37,054	22,239
Cost of sales (exclusive of amortization of intangible assets)	(26,264)	(17,835)	(11,675)
Gross profit	43,929	19,219	10,564
Research and development expenses	(6,376)	(5,497)	(5,589)
Selling and marketing expenses	(36,915)	(25,704)	(17,452)
General and administrative expenses	(23,010)	(23,308)	(13,915)
Amortization of intangible assets	(4,494)	(3,169)	(1,610)
Other operating (expense) income, net	(461)	559	1,161
Operating loss	(27,327)	(37,900)	(26,841)
Financial income	2,570	241	11
Financial expenses	(18,342)	(6,385)	(2,172)
Loss before income tax	(43,099)	(44,044)	(29,002)
Income tax	(1)	0	0
Loss for the year	$ (43,100)	$ (44,044)	$ (29,002)
Loss per share attributable to parent
Basic (in Dollars per share)	$ (1.66)	$ (2.78)	$ (2.38)

Consolidated Statement of Pro_2

Consolidated Statement of Profit or Loss (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [abstract]
Diluted	$ (1.66)	$ (2.78)	$ (2.38)

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statement of Comprehensive Income [Abstract]
Loss for the year	$ (43,100)	$ (44,044)	$ (29,002)
Items that will be reclassified to profit or loss:
Exchange differences arising from translation of foreign operations	(149)	593	264
Total other comprehensive income (loss)	(149)	593	264
Total comprehensive loss for the year (net of tax)	$ (43,249)	$ (43,451)	$ (28,738)

Consolidated Statement of Finan

Consolidated Statement of Financial Position - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Non-current assets
Goodwill	$ 35,926	$ 35,926
Intangible assets	44,337	46,166
Property, plant and equipment	4,956	3,791
Right-of-use assets	4,989	4,103
Financial assets	763
Total non-current assets	90,971	89,986
Current assets
Inventories	2,779	2,327
Trade receivables	11,088	9,357
Prepaid expenses and other current assets	1,914	1,962
Cash and cash equivalents	22,380	15,503
Total current assets	38,161	29,149
TOTAL ASSETS	129,132	119,135
EQUITY
Share capital	173,931	133,454
Issuance premium	153,177	153,177
Accumulated deficit	(331,446)	(288,346)
Share-based compensation	12,139	11,474
Translation reserve	(593)	(444)
Total equity	7,208	9,315
Non-current liabilities
Loans and borrowings	35,564	34,914
Lease liabilities	3,578	3,091
Other non-current financial liabilities	63,259	53,537
Total non-current liabilities	102,401	91,542
Current liabilities
Loans and borrowings	643	616
Lease liabilities	1,480	1,172
Trade payables	8,811	10,178
Other current liabilities	5,694	3,985
Other current financial liabilities	2,895	2,327
Total current liabilities	19,523	18,278
Total liabilities	121,924	109,820
TOTAL EQUITY AND LIABILITIES	$ 129,132	$ 119,135

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - USD ($) $ in Thousands	Number of shares	Accumulated Deficit	Share-based compensation	Translation Reserve	Total
Balance at Dec. 31, 2020	$ 213,065	$ (215,300)	$ 9,385	$ (1,301)	$ 5,849
Balance (in Shares) at Dec. 31, 2020	9,069,145
Loss for the year		(29,002)			(29,002)
Other comprehensive income				264	264
Total comprehensive income for the year		(29,002)		264	(28,738)
Issuance of shares, net of transaction costs	$ 68,566				68,566
Issuance of shares, net of transaction costs (in Shares)	6,527,777
Share-based compensation costs			1,222		1,222
Balance at Dec. 31, 2021	$ 281,631	(244,302)	10,607	(1,037)	46,899
Balance (in Shares) at Dec. 31, 2021	15,596,922
Loss for the year		(44,044)			(44,044)
Other comprehensive income				593	593
Total comprehensive income for the year		(44,044)		593	(43,451)
Issuance of shares as part of GPS acquisition	$ 5,000				5,000
Issuance of shares as part of GPS acquisition (in Shares)	691,171
Share-based compensation costs			867		867
Balance at Dec. 31, 2022	$ 286,631	(288,346)	11,474	(444)	9,315
Balance (in Shares) at Dec. 31, 2022	16,288,093
Loss for the year		(43,100)			(43,100)
Other comprehensive income				(149)	(149)
Total comprehensive income for the year		(43,100)		(149)	(43,249)
Issuance of shares, net of transaction costs	$ 39,599				39,599
Issuance of shares, net of transaction costs (in Shares)	10,750,000
Issuance of shares as part of amended GPS asset purchase agreement	$ 878				878
Issuance of shares as part of amended GPS asset purchase agreement (in Shares)	250,000
Share-based compensation costs			665		665
Balance at Dec. 31, 2023	$ 327,108	$ (331,446)	$ 12,139	$ (593)	$ 7,208
Balance (in Shares) at Dec. 31, 2023	27,288,093

Consolidated Statement of Cash

Consolidated Statement of Cash Flow - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Operating loss	$ (27,327)	$ (37,900)	$ (26,841)
Depreciation	2,365	1,740	1,426
Amortization of intangible assets	4,494	3,169	1,610
Impairment		44
Share-based compensation	665	867	1,222
Other non-cash transactions	421	(473)	(325)
Cash used in operations before working capital changes	(19,382)	(32,553)	(22,908)
Increase (-) / decrease (+) in inventories	(452)	(416)	413
Increase (-) in receivables	(1,683)	(5,122)	(1,383)
Increase (+) in payables	20	3,973	1,330
Net cash outflow from operating activities	(21,497)	(34,118)	(22,548)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(2,747)	(2,789)	(896)
Acquisition and generation of intangible assets	(2,272)	(1,374)
Acquisition of Genomic Prostate Score Business		(25,000)
Interests received	1,088	125	11
Net cash outflow from investing activities	(3,931)	(29,038)	(885)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of shares, net of transaction costs	39,599		68,566
Proceeds from loan obligation		34,291
Repayment of loan obligation and debt extinguishment costs	(1,659)	(10,805)
Amendment fee related to GPS Asset Purchase Agreement	(250)
Payment of lease liability	(1,610)	(1,358)	(1,057)
Payment of interest	(3,610)	(1,412)	(1,011)
Other financial expenses	(190)
Net cash inflow from financing activities	32,280	20,716	66,498
Net increase (+) / decrease (-) in cash and cash equivalents	6,852	(42,440)	43,065
Cash and cash equivalents at beginning of the financial year	15,503	58,498	15,953
Effect on exchange rate changes	25	(555)	(520)
Cash and cash equivalents at end of the financial year	$ 22,380	$ 15,503	$ 58,498

Status and Principal Activity

Status and Principal Activity	12 Months Ended
	Dec. 31, 2023
Status and Principal Activity [Abstract]
Status and principal activity	NOTE 1: Status and principal activity When used in this report, all references to “MDxHealth”, the “company”, “we”, “our” and “us” refer to MDxHealth, SA and its subsidiaries. MDxHealth is a limited liability company domiciled in Belgium, with offices and labs in Belgium, the United States and The Netherlands. MDxHealth is a commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. The Company’s novel prostate cancer genomic testing solutions combine advanced clinical modeling with genomic data to provide each patient with a personalized cancer risk profile, which provides more accurate and actionable information than standard risk factors (e.g., PSA, DRE, age) used by clinicians. The Company’s Select mdx and Confirm mdx solutions address men at risk for developing prostate cancer, providing physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications. The Company’s Genomic Prostate Score (GPS) solution addresses men newly diagnosed with prostate cancer, providing physicians with a clear clinical pathway to make the most informed treatment decision for their individual disease, including active surveillance. The Company’s collective decades of experience in precision diagnostics and its portfolio of novel biomarkers for diagnostic, prognostic and predictive molecular assays supports its active pipeline of new testing solutions for prostate and other urologic diseases. MDxHealth offers its laboratory solutions from its state-of-the-art, 13,448 square feet, College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified, molecular laboratory facility located at its U.S. headquarters in Irvine, California as well as a CLIA-certified lab in Plano, Texas. MDxHealth also operates a research and development-focused molecular laboratory facility, MDxHealth B.V., located in Nijmegen, the Netherlands. The Company is headquartered in Belgium. The parent company, MDxHealth SA, has its registered and corporate office in Cap Business Center, Rue d’Abhooz 31, 4040 Herstal, Belgium. MDxHealth, Inc., the Company’s U.S. subsidiary, is located at 15279 Alton Parkway, Suite 100, Irvine, CA 92618, United States. MDxHealth B.V., the Company’s Dutch subsidiary, is located at Transistorweg 5, 6534 Nijmegen, The Netherlands. American Depositary Shares (“ADS”), each representing 10 ordinary shares of the Company, began trading on the Nasdaq Capital Market on November 4, 2021. On November 13, 2023, the Company completed a 1-for-10 reverse stock split of its ordinary shares, after which each ADS represented one ordinary share. On November 27, 2023, the Company completed the mandatory exchange of all of its ADSs for one ordinary share each and subsequently terminated the Company’s ADS facility, at which time the ordinary shares were admitted to listing on the Nasdaq Capital Market under the symbol “MDXH”. Following a transition period of three weeks, the Company de-listed its ordinary shares from Euronext Brussels and, as of December 15, 2023, its ordinary shares began solely trading on the Nasdaq Capital Market. The disclosures in these financial statements give retroactive effect to these changes.

Summary of Material Accounting

Summary of Material Accounting Policies	12 Months Ended
	Dec. 31, 2023
Summary of Material Accounting Policies [Abstract]
Summary of Material Accounting Policies	NOTE 2: Summary of Material Accounting Policies 2.1. Basis of preparation and statement of compliance MDxHealth’s consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) and interpretations issued by the IFRS Interpretation Committee (IFRS-IC) applicable to companies reported under IFRS. The financial statements comply with IFRS as issued by the International Accounting Standards Board (IASB), collectively “IFRS”. In addition the financial statements are also prepared in accordance with IFRS as adopted by the EU (“EU IFRS”). The principal accounting policies applied in the preparation of the consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. The functional and presentation currency is the U.S. Dollar ($) and all amounts are presented in thousands of U.S. Dollars, rounded to the nearest thousand, unless otherwise indicated. Reclassifications Certain prior period balances have been reclassified to conform to current period presentation of the Company’s consolidated financial statements and accompanying notes. Such reclassifications have no effect on previously reported results of operations, accumulated deficit, subtotals of operating, investing or financing cash flows or consolidated balance sheet totals. 2.2. Basis of consolidation The consolidated financial statements incorporate the financial statements of MDxHealth SA (Belgium) and its wholly owned subsidiaries, including MDxHealth Inc. (United States), and MDxHealth BV (The Netherlands) for each fiscal year ending on December 31. Subsidiaries are all entities over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. The acquisition method of accounting is used to account for business combinations by the Company. All intercompany balances, profits and transactions are eliminated upon consolidation. 2.3. Going Concern The Company has experienced net losses and significant cash used in operating activities since its inception in 2003, and as of December 31, 2023, had an accumulated deficit of $331.4 million, a net loss of $43.1 million, and net cash used in operating activities of $21.5 million. Management expects the Company to continue to incur net losses and have significant cash outflows for at least the next twelve months. While these conditions, among others, could raise doubt about its ability to continue as a going concern, these consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of its assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company’s cost structure. As of December 31, 2023, the Company had cash and cash equivalents of $22.4 million. Taking into account the above financial situation and on the basis of the most recent business plan including the Company’s expected ability to access additional cash through debt, equity, or other means, the Company believes that it has sufficient cash to be able to continue its operations for at least the next twelve months from the date of issuance of these financial statements, and accordingly has prepared the consolidated financial statements assuming that it will continue as a going concern. This assessment is based on forecasts and projections within management’s most recent business plan as well as the Company’s expected ability to access additional cash through debt, equity or other means, for which at this moment a material uncertainty exists that casts substantial doubt on the Company’s ability to continue as a going concern. The Company also believes the going concern assumption is justified based on its ability to realize cost savings in case it will not be successful in raising additional cash through debt, equity or other means. Macroeconomic Factors The Company does not believe that the Ukraine war or the war in Israel/Gaza has an impact on the Company’s ability to continue as a going concern. There is no direct or indirect impact of these conflicts on the day-to-day business of the Company. The Company is not materially impacted by inflation, supply disruption or cyber-attacks due to the current geopolitical conflict. With regards to climate-related matters, the Company is not impacted in a material way by extreme weather conditions. 2.4. Use of estimates and judgments Management makes certain critical accounting estimates and management judgments when applying the Company’s accounting policies, which affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are continuously evaluated based on historical experience and other factors, including expectations of future events, which are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions. Judgements: Financial Liabilities and Assets (Note 16) The warrant issued to Exact Sciences as well as the right held by MDxHealth to pay the earnout obligation either in cash or in shares, up to certain limits, were considered as embedded derivatives of the host financial (earnout) liability and not closely related to the host financial liability given the differences in risk and exposure: ● The fair value of the Company’s option to settle the earnout obligation in cash or through the issuance of additional shares of the Company was measured based on a Monte Carlo valuation model which takes into account several factors including the expected evolution in Company’s share price as well as the 7.5% ownership limit of the outstanding shares of MDxHealth, as described above. This valuation model is considered as level 3 input and was valued as a $0.8 million financial asset; and ● The fair value of the warrant held by Exact Sciences to acquire up to 1,000,000 of the Company’s shares at an exercise price of $5.265 per share, was measured based upon a Binomial tree valuation model which takes into account several factors including the expected evolution in the Company’s share price. This valuation model is considered as level 3 input and was valued at $2.2 million financial liability. Revenue recognition (Note 4): As further described in Note 2.7 (paragraph “Determining the Transaction Price”), the Company analyzes historical collection data on a quarterly basis and makes adjustments to its estimates. In accordance with IFRS 15, revenue is recognized where such a variable consideration is included in the transaction price only to the extent that it is highly probable that the amount of revenue recognized will not be subject to significant future reversals as a result of subsequent re-estimation. Going Concern (Note 2.3) Management needs to make significant judgements whether the Company will have sufficient liquidity to continue operations during the next twelve months. Refer to Note 2.3 for management assessment. Estimates: The areas where assumptions and estimation uncertainties in the financial statements have potentially the most significant effect in 2023, are listed below: Financial Liabilities and Assets (Note 16) Other financial assets and liabilities are accounted for at fair value through the statement of profit or loss and include the following: The fair value of the contingent consideration payable to Exact Sciences (for the GPS acquisition) and to NovioGendix, which are presented in the yearend statement of financial position under “other non-current financial liabilities” and “other current financial liabilities” are based on an estimated outcome of the conditional purchase price and contingent payments arising from contractual obligations (level 3 input). These were initially recognized as part of the purchase price and then subsequently measured for fair value. Any changes to fair value are recorded in the statement of profit or loss through either “other operating (expense) income”, “financial income” or “financial expense” depending on the underlying driver for the fair value adjustment. The fair value of the GPS contingent consideration is based on the estimated timing and amount of the earnout payments. This estimate is then discounted to its net present value, taking into account the expected time when the earnout would become payable in 2025, 2026, and 2027. This contingent consideration was initially recorded along with the purchase price allocation of this business combination as detailed in Note 3. In August 2023, the Company and Exact Sciences amended their existing GPS asset purchase agreement in consideration for an amendment fee of $250,000 in cash and 250,000 of the Company’s shares, a 5-year subscription right (warrant) to acquire up to 1,000,000 of the Company’s shares at an exercise price of $5.265 per share (representing a 50% premium to the market price of the shares as of August 18, 2023), and an increase in the potential aggregate earnout amount from $70 million to $82.5 million. At the option of MDxHealth, the earnout amounts can be settled in cash or through the issuance of additional shares of the Company (valued in function of a volume weighted average trading price of the Company's shares at the end of the relevant earnout period) to Exact Sciences, provided that the aggregate number of shares held by Exact Sciences shall not exceed more than 7.5% (increased from 5% in the initial agreement) of the outstanding shares of MDxHealth. The amendment resulted in a fair value adjustment to the contingent consideration liability of $9.7 million for the year ended December 31, 2023, of which 9.1 million was recorded in “financial expenses” and resulted from changes in the weighted-average cost of capital (WACC) as well as changes in the terms of the earnout following the GPS asset purchase agreement amendment in August 2023, while the remaining $0.6 million was recorded under “other operating (expense) income, net”. The contingent consideration liability is considered as a financial liability based on level 3 input and was valued at $62.6 million as of December 31, 2023, using a discount rate of 12.83%. The fair value of the contingent consideration related to NovioGendix is based on a risk-adjusted future cash flows of different scenarios discounted using an interest rate of 12.83%. The fair value of the liability for the year ended December 31, 2023, was valued at $1.2 million, of which $550,000 is considered to be current. The fair value of the derivative financial liabilities related to the Innovatus derivative call option (as detailed in Note 16) was performed using a binomial pricing model which takes into account several factors including the expected evolution in Company’s share price and are considered as level 3 input. The fair value of the liability for the year ended December 31, 2023, is estimated at $192,000. Impairment Testing (Notes 3, 10 and 11) The Company recorded Goodwill of $35.9 million as part of the GPS business combination in the prior year (detailed in Note 3), which is subject to annual impairment testing. The Company has performed an impairment test as of December 31, 2023, at the level of the entire company which is in line with the level at which management monitors its profitability. The Company’s cash-generating unit (CGU) is expected to benefit from the synergies of the business combination. The impairment testing is based on a discounted cash flow (DCF) model, with cash flows for the next five years derived from the internal budgets and a residual value that assumes a perpetual growth rate of 2%. The value-in-use is sensitive to the discount rate used for the DCF model as well as the expected future cash inflows and the growth rate used for extrapolation purposes. Key underlying estimates are considered to be the estimated cashflows and the weighted-average cost of capital, and are further described in Note 10. Share-Based Payments (Note 24) Management estimates the fair value of the equity-settled share-based payment transactions by using the Black-Scholes option valuation model: ● The dividend return is estimated by reference to the historical dividend payment of the Company; currently, this is estimated to be zero as no dividends have been paid since inception; ● The expected volatility was determined using the average volatility of the stock over the last two years at the date of grant; ● Risk-free interest rate is based on the interest rate applicable for the 10-year Belgian government bond at the grant date given all grants during 2023 were done at the moment the Company was still listed on Euronext. 2.5. New Standards, Interpretations and Amendments 2.5.1. New Standards, Interpretations and Amendments adopted by the Company The accounting policies have been consistently applied by the Company and are consistent with those used in previous years. The following amendments and interpretations issued by the IASB and IFRIC apply for the first time in 2023, but do not have a significant impact on the consolidated financial statements of the Group. ● IFRS 17 Insurance Contracts (issued on 18 May 2017); including Amendments to IFRS 17 (issued on 25 June 2020) ● Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (issued on 12 February 2021) ● Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2: Disclosure of Accounting policies (issued on 12 February 2021) ● Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction (issued on 7 May 2021) ● Amendments to IFRS 17 Insurance contracts: initial application of IFRS 17 and IFRS 9 – Comparative information (issued on 9 December 2021 ● Amendments to IAS 12 Income taxes: International Tax Reform – Pillar Two Model Rules (issued on 23 May 2023) This adoption has not had any material impact on the disclosures or on the amounts reported in these financial statements. 2.5.2. Standards and Interpretations issued but not yet effective in the current period Certain new accounting standards and amendments to standards have been published, but were not mandatory for the December 31, 2023, reporting period. No amendments to standards that are issued but not yet effective are considered to materially affect the Company’s accounting policies or any of the disclosures when applied for the first time. The following amendments have been issued, but are not mandatory for the financial year beginning January 1, 2023: ● Amendments to IAS 1 ‘Presentation of Financial Statements: Classification of Liabilities as current or non-current’ (effective January 1, 2024), affect only the presentation of liabilities in the statement of financial position — not the amount or timing of recognition of any asset, liability income or expenses, or the information that entities disclose about those items. The amendments: o clarify that the classification of liabilities as current or non-current should be based on rights that are in existence at the end of the reporting period and align the wording in all affected paragraphs to refer to the “right” to defer settlement by at least twelve months and make explicit that only rights in place “at the end of the reporting period” should affect the classification of a liability; o clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability; and make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services; and o clarify how conditions with which an entity must comply within 12 months after the reporting period, such as covenants, affect the corresponding liability’s classification. ● Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback (effective January 1, 2024). The amendments explain how an entity accounts for a sale and leaseback after the date of the transaction, specifically where some or all the lease payments are variable lease payments that do not depend on an index or rate. They state that, in subsequently measuring the lease liability, the seller-lessee determines ‘lease payments’ and ‘revised lease payments’ in a way that does not result in the seller-lessee recognizing any amount of the gain or loss that relates to the right of use it retains. Any gains and losses relating to the full or partial termination of a lease continue to be recognized when they occur as these relate to the right of use terminated and not the right of use retained. ● Amendments to IAS 7 ‘Statement of Cash Flows’ and IFRS 7 ‘Financial Instruments: Disclosures’1: Supplier Finance Arrangements, effective 1 January 2024 ● Amendments to IAS 21 ‘The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability’1, effective 1 January 2025 The Company is analyzing the impact, if any, on its consolidated financial statements in view of the application of the amendment of IAS 1. 2.6. Foreign currency translation Functional and presentation currency Items included in the financial statements of each of the Company’s entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The Company’s functional and presentation currency is the U.S. dollar based on the continuing development of the commercial activities in the U.S. market. Foreign currency transactions are translated into the functional currency using the exchange rates at the date of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss. The results and financial positions of foreign operations that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● Assets and liabilities for each statement of financial position presented are translated at the closing rate at the date of that balance sheet. At December 31, 2023, the official exchange rate applied for assets and liabilities was €1 to $1.105 (2022: €1 to $1.066) quoted by the European Central Bank. ● Income and expenses for each statement of profit or loss and statement of comprehensive income are translated at average exchange rates. At December 31, 2023, the official exchange rate applied for income and expenses was €1 to $1.0813 (2022: €1 to $1.053) quoted by the European Central Bank. ● All resulting exchange differences are recognized in other comprehensive income. 2.7. Revenue recognition Performance obligations and timing of revenue recognition The majority of the Company’s revenue is derived from laboratory services with revenue recognized at a point in time when control of the services has transferred to the customer. This is generally when the test results are delivered to the customer. Minor other Company’s revenue is derived from license fees and royalties: ● License fees are recognized when the Company has fulfilled all conditions and obligations. If the Company has continuing performance obligations towards the fees, the fee will be recognized on a straight-line basis over the contractual performance period. ● Royalties are recognized as revenue once the amounts due can be reliably estimated based on the sale of the underlying products and services and when the collection of the royalties can be reasonably assured. License up-front (signature fees) and non-refundable fees for access to prior research results and databases are recognized when earned, if the Company has no continuing performance obligations and all conditions and obligations are fulfilled. If the Company has continuing performance obligations towards the fees, the fee will be recognized on a straight-line basis over the contractual performance period. Royalties are generated from the sales by third parties of products or services which incorporate the Company’s proprietary technology. Royalties are recognized as revenue once the amounts due can be reliably estimated based on the sale of the underlying products and services and when the collection of the royalties can be reasonably assured. Determining the transaction price A large portion of the Company’s revenues are derived from Medicare, which reimburses the Company for tests performed on its insured patients. Medicare has set a fixed price (via a Local Coverage Determination or “LCD”) for the Company’s Confirm mdx, Select mdx, and GPS tests. Therefore, the amount of revenue recognized from Medicare for these tests is determined by reference to the LCD pricing. For other patients insured by commercial insurance companies where there is no certainty of the amount that will be paid for services rendered, the Company uses historical collection data – on an individual payor basis – to estimate its future collection and corresponding revenues that should be recognized for each type of test. The Company analyzes historical collection data on a monthly basis and makes monthly adjustments to its estimates. In accordance with IFRS 15, revenue is recognized where such a variable consideration is included in the transaction price only to the extent that it is highly probable that the amount of revenue recognized will not be subject to significant future reversals as a result of subsequent re-estimation. When historical collection data is insufficient to estimate future collections, the Company defaults to cash basis, meaning that revenues will not be recognized until actual cash payment is received from the payor. Total revenue in any given year includes amounts related to tests performed in previous years that relate to: ● revenue from transactions in previous years that did not previously meet the revenue recognition criteria; ● differences between the revenue recognized in previous years and the actual amount received; and ● reversals of revenue relating to balances that are outstanding for more than 9 months. 2.8. Segment information Information for the Company’s operating segments has been determined by reference to the information used by the chief operating decision maker (“CODM”) of the Company to review the performance of the Company and in making decisions on allocation of resources, the nature of the activities and the management structure and accountabilities. The Company’s CEO has been identified as the chief operating decision maker in accordance with his designated responsibility for the allocation of resources to operating segments and assessing their performance through periodic reporting. The CODM periodically reviews the Company’s performance based on information at a company level. The Company monitors the profitability of the group as a whole given revenues are generated from clinical laboratory service testing and does accordingly not distinguish different business segments. 2.9. intangible assets Initial measurement: Externally acquired Intangible assets are recognized on business combinations if they are separable from the acquired entity or give rise to other contractual/legal rights. The amounts ascribed to such intangibles are determined using appropriate valuation techniques. Intangible assets are recognized on the business combinations of NovioGendix in 2015 (Select mdx) and GPS in 2022 and include: ● Externally acquired intellectual property, including patents, technology and related IP; and ● Customers. All were valued through application of the relief from royalty method, except for the customers which were valued on the basis of multi-period excess earnings method. Externally acquired intangible assets also include patents and software licenses which are initially recognized at cost. Internally generated intangible assets (development costs) Development costs are capitalized when requirements for capitalization during the development phase have been met. In absence of meeting the requirements, these are expensed in the period in which they were incurred as research and development expenses. Internally generated intangible assets relate to Confirm mdx, Select mdx, Resolve mdx and GPS. Subsequent measurement Intangible assets are carried at their cost less any accumulated amortization and any accumulated impairment losses amortized on a straight-line basis over their estimated useful lives on the following basis: ● Patents & software: shorter of (a) 5 years; or (b) the software license period / patent life ● Intellectual property: 10-15 years ● Customers: 6.5 years ● Capitalized development costs: 5 years Amortization over the asset’s useful life shall begin when the asset is available for use. Amortization of intangible assets are presented as a separate line in the consolidated statement of profit or loss. 2.10. Property, plant and equipment Property, plant and equipment are stated at historical cost less accumulated depreciation and impairment. Repair and maintenance costs are charged to the income statement as incurred. Depreciation is charged to write off the cost or valuation of assets over their useful lives, using the straight-line method, on the following basis: ● Equipment: 5 years ● IT hardware and software: 3 years ● Furniture: 5 years ● Vehicles: 5 years ● Leasehold improvements: in line with the non-cancellable lease period of the related lease 2.11. Right-of-use assets and liabilities Right-of-use assets: The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Depreciation periods range between 3 and 6 years. Right-of-use assets are subject to impairment. Lease liabilities: At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date which is in the following ranges: ● Buildings: 10% and 12.75% ● Vehicles: 2.5% and 3.75% ● Materials: 9.75% and 12% After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. 2.12. Impairment of assets Goodwill and intangible assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. The Company monitors its Goodwill at consolidated Company level which is the level of the Company of cash-generating units (CGUs) benefiting from the synergies. Non-financial assets other than Goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. 2.13. Inventories Inventories are initially recognized at cost, and subsequently at the lower of cost and net realizable value. Cost comprises merely purchase costs, as the inventory consists solely of raw materials. Raw materials are not ordinarily interchangeable, and they are as such accounted for using the specific identification of their individual cost. The Company does not account for work in progress and finished products. 2.14. Cash and cash equivalents Cash and cash equivalents are carried on the consolidated statement of financial position at nominal value. For the purposes of the cash flow statements, cash and cash equivalents comprise cash on hand, deposits held on call with banks, other short-term highly liquid investments and bank overdrafts. Bank overdrafts, if any, are included in borrowings included in current liabilities. 2.15. Taxation Current tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Deferred income tax is provided in full using the “balance sheet liability method”, on temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax liabilities are recognized for all taxable differences. Deferred tax assets are recognized for all deductible temporary differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority. 2.16. Share Capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. 2.17. Financial Assets The financial assets consist mainly of trade receivables and other current assets (deposits) as well as the Company’s option to settle the earnout obligation to Exact Sciences in cash or through the issuance of additional shares of the Company (refer to Note 3

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2023
Business Combination [Abstract]
Business combination	NOTE 3: Business combination Acquisition of Genomic Prostate Score® (GPS) test (formerly Oncotype DX GPS) from Exact Sciences On August 2, 2022, the Company announced it has entered into an agreement with Genomic Health, Inc., a subsidiary of Exact Sciences Corporation (“Exact Sciences”), to acquire the GPS test from Exact Sciences. MDxHealth acquired GPS in order to expand its menu of tests targeted into urology and prostate cancer and in order to position the Company as one of the leaders in the urology and prostate cancer space with one of the most comprehensive menus of precision diagnostics. Under the terms of the agreement, the Company acquired the GPS prostate cancer business of Exact Sciences for an aggregate purchase price of up to $100 million, of which an amount of $25 million was paid in cash and an amount of $5 million was settled through the delivery of 691,171 shares of the Company, at a price per share of $7.23. Following the closing, which took place on August 2, 2022, an additional aggregate earnout amount of up to $70 million was to be paid by the Company to Exact Sciences over a three year period, commencing in 2024, in tranches equal to a portion of the annual revenues attributable to the GPS prostate cancer business for the preceding fiscal year; provided, in each instance, that such revenues exceed certain minimum revenue milestones for such fiscal year. At the option of MDxHealth, the earnout amounts can be settled in cash or through the issuance of additional shares of the Company (valued in function of a volume weighted average trading price of the Company’s shares at the end of the relevant earnout period) to Exact Sciences, provided that the aggregate number of shares held by Exact Sciences shall not exceed more than 5% of the outstanding shares of the MDxHealth. The Acquisition was accounted for under the acquisition method of accounting and was being treated as a business combination in accordance with IFRS given that there are inputs from the intellectual property and customers acquired, a substantive process, consisting of a workforce that was hired from Exact Sciences, which allows the Company to generate outputs as from day 1 of the acquisition. The purchase price was allocated based on the estimated fair value of net assets acquired and liabilities assumed at the date of the acquisition. The acquisition consideration was comprised of (in thousands of $): Cash 25,000 Stock 5,000 GPS Contingent consideration 50,483 Total acquisition consideration 80,483 The purchase price in excess of the fair value of net assets acquired, has been considered as residual Goodwill for an amount of $35.9 million. The fair value of the identifiable assets at the date of acquisition were: Thousands of $ Carrying Fair Fair Intangible assets IP / Brand - 36,550 36,550 Intangible assets Customer relationships - 8,007 8,007 Total identified assets - 44,557 44,557 Goodwill - 35,926 35,926 Acquisition price - - 80,483 We have performed a fair value analysis of the business combination, with corresponding adjustments to the intangible assets. The accounting for the business combination resulted in fair values at date of acquisition of $44.6 million for the IP/brand and customer relationships, based on the relief-from-royalty valuation method, with a royalty rate of 9.56% and a remaining useful life of 15 years for the IP/Brand and a useful life of 6.5 years for the customer relationships. The discount rate (post-tax WACC) used for the valuation was set at 14.95%. The goodwill recognized is primarily attributable to the trained and knowledgeable workforce and to the expected synergies that will be realized at level of operations, existing customer base, and sales & marketing. Following the closing, an additional aggregate earnout amount of up to $70 million is to be paid by MDxHealth to Exact Sciences upon achievement of certain revenue milestones related to fiscal years 2023 through 2025. The contingent consideration was assessed at $52.9 million at December 31, 2022. The liability recognized reflects a probability-weighted estimate at the current net present value at the date of acquisition, which is expected to become payable, as further detailed in Note 16. Fair value adjustments to this contingent consideration liability are recognized in the statement of profit or loss as described in Note 8. The net deferred tax asset resulting from this purchase price allocation was not recognized given insufficient future taxable profits. The recognized goodwill is expected to be fully tax deductible upon actual payment of the contingent consideration. The total acquisition-related costs recognized as an expense in general and administrative expenses for the year ended December 31, 2022, were $3.7 million. The GPS acquisition contributed $30.9 million and $9.3 million to the Company’s consolidated revenues for the periods ended December 31, 2023 and 2022, respectively. The Company is unable to determine what the full year 2022 GPS revenues would have been had the acquisition been completed as of January 1, 2022, given that the Company would have to make assumptions related to GPS while it was owned and sold by Exact Sciences and to do so would be impracticable. The Company financed the acquisition in part through a $35 million loan and security agreement with an affiliate of Innovatus Capital Partners, LLC (“Innovatus”), which replaced the Company’s existing €9 million debt facility with Kreos Capital (“Kreos”). Refer to Note 16 for further details. On August 23, 2023, MDxHealth and Exact Sciences Corporation amended their existing Oncotype DX GPS prostate cancer business asset purchase agreement, deferring the Company’s initial earnout payment by 3 years, from 2024 to 2027, in consideration for an amendment fee of $250,000 in cash and 250,000 of the Company’s shares, a 5-year subscription right (warrant) to acquire up to 1,000,000 of the Company’s shares at an exercise price of $5.265 per share (representing a 50% premium to the market price of the shares as of August 18, 2023), and an increase in the potential aggregate earnout amount from $70 million to $82.5 million. The resulting financial charges of this amendment are further described in Note 8. The Company agreed to convene a general shareholders’ meeting to approve the subscription right. Under the terms of the amended asset purchase agreement, MDxHealth has agreed to make earnout payments to Exact Sciences in each of fiscal years 2025, 2026 and 2027, based upon certain revenues related to fiscal years 2024, 2025 and 2023, respectively. At the option of MDxHealth, the earnout amounts can be settled in cash or through the issuance of additional shares of the Company (valued in function of a volume weighted average trading price of the Company’s shares at the end of the relevant earnout period) to Exact Sciences, provided that the aggregate number of shares held by Exact Sciences shall not exceed more than 7.5% (increased from 5% in the initial agreement) of the outstanding shares of the Company.

Revenue and Cost of Sales

Revenue and Cost of Sales	12 Months Ended
	Dec. 31, 2023
Revenue and Cost of Sales [Abstract]
Revenue and cost of sales	NOTE 4: Revenue and cost of sales Revenue Thousands of $ 2023 2022 2021 Services 69,965 36,965 21,937 Royalties and other revenues 228 89 302 Total revenue 70,193 37,054 22,239 Revenues related to royalties, licenses and other revenues are generally recognized over time as described in Note 2.7. The Company did not recognize any contract assets or contracts liabilities. Total revenue for 2023 was $70.2 million, an increase of 89% as compared to total revenue of $37.1 million for 2022. 2023 revenues were comprised of $30.9 million from GPS, $24.8 million from Confirm mdx, $9.7 million from Resolve mdx, with the remaining revenues from Select mdx and other. Total revenue of $37.1 million for 2022 increased 67% compared to total revenue of $22.2 million for 2021. 2022 revenues were comprised of $21.8 million from Confirm mdx, $9.3 million from GPS, $4.9 million from Resolve mdx, with the remaining revenues from Select mdx and other. Medicare Reimbursement for diagnostic tests furnished to Medicare beneficiaries (typically patients aged 65 or older) is usually based on a fee schedule set by the U.S. Centers for Medicare & Medicaid Services (“CMS”), a division of the U.S. Department of Health and Human Services (“HHS”). As a Medicare-enrolled service provider, the Company bills the regional Medicare Administrative Contractor (“MAC”) for CMS that covers the region where the testing service is performed by the Company. The Confirm mdx test obtained a positive Medicare local coverage determination (“LCD”) in 2014, the GPS test obtained a positive Medicare coverage LCD in 2015, and the Select mdx test obtained a positive Medicare coverage LCD in 2023, each of which provides coverage for Medicare patients throughout the United States. In 2023, Medicare represented the only payer generating over 10% of the Company’s revenues, for a total of $27.7 million (2022: $15.8 million; 2021: $8.5 million). At the end of 2023, the Company had concluded agreements with 140 commercial payors for Confirm mdx (2022: 129; 2021: 119), 84 commercial payors for Select mdx (2022: 62; 2021: 54) and 62 commercial payors for GPS (2022:29; 2021: 0). Segment revenue The Company does not distinguish different business segments since most revenues are generated from clinical laboratory service testing, or the out-licensing of the Company’s patented DNA methylation platform and biomarkers. However, the Company does distinguish different geographical operating segments based on revenue since the revenues are generated both in United States of America and Europe. In 2023, the Company earned 99.7% (2022: 99.8%; 2021: 98.6%) of its revenue from external customers from its clinical laboratory testing services and out-licensing of intellectual property. Although the Company is incorporated in Belgium, the 2023 revenues generated in Belgium were not material. In 2023, the clinical laboratory testing in the U.S. CLIA laboratories represented 99% of the Company’s revenue (2022: 99%; 2021: 97%), while the out-licensing of intellectual property revenue in Europe represented less than 1% (2022: less than 1%; 2021: 1.5%). The amount of its revenue from external customers broken down by location is shown in the table below: Thousands of $ 2023 2022 2021 United States of America 69,708 36,768 21,785 Europe 476 277 441 Rest of the world 9 9 13 Total segment revenue 70,193 37,054 22,239 At the end of 2023, 91% of the non-current assets were located in the US (2022: 93%; 2021: 38%) and the remaining 9% in Europe (2022: 7%; 2021: 62%). The increase in non-current assets located in the U.S. is mainly due to acquired intangible assets in the GPS business combination in 2022 as detailed in Note 3. Cost of sales Thousands of $ 2023 2022 2021 Cost of sales 26,264 17,835 11,675 Total cost sales 26,264 17,835 11,675 The costs of sales include the costs associated with providing testing services to third parties and include the cost of materials, labor (including salaries, bonuses, and benefits), transportation, collection kits, and allocated overhead costs associated with processing samples. Allocated overhead costs include depreciation of laboratory equipment, facility occupancy and information technology costs. Costs associated with processing samples are expensed when incurred, regardless of the timing of revenue recognition. Amortization of intangible assets are excluded from cost of sales and are presented separately in the statement of profit or loss, as further detailed in Note 5.

Nature of Expenses

Nature of Expenses	12 Months Ended
	Dec. 31, 2023
Nature of Expenses [Abstract]
Nature of expenses	NOTE 5: Nature of expenses Research and development expenses Thousands of $ Notes 2023 2022 2021 Personnel costs 6 3,693 2,453 1,949 Depreciation 12 428 212 276 Impairment 11 - 44 - Lab consumables 639 713 793 Patent expenses 83 430 577 External collaborator fees 199 783 1,020 Clinical validation 765 584 842 Other expenses 569 278 132 Total research and development expenses 6,376 5,497 5,589 Research and development expenses consist of costs incurred for the development and improvement of our products. These expenses consist primarily of labor costs (including salaries, bonuses, benefits, and share-based compensation), reagents and supplies, clinical studies, outside services, patent expenses, depreciation of laboratory equipment, facility occupancy and information technology costs. Research and development expenses also include costs associated with assay improvements and automation workflow for our current suite of products. For the year ended December 31, 2023, research and development expenses increased by $0.9 million, or 16%, primarily due to annual compensation increases, as well as an increase in ongoing clinical studies, partially offset by savings in patent expenses, lab consumables, and external collaborator fees. For the year ended December 31, 2022, research and development expenses decreased $0.1 million, or 2%, compared to 2021, primarily due to decreases in clinical study costs, external research and collaborator fees offset by increases in personnel costs. Selling and Marketing expenses Thousands of $ Notes 2023 2022 2021 Personnel costs 6 27,952 19,070 13,402 Depreciation 12 888 750 504 Professional fees 710 1,259 523 Marketing expenses 5,075 2,843 1,761 Travel expenses 1,061 789 340 Offices & facilities expenses 459 356 436 Other expenses 770 637 486 Total selling and marketing expenses 36,915 25,704 17,452 The Company’s selling and marketing expenses are expensed as incurred and include costs associated with its sales organization, including its direct clinical sales force and sales management, medical affairs, client services, marketing and managed care, as well as technical lab support and administration. These expenses consist primarily of labor costs (including salaries, bonuses, benefits, and share-based compensation), customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated overhead costs. For the year ended December 31, 2023, selling and marketing expenses increased by $11.2 million, or 44%, compared to 2022, primarily due to an increase in personnel costs related to the Company’s acquisition of the GPS business in August 2022, as well as increased direct marketing expenses, travel expenses, facilities expenses, and depreciation offset by a decrease in outside professional fees. For the year ended December 31, 2022, selling and marketing expenses increased $8.3 million, or 47%, compared to 2021, primarily due to increase in personnel costs and marketing expenses related to the Company’s acquisition of the GPS business. General and administrative expenses Thousands of $ Notes 2023 2022 2021 Personnel costs 6 10,184 8,995 9,009 Depreciation 12 737 734 646 Professional fees 6,706 7,762 1,678 Public company expenses 2,701 4,025 1,108 Travel expenses 130 79 9 Offices & facilities expenses 1,266 1,142 845 Royalties to third parties 28 47 152 Board fees 366 394 314 Other expenses 892 130 154 Total general and administrative expenses 23,010 23,308 13,915 General and administrative expenses include costs for certain executives, accounting and finance, legal, revenue cycle management, information technology, human resources, and administrative functions. These expenses consist primarily of labor costs (including salaries, bonuses, benefits, and share-based compensation), professional service fees such as consulting, accounting, legal, general corporate costs, and public-company costs associated with the Company’s listing, as well as allocated overhead costs (rent, utilities, insurance, etc.). General and administrative expenses decreased in 2023 by $0.3 million or 1%. Despite an increase in personnel costs of $1.2 million, there were decreases in public company expenses as well as a decrease in professional fees from the 2022 acquisition of GPS. Professional fees for 2023 included one-time expenses related to the transition of its sole listing on NASDAQ as well as the amended asset purchase agreement with Exact Sciences. General and administrative expenses increased in 2022 by $9.4 million or 68%, of which $3.7 million were one-time expenses related to the GPS acquisition (included in Professional fees), with the remaining $5.7 million increase primarily related to higher insurance, professional fees and public company expenses. Amortization of intangible assets Thousands of $ 2023 2022 2021 Research and development 3,157 2,060 1,084 Selling and marketing 1,315 878 292 General and administrative 22 231 234 Total amortization of intangible assets 4,494 3,169 1,610 Amortization of intangible assets primarily relates to the acquired intellectual property, brand, and customer relationships of the GPS business combination, as detailed in Note 3. In 2023, the Company segregated “amortization of intangible assets” from other operating categories in the statement of profit or loss and is presenting amortization of intangible assets as a separate category. Prior periods balances have been reclassified to conform to current period presentation.

Personnel Costs

Personnel Costs	12 Months Ended
	Dec. 31, 2023
Personnel Costs [Abstract]
Personnel costs	NOTE 6: Personnel costs Thousands of $ 2023 2022 2021 The number of employees at the end of the year was: Laboratory operations 79 67 42 R&D staff 31 19 14 S&M staff 106 101 71 G&A staff 84 71 64 Total number of employees 300 258 191 Their aggregate remuneration comprised: Wages and salaries 31,388 23,066 18,150 Social security costs 2,682 1,684 1,257 Pension costs 1,153 724 594 Health insurance expenses 5,058 3,167 2,324 Share-based compensation 665 867 1,222 Other costs 883 1,010 813 Total personnel costs 41,829 30,518 24,360 The personnel numbers in the table reflect year-end numbers, with 42 sales and marketing employees hired in August 2022 as part of the GPS acquisition.

Other Operating (Expense) Incom

Other Operating (Expense) Income, Net	12 Months Ended
	Dec. 31, 2023
Other Operating (Expense) Income, Net [Abstract]
Other operating (expense) income, net	NOTE 7: Other operating (expense) income, net Thousands of $ 2023 2022 2021 Grant subsidies – The Netherlands 62 5 382 Grant subsidies – USA - - 659 Fair value adjustments (588 ) 515 176 Other operating income 65 39 53 Other operating expenses - - (109 ) Total other operating (expense) income, net (461 ) 559 1,161 Other operating (expense) income, net for the year ended December 31, 2023, primarily consisted of a negative fair value adjustment of $588,000, which primarily consisted of an adjustment for the contingent consideration liability, partially offset by a positive fair value adjustment of $37,000 related to the NovioGendix contingent liability. Other operating (expense) income, net for the year ended December 31, 2022, primarily consisted of a positive fair value adjustment of $632,000 of the contingent consideration related to the acquisition of NovioGendix in 2015, partially offset by a negative fair value adjustment of $117,000 related to the initial Kreos drawdown derivative financial instrument. Other operating (expense) income, net for the year ended December 31, 2021, primarily consisted of a $659,000 grant from the U.S. Department of Health and Humas Services as well as a $382,000 grant from the Dutch government NOW grants, both considered support for COVID-19 inefficiencies.

Financial Income and Expense

Financial Income and Expense	12 Months Ended
	Dec. 31, 2023
Financial Income and Expense [Abstract]
Financial income and expense	NOTE 8: Financial income and expense Financial Income Thousands of $ 2023 2022 2021 Interest income 1,088 125 11 Innovatus derivative instrument 719 116 - Fair value of option to pay GPS earnout in shares 763 - - Financial income, net 2,570 241 11 Financial Expenses Thousands of $ 2023 2022 2021 Interest on Kreos loan - (660 ) (1,566 ) Interest on Innovatus loan (5,232 ) (1,615 ) - Interest on other loans and leases (350 ) (361 ) (309 ) Kreos settlement - (1,047 ) - Fair value adjustments GPS contingent consideration (9,105 ) (2,398 ) - NovioGendix contingent consideration (49 ) (197 ) (194 ) Kreos derivative instrument (135 ) - (96 ) Exact Sciences 5-year warrants (2,153 ) - - Other financial loss (190 ) (107 ) (7 ) GPS amendment: additional consideration payment in cash (250 ) - - GPS amendment: additional consideration payment in shares (878 ) - - Financial expenses, net (18,342 ) (6,385 ) (2,172 ) For the year ended December 31, 2023, financial expenses, were primarily comprised of a negative fair value adjustment for the GPS contingent consideration of $9.1 million resulting from changes in net present value, interest charges of $5.2 million related to the Innovatus debt facility (as further detailed in Note 16), and $2.2 million related to the 5-year warrant issued to Exact Sciences as part of the amended GPS asset purchase agreement (as further detailed in Note 3). Other financial loss relates to bank costs incurred during the year.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2023
Income Tax [Abstract]
Income Tax	NOTE 9: Income Tax No income taxes were payable in view of the losses incurred by the Company. On December 31, 2023, the Company had a consolidated net tax loss carried forward amounting to $308.7 million (2022: $285.3 million; 2021: $258.5 million). The tax losses related to MDxHealth SA in Belgium are available for carry forward. Until 2021, tax losses related to MDxHealth BV in the Netherlands are available for carry forward to a period of 6 years. As of 2022, tax losses related to MDxHealth BV in the Netherlands are available for carry forward indefinitely. The tax losses of MDxHealth Inc., related to the years beginning on or after January 1, 2018, are available for carry forward indefinitely. Tax losses related to the years before January 1, 2018, can be carried forward to a period of 20 years. Tax credits (investment deductions) amounted to $0 in 2023, $402,000 in 2022, and $372,000 in 2021. It is uncertain if the Company will have taxable profits in the near future to allow all or part of the deferred tax asset to be utilized and as a result, no deferred tax asset was recognized in 2023, 2022, and 2021. The tax reconciliation and the impact of the unrecognized deferred tax assets is as follows: Thousands of $ Income Statement For the years ended December 31 2023 2022 2021 Loss for the year (43,100 ) (44,044 ) (29,002 ) Income tax expense (1 ) 0 0 Loss before income tax (43,099 ) (44,044 ) (29,002 ) Tax using the MDxHealth’s domestic tax rate 10,775 11,011 7,251 Effect of unused tax losses not recognized as deferred tax assets (10,775 ) (11,011 ) (7,251 )

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2023
Goodwill [Abstract]
Goodwill	NOTE 10: Goodwill On August 2, 2022, the Company acquired the GPS test from Exact Sciences (refer to Note 3 for further details). The purchase price in excess of the fair value of the net assets acquired has been considered as residual goodwill for an amount of $35.9 million. The Company is required to test Goodwill for impairment on an annual basis. The recoverable amount is determined based on a value-in-use calculation. The use of this method requires the estimation of future cash flows and the determination of a discount rate in order to calculate the present value of the cash flows. The company monitors its Goodwill at the consolidated company level, which is the level of its cash generating unit (CGU) benefiting from the synergies. The recoverable amount of the CGU has been determined from the value-in-use calculation based on the Company’s cash flow projections covering a period of 5 years through December 31, 2028. The amount by which the CGU’s recoverable value exceeds its carrying value is $88.8 million. The changes in the carrying value of Goodwill at December 31, 2023, 2022, and 2021 can be presented as follows: Thousands of $ Goodwill At January 1, 2022 - Additions through business combination 35,926 Impairment - Currency translation adjustments - Carrying value at December 31, 2022 35,926 At January 1, 2023 35,926 Additions through business combination - Impairment - Currency translation adjustments - Carrying value at December 31, 2023 35,926 The assumptions used are as follows: Assumptions used December 31, Discount rate (post-tax) 12.83 % Terminal growth rate 2 % The discount rate is based on comparable companies in the industry together with company-specific risks. Terminal growth rate is based on management estimates and industry data. The Company’s impairment review is sensitive to changes in the assumptions used, most notably the discount rate and the terminal growth rate. An increase of 1% in the discount rate would cause the value-in-use of the CGU to reduce by $18.9 million but would not give rise to an impairment. A 1% reduction in perpetuity growth rate would cause the value-in-use of the CGU to decrease by $13.6 million but would not give rise to an impairment. Based on sensitivity analysis performed at December 31, 2023, an increase of the post-tax discount rate by 7.28% up to 20.11% would result in the carrying amount exceeding the recoverable amount. Based on the above information, management concluded that there is no Goodwill impairment in 2023.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2023
Intangible Assets [Abstract]
Intangible assets	NOTE 11: Intangible assets Thousands of $ Patents Internally Externally Customers TOTAL Gross value At January 1, 2022 5,134 9,323 4,500 - 18,957 Additions 1,049 325 1,374 Additions through business combination (Note 3) 36,550 8,007 44,557 Currency translation adjustments Gross value at December 31, 2022 5,134 10,372 41,375 8,007 64,888 Accumulated amortization and impairment (4,910 ) (7,736 ) (2,863 ) - (15,509 ) Additions (224 ) (942 ) (1,490 ) (513 ) (3,169 ) Impairment (44 ) (44 ) Accumulated amortization and impairment at December 31, 2022 (5,134 ) (8,722 ) (4,353 ) (513 ) (18,722 ) Net value at December 31, 2022 0 1,650 37,022 7,494 46,166 Gross value At January 1, 2023 5,134 10,372 41,375 8,007 64,888 Additions 2,660 2,660 Gross value at December 31, 2023 5,134 13,032 41,375 8,007 67,548 Accumulated amortization and impairment (5,134 ) (8,722 ) (4,353 ) (513 ) (18,722 ) Additions (343 ) (2,919 ) (1,232 ) (4,494 ) Currency translation adjustments 5 5 Accumulated amortization and impairment at December 31, 2023 (5,134 ) (9,060 ) (7,272 ) (1,745 ) (23,211 ) Net value at December 31, 2023 0 3,972 34,103 6,262 44,337 Amortization of intangible assets is included as a separate line in the statement of profit or loss. The externally acquired intangible assets include technology acquired in the business combination with NovioGendix in 2015 and with the acquisition of the GPS test in August 2022, and increased by $36.6 million in 2022 due to the GPS acquisition. The estimated remaining amortization period amounts to 1.6 years for the NovioGendix IP and to 13.6 years for the GPS IP. Customer relationships includes customers acquired in the GPS acquisition, resulting in the fair value at acquisition date of $8.0 million. The GPS customer relationships are amortized over 6.5 years, the estimated remaining amortization period amounts to 5 years. The internally-developed intangible assets relate to the capitalized development expenses for Confirm mdx and Select mdx over the past years as well as for the development of the GPS assay in-house and our Resolve mdx assay. The estimated remaining amortization period amounts to 0.2 years for Confirm mdx and Select mdx, 4 years for GPS, and 3.3 years for Resolve mdx. In 2023, the Company capitalized $2.7 million (2022: $1.0 million; 2021: $0) in GPS and Resolve mdx development expenses.

Property, Plant and Equipment a

Property, Plant and Equipment and Right of-Use Assets	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment and Right of-Use Assets [Abstract]
Property, plant and equipment and right of-use assets	NOTE 12: Property, plant and equipment and right of-use assets Property, plant and equipment Thousands of $ Laboratory equipment Furniture IT Leasehold TOTAL Gross value At January 1, 2022 5,285 569 673 1,341 7,868 Additions 1,695 104 277 713 2,789 Disposals (258 ) (258 ) Exchange rate difference arising 88 (4 ) (5 ) 4 83 Gross value at December 31, 2022 7,068 669 687 2,058 10,482 Accumulated depreciation At January 1, 2022 (4,817 ) (315 ) (459 ) (606 ) (6,197 ) Additions (276 ) (72 ) (159 ) (166 ) (673 ) Disposals 258 258 Exchange rate difference arising (91 ) 7 3 2 (79 ) Accumulated depreciation at December 31, 2022 (5,184 ) (380 ) (357 ) (770 ) (6,691 ) Net value at December 31, 2022 1,884 289 330 1,288 3,791 Gross value At January 1, 2023 7,068 669 687 2,058 10,482 Additions 1,312 200 303 741 2,556 Disposals - - (111 ) - (111 ) Transfer from leases 498 - - - 498 Exchange rate difference arising (62 ) (2 ) (2 ) (2 ) (68 ) Gross value at December 31, 2023 8,816 867 877 2,797 13,357 Accumulated depreciation At January 1, 2023 (5,184 ) (380 ) (357 ) (770 ) (6,691 ) Additions (558 ) (102 ) (228 ) (500 ) (1,388 ) Disposals - - 108 - 108 Transfer from leases (498 ) - - - (498 ) Exchange rate difference arising 62 2 2 2 68 Accumulated depreciation at December 31, 2023 (6,178 ) (480 ) (475 ) (1,268 ) (8,401 ) Net value at December 31, 2023` 2,638 387 402 1,529 4,956 During 2023, the Company acquired $1.3 million of laboratory equipment and $741,000 of leasehold improvements. In 2022, the company also acquired $1.7 million of laboratory equipment and $713,000 of leasehold improvements. The primary purpose of these acquisitions was to add testing capacity for its new GPS and Resolve assays. Right of-use assets Thousands of $ buildings vehicles Equipment TOTAL Gross value Balance at January 1, 2022 5,130 218 897 6,245 Additions 1,435 58 334 1,827 Exchange rate differences (1 ) (1 ) Gross value at December 31, 2022 6,565 276 1,230 8,071 Accumulated depreciation Balance at January 1, 2022 (1,929 ) (129 ) (840 ) (2,898 ) Additions (945 ) (51 ) (71 ) (1,067 ) Exchange rate difference - - (3 ) (3 ) Accumulated depreciation on December 31, 2022 (2,874 ) (180 ) (914 ) (3,968 ) Net value at December 31, 2022 3,691 96 316 4,103 Gross value Balance at January 1, 2023 6,565 276 1,230 8,071 Additions 726 - 1,562 2,288 Disposals - (114 ) (325 ) (439 ) Transfer to tangible assets - - (498 ) (498 ) Gross value on December 31, 2023 7,291 162 1,970 9,423 Accumulated depreciation Balance at January 1, 2023 (2,874 ) (180 ) (914 ) (3,968 ) Additions (1,079 ) (34 ) (252 ) (1,365 ) Disposals - 70 325 395 Transfer to tangible assets - - 498 498 Exchange rate differences 7 - - 7 Accumulated depreciation on December 31, 2023 (3,946 ) (144 ) (343 ) (4,433 ) Net value at December 31, 2023 3,345 18 1,626 4,989 In June 2022, the company entered into a 36-month lease agreement (the “Plano lease”) for approximately 3,000 square feet of lab space in Plano, Texas with an effective date of June 2022. The Plano lease was amended in November 2022 to add approximately 1,500 square feet of office space. Under the terms of the Plano lease, the lease will automatically renew for successive 12-month periods after the end of the original term of the agreement. In December 2023, the Plano lease was amended to add approximately 1,300 square feet of office space. Under the terms of the lease agreements mentioned, the rental payments escalate through the term of each agreement and the Company is subject to additional charges for common area maintenance and other costs. In October 2022, the company renewed its lease agreement for a term of 60 months for its facilities in Nijmegen, The Netherlands. The new lease agreements from 2023 represent additional right of use assets of a total value of $2.3 million. The following amounts related to leases are recognized in the statement of profit or loss: Thousands of $ 2023 2022 2021 Depreciation expense 1,187 1,067 905 Interest expense on lease liabilities 284 314 229

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
Inventories	NOTE 13: Inventories Thousands of $ 2023 2022 Raw materials and consumables 2,779 2,327 Total Inventories $ 2,779 $ 2,327 Inventories are recognized at the lower of cost or net realizable value. Inventories recognized as an expense during the year ended December 31, 2023, amounted to $5.7 million (2022: $3.6 million; 2021: $3.2 million). These were included in cost of sales.

Trade and Other Receivables

Trade and Other Receivables	12 Months Ended
	Dec. 31, 2023
Trade and other receivables [Abstract]
Trade and other receivables	NOTE 14: Trade and other receivables Trade receivables Thousands of $ 2023 2022 Trade receivables 11,088 9,357 Total trade receivables 11,088 9,357 Trade receivables mainly consist of claims due from our patients’ insurance companies related to our diagnostic tests. Considering the Company’s revenue recognition methodology further described in Note 2.7, total accounts receivable balance could be presented in relation with the claim date of each sample as follows: A/R by claim date Months Thousands of $ 1-3 4-6 7-12 Not due Total Confirm mdx 2,225 876 639 - 3,740 Select mdx 291 101 128 (8 ) 512 Resolve mdx 1,278 629 401 - 2,308 GPS 3,237 783 508 - 4,528 Total Trade Receivables 7,031 2,389 1,676 (8 ) 11,088 A/R by claim date Months Thousands of $ 1-3 4-6 7-12 Not due Total Confirm mdx 1,865 821 765 - 3,451 Select mdx 134 101 78 25 338 Resolve mdx 1,966 458 158 - 2,582 GPS 1,907 895 - - 2,802 Other 163 - - 21 184 Total Trade Receivables 6,035 2,275 1,001 46 9,357 Prepaid expenses and other current assets Thousands of $ 2023 2022 Prepayments 1,585 1,710 Deposits 110 101 Recoverable VAT 183 97 Grants to be received - 54 Other 36 - Total prepaid expenses and other current assets $ 1,914 $ 1,962 Prepaid expenses mainly consist of prepaid insurance premiums and prepaid maintenance contracts. All financial assets carried at amortized cost are shown net of expected credit losses which are not deemed material.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	NOTE 15: Cash and cash equivalents Thousands of $ 2023 2022 Cash and cash equivalents 22,380 15,503 Total cash and cash equivalents $ 22,380 $ 15,503 The bank balances and cash held by the Company and short-term bank deposits have an original maturity of less than 3 months. The carrying amount of these assets approximates their fair value. The Company had no restricted cash in 2023 and 2022.

Loans, Borrowings, Leases oblig

Loans, Borrowings, Leases obligations and Other Financial Liabilities	12 Months Ended
	Dec. 31, 2023
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Abstract]
Loans, Borrowings, Leases obligations and other financial liabilities	NOTE 16: Loans, Borrowings, Leases obligations and other financial liabilities Loans, Borrowings & Lease liabilities Thousands of $ 2023 2022 Non-current loans and borrowings Loans 35,564 34,914 Lease liabilities (*) 3,578 3,091 Total non-current loans and borrowings $ 39,142 $ 38,005 Thousands of $ 2023 2022 Current loans and borrowings Loans 643 616 Lease liabilities (*) 1,480 1,172 Total current loans and borrowings $ 2,123 $ 1,788 (*) the evolution in the right of use assets is further disclosed in Note 12. Innovatus debt facility On August 2, 2022, the Company entered into a $70 million loan and security agreement with Innovatus Life Sciences Lending Fund I, LP (“Innovatus”), which loan also replaced the Company’s €9 million debt facility with Kreos Capital. At closing, an amount of $35 million was drawn, with an additional $35 million remaining available as a $20 million term B loan and a $15 million term C loan that can be drawn in 2024 and 2025 respectively, subject to certain conditions whereby there can be no assurance that these conditions will be satisfied and that the Company will be able to draw any further term loan amounts under this facility. The loans are secured by assets of the Company including intellectual property rights. Remaining proceeds of the loans will be used for working capital purposes and to fund general business requirements. The loans accrue interest at a floating per annum rate equal to the sum of (a) the greater of (i) the prime rate published in The Wall Street Journal in the “Money Rates” section or (ii) 4.00%, plus (b) 4.25%, and require interest-only payments for the initial four years. As contractually agreed, and at the election of the Company, a portion of the interest becomes payable in-kind by adding an amount equal to 2.25% of the outstanding principal amount to the then outstanding principal balance on a monthly basis until August 2, 2025. The loans mature on August 2, 2027. The lenders shall have the right to convert, prior to August 2, 2025, up to 15% of the outstanding principal amount of the loans into shares of the Company at a price per share equal to $11.21, reflecting a substantial premium to the trading price prior to the announcement of the acquisition. Amounts converted into shares of the Company will be reduced from the principal amount outstanding under the loan. Notable fees payable to Innovatus consist of a facility fee equal to 1% of the total loan commitment, due on the funding date of the relevant loans, and an end-of-loan fee equal to 5% of the amount drawn, payable upon final repayment of the relevant loans. Security has been granted over all assets (including IP rights) owned by the Company and MDxHealth, Inc. The loan agreement contains customary financial covenants and general affirmative and negative covenants, including limitations on the Company’s ability to transfer or dispose of assets, change our business, merge with or acquire other companies, incur additional indebtedness and liens, make investments, pay dividends and conduct transactions with affiliates. The Innovatus debt facility has been accounted for as a hybrid financial instrument which includes a host financial liability as well as an embedded derivative financial instrument being an equity conversion call option at a fixed rate of up to 15% of the aggregate outstanding principal amount through August 2, 2025. The embedded derivative is not considered to be closely related to the host financial liability given the differences in economics and risks, and as such both are accounted for separately: ● The host financial liability is recognized at amortized cost applying the effective interest rate method and has been accounted for as non-current loans and borrowings; ● The embedded derivative convertible (American) call option is recognized at fair value using a binomial tree option pricing model whereby the fair value is based on the actual stock price and the estimated volatility of the Company’s shares on Nasdaq since the Company’s IPO on November 4, 2021, and through the valuation date. The volatility measured on August 2, 2022, which was the closing date of the Innovatus debt facility, was 62.85% and at December 31, 2023 was 72.92% (2022: 64.82%). Any changes to the fair value of the embedded derivative will be recognized through the statement of profit or loss. The derivative financial instrument has been accounted for as other current financial liabilities. Kreos debt facility As part of the new debt facility with Innovatus, the Company’s debt facility with Kreos for an outstanding principal amount of €9 million has been fully repaid in cash in September 2022, for a total amount of $10.8 million. This repayment included the two convertible loans of €180,000 ($185,364) and €202,500 ($208,535) that were not converted by Kreos and that were entered into as part of amendments to the original Kreos debt facility. The 2022 repayment did not include the derivative financial liability for the initial Kreos drawdown fee which had an estimated fair value on December 31, 2022, of $891,000 and is included in Other financial liabilities as a separate financial instrument valued at fair-value through statement of profit or loss for the year ended December 31, 2022. This financial liability is payable upon demand in cash, or convertible into the Company’s common stock, upon election by Kreos. In June 2023, Kreos provided notice to the Company of the cancelation of the convertible loan associated with the initial drawdown fee and requested repayment in cash. As such, Kreos was entitled to a cash repayment of €945,000 ($1.0 million) which is equal to 150% of the initial drawdown fee of €630,000. The Company has paid €472,500 ($513,419) in July 2023, and an additional €472,500 ($513,419) in October 2023, and has no further liabilities toward Kreos as of December 31, 2023. On April 20, 2020, the Company, through its U.S. subsidiary, MDxHealth Inc., has entered into a “Paycheck Protection Program” (PPP) loan with the U.S. Small Business Administration (SBA) in the amount of $2,316,000 as part of the U.S Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan has a term of five years and carries an interest rate of 1.0% per year. Payments on the loan are deferred for the first eighteen months following disbursement of the loan, with principal and interest payments beginning on the nineteenth month. Interest on the loan continues to accrue during the eighteen-month deferment period. Cash proceeds from the loan were received in July 2020. As of December 31, 2023, the outstanding amount on the PPP loan was $1.0 million. In addition to the contracted loans, the Company has several lease obligations. The leases have terms of 3 to 5 years. Maturity of loans and borrowings are as follows at the balance sheet date: Thousands of $ 2023 2022 Loans Within one year 643 630 Years two to five 35,564 38,439 Leases Within one year 1,900 1,551 Years two to five 3,955 2,330 Note: all figures shown in this table are undiscounted and reflect future cash payments (capital and interests) Other financial liabilities Thousands of $ 2023 2022 Other financial liabilities Other non-current financial liabilities 63,259 53,537 Other current financial liabilities 2,895 2,327 Total other financial liabilities 66,154 55,864 GPS Contingent consideration As part of the acquisition of the GPS business from Exact Sciences in August 2022, and the subsequent amended asset purchase agreement from August 2023, an aggregate earnout amount of up to $82.5 million is to be paid by MDxHealth to Exact Sciences upon achievement of certain revenue milestones related to fiscal years 2023 through 2025, with the maximum earnout payable in relation to 2023 and 2024 not to exceed $30 million and $40 million, respectively. The liability recognized reflects a probability-weighted estimate at the current net present value which is expected to become payable. Future fair value adjustments to this contingent consideration will be recognized in the statement of profit or loss. The value of the contingent liability for GPS including the fair value adjustment accounted for under other non-current financial liabilities is $62.6 million as of December 31, 2023. MDxHealth option to settle earnout obligation in shares The fair value of the Company’s option to settle the earnout obligation in cash or through the issuance of additional shares of the Company, was measured using a Monte Carlo valuation model which takes into account several factors including the expected evolution in Company’s share price. This valuation model is considered as level 3 input and was assessed at $0.8 million financial asset, as of December 31, 2023. Exact Sciences 5-year warrants to acquire 1 million shares of MDxHealth The fair value of the warrant held by Exact Sciences to acquire up to 1 million shares of MDxHealth was measured using a Binomial tree valuation model which takes into account several factors including the expected evolution in the Company’s share price. This valuation model is considered as level 3 input and was assessed at $2.2 million financial liability as of December 31, 2023. Innovatus embedded derivative convertible call option The embedded derivative convertible (American) call option is recognized at fair value within other current financial liabilities and is measured using a Binomial tree valuation model which takes into account several factors including the expected evolution in the Company’s share price. The fair value of the liability is estimated at $192,000 for the year ended December 31, 2023. Kreos derivative financial instrument (“initial drawdown fee”) As of December 31, 2023, the convertible loan associated with the initial drawdown fee payable to Kreos has been fully off in cash and as such, the fair value of the financial derivative has been reduced to zero as no further liabilities to Kreos exist. As of December 31, 2022, the fair value of the financial derivative related to the initial drawdown fee of the Kreos loan was computed as the sum of the probability-weighted values of the fair values associated with each of the possible outcomes and amounted to $891,000 as of December 31, 2022. The derivative financial instrument is accounted for within other current financial liabilities for the year ended December 31, 2022. Other financial liabilities Other financial liabilities include the contingent consideration related to the acquisition of NovioGendix in 2015 and amounts to $1.2 million of which $550,000 is considered to be current. The contingent consideration is valued at fair value through the statement of profit or loss. The fair value of this contingent consideration is reviewed on a periodic basis. The fair value is based on a risk-adjusted future cash flows of different scenarios discounted using an interest rate of 12.83%. The structure of the possible scenarios and the probability assigned to each scenario is reassessed by management at every reporting period and requires judgement from management about the outcome and probability of the different scenarios (refer to Note 26 for further details). A reconciliation of cash and non-cash movements of loans and borrowings, lease liabilities and other financial liabilities is presented below: Thousands of $ Loans and Other financial For the years ended December 31 2023 2022 2023 2022 Beginning balance 35,530 12,092 55,864 2,427 Cash movements Loans and borrowings repaid 1 (637 ) (10,805 ) (1,022 ) Loans and borrowings received (Innovatus) 34,291 Non-cash movements GPS Contingent Consideration 50,483 Recognition of Innovatus embedded derivative convertible call option (1,026 ) 1,026 Kreos effective interest rate adjustment and extinguishment costs 1,328 Innovatus - effective interest rate adjustment 1,314 660 Foreign exchange rate impact / other (1,010 ) (4 ) (35 ) Fair value changes through profit and loss 11,316 1,963 Ending balance $ 36,207 $ 35,530 $ 66,154 $ 55,864 1 The amount includes interest paid on loans and borrowings Fair value adjustments recognized during 2023 for other financial liabilities relate to: Thousands of $ 2023 Increase of NovioGendix contingent consideration 16 Increase of Kreos derivative financial instrument (“initial drawdown fee”) 135 Increase of GPS contingent consideration 9,730 Decrease of Innovatus embedded derivative convertible call option (718 ) Exact Sciences 5-Year Warrants 2,153 Total fair value adjustment 11,316 Thousands of $ Lease liabilities For the years ended December 31 2023 2022 Opening balance 4,263 3,464 Cash movements Repayment of lease liabilities (1,610 ) (1,358 ) Non-cash movements Interest accretion 355 314 New leases 2,050 1,843 Closing balance 5,058 4,263

Contractual Obligations

Contractual Obligations	12 Months Ended
	Dec. 31, 2023
Contractual Obligations [Abstract]
Contractual obligations	NOTE 17: Contractual obligations Thousands of $ 2023 2022 Outstanding commitments for future minimum rent payments, which fall due as follows: Less than one year 90 156 Years 2-5 53 60 Total contractual obligations 143 216 For 2023 and 2022, we refer to Note 12 and 16 for the lease liabilities subsequent adoption and application of IFRS 16. Outstanding commitments for future minimum rent payments include rental fees related to leased facilities, and equipment for assets with a value below $5,000 or with short-term duration. These lease contracts can be terminated early with certain indemnity fees. All figures shown assume that the lease contracts will not be terminated early.

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Dec. 31, 2023
Trade and Other Payables [Abstract]
Trade and other payables	NOTE 18: Trade and other payables Trade accounts payable Thousands of $ 2023 2022 Trade accounts payable 4,889 5,061 Accruals for invoices to be received 3,922 5,117 Total trade accounts payable 8,811 10,178 Other current liabilities Thousands of $ 2023 2022 Payroll 5,222 3,932 Other accruals 472 53 Total other current liabilities 5,694 3,985

Financial Instruments and Fair

Financial Instruments and Fair Value	12 Months Ended
	Dec. 31, 2023
Financial Instruments and Fair Value [Abstract]
Financial instruments and fair value	NOTE 19: Financial instruments and fair value The table shows the Company’s significant financial assets and liabilities. All financial assets and liabilities are carried at amortized cost with the exception of the contingent considerations in relation to acquisitions and derivative financial instruments reported at fair value through the statement of profit or loss. All financial assets and liabilities are considered to have carrying amounts that do not materially differ from their fair value. Thousands of $ 2023 2022 Fair value hierarchy Assets At amortized cost Trade receivables 11,088 9,357 Cash and cash equivalents 22,380 15,503 Total financial assets 33,468 24,860 Liabilities At fair value: Other financial liabilities GPS contingent consideration 62,611 52,881 Level 3 Exact Sciences 5-Year Warrants 2,153 - Level 3 NovioGendix contingent consideration 1,198 1,182 Level 3 Innovatus derivative instrument 192 910 Level 3 Kreos derivative instrument - 891 Level 3 Subtotal financial liabilities at fair value 66,154 55,864 At amortized cost: Loans and borrowings 36,207 35,530 Level 2 Lease liabilities 5,058 4,263 Trade payables 8,811 10,178 Subtotal financial liabilities at amortized cost 50,076 49,971 Total financial liabilities 116,230 105,835 Recognized fair value measurements – valuation technique and principal inputs The fair value of the financial instruments has been determined on the basis of the following methods and assumptions: ● The carrying value of the cash and cash equivalents, the trade receivables, other current assets and the trade payables approximate their fair value due to their short-term character; ● The fair value of loans and borrowings applying the Effective Interest Rate method approximates their carrying value (level 2). ● Innovatus debt facility ● Paycheck Protection Program (PPP) ● Kreos debt facility ● Leases are measured at the present value of the remaining lease payments, using a discount rate based on the incremental borrowing rate at the commencement date of these leases. Their fair value approximates their carrying value. ● The fair value of contingent consideration payable to Exact Sciences (for the GPS acquisition) and NovioGendix (presented in the yearend statement of financial position under “other non-current financial liabilities” and “other current financial liabilities”) is based on an estimated outcome of the conditional purchase price/contingent payments arising from contractual obligations (level 3). This is initially recognized as part of the purchase price and subsequently fair valued with changes recorded through other operating income in the statement of profit or loss. o GPS o NovioGendix ● The fair value of the derivative financial liabilities related to the Innovatus derivative call option (as detailed in Note 16) was performed using a binomial pricing model which takes into account several factors including the expected evolution in share price and are considered as level 3 input. The fair value of the liability is estimated at $192,000 for the year ended December 31, 2023. An increase in volatility by 10% would result in an increase of the liability by $102,000, and a decrease in volatility by 10% would result in a decrease of the liability by $65,000. ● Exact Sciences 5-Year Warrants: The fair value of the warrant held by Exact Sciences to acquire up to 1 million shares of MDxHealth was measured using a Binomial tree valuation model which takes into account several factors including the expected evolution in the Company’s share price starting from the share price on December 31, 2023 of $3.94 with an estimated volatility of 72.99% and a contractual strike price of $5.265. This valuation model is considered as a level 3 input and was assessed at $2.2 million financial liability as of December 31, 2023. An increase in volatility by 10% would result in an increase of the liability by $253,000, and a decrease in volatility by 10% would result in a decrease of the liability by $277,000. ● Financial instruments are evaluated based on the mark-to-market report and the unrealized gains (loss) are recognized through the statement of profit or loss. Fair value hierarchy: The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique: ● Level 1 ● Level 2 ● Level 3 No financial assets or financial liabilities have been reclassified between the valuation categories during the year. A reconciliation of cash and non-cash movements of level 3 financial liabilities is presented below: Thousands of $ Financial Derivative Instruments (Kreos and Innovatus) Contingent Consideration (NovioGendix and GPS) For the years ended December 31 2023 2022 2023 2022 Beginning balance 1,801 810 54,063 1,617 Cash movements Loans and borrowings repaid (1,022 ) (250 ) Non-cash movements GPS contingent consideration 50,483 Exact Sciences 5-year warrant 2,153 Innovatus embedded derivative convertible call option 1,026 Effective interest rate adjustment (4 ) Foreign exchange rate impact / other movements (35 ) Fair value changes through profit and loss (719 ) 9,996 1,963 Change to level 1 fair value hierarchy 136 Ending balance 192 1,801 65,962 54,063

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2023
Loss Per Share [Abstract]
Loss per share	NOTE 20: Loss per share The basic loss per share is calculated by dividing the net result attributable to shareholders by the weighted average number of shares outstanding during the year, adjusted for the 1-for-10 reverse stock split that took place in November 2023. Years ended December 31 2023 2022 2021 Loss for the year, in thousands of $ (43,100 ) (44,044 ) (29,002 ) Basic and diluted loss per share, in $ (1.66 ) (2.78 ) (2.38 ) Weighted average number of shares 2023 2022 2021 Weighted average number of shares for basic and diluted loss per share 25,910,696 15,865,817 12,193,574 At December 31, 2023, 2022, and 2021, the Company had potential dilutive shares in the form of warrants, contingent considerations and convertible loans (see Note 16 and Note 24 for further details). Diluted loss per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

Financial Risk Management

Financial Risk Management	12 Months Ended
	Dec. 31, 2023
Financial Risk Management [Abstract]
Financial Risk Management	NOTE 21: Financial Risk Management Capital management Capital is comprised of equity attributable to shareholders, borrowings, and cash and cash equivalents. The Company aims to maintain a strong capital base in order to maintain investor and creditor confidence and to sustain the future development of the business. The Company’s objectives when managing capital are to maintain sufficient liquidity to meet its working capital requirements, fund capital investment and purchases, and safeguard its ability to continue operating as a going concern. The Company monitors capital regularly to ensure that the statutory capital requirements are met and may propose capital increases at shareholders’ meetings to ensure the necessary capital remains intact. Credit risk Credit risk arises from cash and cash equivalents, short-term bank deposits, as well as credit exposure to collaboration partners. Credit risk refers to the risks that counterparty will default on its contractual obligations resulting in financial loss to the Company. At the end of 2023, the Company operated with more than 1,000 different customers, systematically reducing credit risk compared to prior periods. In the U.S. healthcare system, and particularly within the molecular diagnostic CLIA laboratory industry, where there are rapid technological advances in diagnostic services, companies provide services to healthcare professionals and their patients, while being reimbursed from commercial and governmental insurance systems. Often these services are provided out of network and without supplier contracts. As a result, there is reimbursement risk, separate from credit risk that is characterized by uncertainty in reimbursement value, delays in payment, and ultimately non-payment. This impacts the Company’s revenue recognition and cash collections. In addition to reimbursement risk associated with commercial third-party payors, credit risk may also arise from amounts due directly from patients. In many cases, payors will cover the entire cost of testing. For example, for tests that fall under the Clinical Laboratory Fee Schedule, there is no co-payment, co-insurance or deductible for patients covered under traditional Medicare. However, patients covered by commercial insurance companies may be responsible for a co-payment, co-insurance, and/or deductible depending on the health insurance plan and individual patient benefit. Credit risk exists for those patients who cannot meet their co-payment or deductible portions. Customers’ compliance with agreed credit terms is regularly and closely monitored. Trade accounts receivable amounted to $11.1 million as of December 31, 2023, and no allowance for expected credit loss was recorded. No ECL has been recorded for other financial assets carried at amortized cost as there is no related credit risk. The credit risk on cash and cash equivalents of $22.4 million is limited given that the counterparties are banks with high credit scores attributed by international rating agencies. The Company had no exposure to Silicon Valley Bank, Silvergate Bank, or Credit Suisse. Interest risk During 2022, the Company entered into a 60-month loan with Innovatus for a total amount of $35 million (refer to Note 16 for further details). The loan accrues interest at a floating per annum rate equal to the sum of (a) the greater of (i) the Prime rate published in The Wall Street Journal in the “Money Rates” section or (ii) 4.00%, plus (b) 4.25%, and require interest-only payments for the initial four years. For every increase of 0.25% in the Prime rate, the Company’s interest expense increases by approximately $90,000 per year. In addition, on April 20, 2020, the Company, through its U.S. subsidiary, MDxHealth Inc., has entered into a “Paycheck Protection Program” (PPP) loan with the U.S. Small Business Administration (SBA) in the amount of $2,316,000 as part of the U.S Coronavirus Aid, Relief, and Economic Security (CARES) Act. The amortized cost is calculated using the effective interest method, which allocates interests and expenses at a constant rate over the term of the instrument; the effective interest rate for the loan is 1.00%. Considering the fixed interest rate, the Company is not exposed to interest risk, thus did not perform any sensitivity analysis. Currency risk The functional currency changed from the EURO to the U.S. Dollar as of July 1, 2014. Consequently, the currency risk is concentrated on European operations. As of December 31, 2023, cash deposits in EURO amounted to €357,000. The Company performed a sensitivity analysis of an increase/decrease of exchange rate on operations of 10%. The exposure of operations to the currency risk is immaterial given the limited size of the European operations and contribution to revenues versus the Company as a whole. Liquidity risk The Company manages liquidity risk by maintaining adequate reserves and by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities. At the date of this report, the Company has 2 loan agreements with banks and state institutions, and 12 leases (see Notes 12 and 16). For the years ended December 31, 2023 Thousands of $ Less than 1-2 3-5 Total Carrying Non derivatives Trade payables 8,811 - - 8,811 8,811 Loans 650 324 37,442 38,416 36,207 Lease liabilities 1,900 1,766 2,189 5,855 5,058 Total 11,361 2,090 39,631 53,082 50,076 For the years ended December 31, 2022 Thousands of $ Less than 1-2 3-5 Total Carrying Non derivatives Trade payables 10,178 - - 10,178 10,178 Loans 630 630 37,809 39,069 35,530 Lease liabilities 1,324 915 2,179 4,418 4,263 Total 12,132 1,545 39,988 53,665 49,971 Note: Except for carrying amount, all figures shown in this table are undiscounted and reflect future cash payments The Company is also committed to a potential additional cash out of an aggregate earnout amount of up to $82.5 million that could become payable in cash by MDxHealth to Exact Sciences upon achievement of certain revenue milestones related to fiscal years 2023 through 2025 and payable during 2025 through 2027. At the option of MDxHealth, the earnout amounts to Exact Sciences can be settled in cash or through the issuance of additional shares of the Company (valued in function of a volume weighted average trading price of the Company's shares at the end of the relevant earnout period) to Exact Sciences, provided that the aggregate number of shares held by Exact Sciences shall not exceed more than 7.5% of the outstanding shares of MDxHealth. The Company is unable to determine the exact amounts payable to Exact Sciences in each of the coming years, as those amounts are dependent on the GPS revenues that the Company will achieve in 2024 and 2025. Other risks The Company subscribes to certain insurance policies to cover matters such as (i) fire, theft, and other damage to its assets, (ii) product and liability insurance and clinical trial insurance, and (iii) D&O insurance. To date, no significant claims have been made under these insurance policies and there is no guarantee that the insurances will cover all damages if they should ever occur.

Share Capital and Reserves

Share Capital and Reserves	12 Months Ended
	Dec. 31, 2023
Share Capital and Reserves [Abstract ]
Share capital and reserves	NOTE 22: Share capital and reserves At December 31, 2023 and 2022, the Company’s share capital was represented by the following number of shares, adjusted for the 1-for-10 reverse stock split that took place in November 2023. Only one class of shares (common shares) exists and they have no par value. For the Years ended December 31 2023 2022 Common shares 27,288,093 16,288,093 Total outstanding shares 27,288,093 16,288,093 On August 11, 2022, to settle a portion of the purchase price for the acquisition by the Company of the GPS test from Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation) announced on August 2, 2022, the Company issued 691,171 shares, at a price per share of $7.23, totaling $5 million. As a result, the Company’s share capital has increased from €118,662,067.69 to €123,539,165.19 and the number of issued and outstanding shares has increased from 15,596,922 to 16,288,093 ordinary shares. In March 2023, the Company completed a registered public offering of 10.75 million shares at a price to the public of $4 per share for total gross proceeds of $43.0 million before deducting commissions and offering expenses of $3.4 million. As a result, the Company’s share capital has increased from €123,539,165.19 to €163,471,629.58, and the number of issued and outstanding shares has increased from 16,288,093 to 27,038,093 ordinary shares. On August 23, 2023, the Company and Exact Sciences Corporation amended their existing Oncotype DX GPS prostate cancer business asset purchase agreement, deferring the Company’s initial earnout payment by 3 years, from 2024 to 2027. As part of this amendment, the Company issued Exact Sciences 250,000 of the Company’s shares. As a result of this issuance, the Company’s share capital increased from €163,471,629.58 to €164,302,752.89 and the number of issued and outstanding shares has increased from 27,038,093 to 27,288,093 ordinary shares. Thousands of $ Thousands of € For the Years ended December 31 Share Issuance Share Issuance As of January 1, 2022 128,454 153,177 106,099 126,481 August 2022 – Issuance of 691,171 shares (*) 5,000 4,876 As of December 31, 2022 133,454 153,177 110,975 126,481 March 2023 – Issuance of 10,750,000 shares (*) 39,599 36,612 August 2023 – Issuance of 250,000 shares 878 812 As of December 31, 2023 173,931 153,177 148,398 126,481 (*) net of expenses The capital stock and the issuance premium amounted to the following: Thousands of $ Thousands of € For the Years ended December 31 2023 2022 2023 2022 Share Capital as per statutory accounts 192,297 148,419 164,303 123,539 Capital increase costs (18,366 ) (14,965 ) (15,905 ) (12,564 ) Share capital under IFRS 173,931 133,454 148,398 110,975 Issuance premium 153,177 153,177 126,481 126,481 Share capital and issuance premium 327,108 286,631 274,879 237,456 The history of the Share Capital can be found in “General Information; Capital and Shares”. By virtue of the resolution of the extraordinary general shareholders’ meeting of the Company held on May 27, 2021, which entered into force on June 1, 2021, the board of directors of the Company has been granted certain powers to increase the Company’s share capital in the framework of the authorized capital. The powers under the authorized capital have been set out in article 6 of the Company’s articles of association. Pursuant to the authorization granted by the extraordinary general shareholders’ meeting of June 30, 2023, the board of directors was authorized to increase the share capital of the Company on one or several occasions by a maximum aggregate amount of €163,471,629.58 (excluding issue premium, as the case may be) for a period of 5 years as from July 7, 2023. The board of directors has used its powers under the authorized capital on the occasion of the amendment of its agreement with Exact Sciences, by issuing 250,000 new shares to Exact Sciences. As a result, the board of directors therefore still has the authority under the authorized capital to increase the Company’s share capital with an aggregate amount of €162,640,506.27 (excluding issue premium, as the case may be). In addition to the outstanding shares of the Company: ● a total of 2,060,000 subscription rights of the Company have been created, of which 1,851,750 subscription rights have been granted as of December 31, 2023, which entitles their holders (assuming all subscription rights are granted and exercised) to subscribe to a total of 1,637,773 new shares with voting rights (see Note 24 for further details). The remaining 208,250 subscription rights have not yet been granted and are currently still managed by the Company’s board of directors; ● under the loan and security agreement entered into by the Company and Innovatus Capital Partners in August 2022, Innovatus has the right to convert, prior to August 2, 2025, up to 15% of the outstanding principal amount of the loans (by means of a contribution in kind of the relevant payables due by the Company under the loans) into shares of the Company at a conversion price per share equal to $11.21 (see note 16 for further details).

Retirement Benefit Plans

Retirement Benefit Plans	12 Months Ended
	Dec. 31, 2023
Retirement Benefit Plans [Abstract]
Retirement benefit plans	NOTE 23: Retirement benefit plans The Company operates defined contribution plans for all its qualifying employees. The assets of these plans are held separately from those of the Company in designated funds. A total cost of $1.2 million in 2023 (2022: $724,000) represents contributions payable to these plans by the Company at rates specified in the rules of the plans. The employees of the Company in Belgium are members of a state-managed retirement benefit plan operated by the government ( i.e. Because the Company must guarantee the statutory minimum return on these plans, not all actuarial and investment risks relating to these plans are transferred to the insurance company or pension fund managing the plans. The Company has considered the potential impact of the employer’s obligation to guarantee a minimum return and that this was assessed not to be significant.

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2023
Share-Based Payments [Abstract]
Share-Based Payments	NOTE 24: Share-based payments Warrants are granted to employees, consultants or directors of the Company and its subsidiaries. Each warrant entitles its holders to subscribe to one new share of the Company at a subscription price determined by the board of directors, within the limits decided upon at the occasion of their issuance. The warrants issued generally have a term of ten years as of issuance. Upon expiration of their term, the warrants become null and void. On November 13, 2023, the company completed a share consolidation with respect to all its outstanding shares by means of a 1-for-10 reverse stock split (the “Share Consolidation”). Although the number of warrants does not change, the reverse stock split affects the number of shares into which the original number of warrants are convertible. Therefore, all share amounts were adjusted to reflect the Share Consolidation. This section provides an overview of the outstanding warrants as of December 31, 2023. The warrants were created within the context of share-based incentive plans for employees, directors and consultants of the Company. The Company has created several pools of warrants under stock option plans for grant to eligible employees, directors, and consultants. Stock option plans were announced on June 23, 2014 (150,000), June 19, 2017 (250,000), June 21, 2019 (300,000), May 27, 2021 (360,000), May 25, 2022 (500,000), and June 30, 2023 (500,000) for a total amount of 2,060,000 warrants created. Outstanding warrants 2023 2022 Warrants created 2,060,000 1,731,080 Warrants available for grant (208,250 ) (163,750 ) Warrants granted 1,851,750 1,567,330 Warrants terminated or lapsed (213,977 ) (283,840 ) Warrants exercised - (57,712 ) Total outstanding at December 31 1,637,773 1,225,778 As of December 31, 2023, there are 1,637,773 warrants outstanding, entitling their holders to subscribe to 1,637,773 shares of the Company. For the year 2023, 455,500 (2022: 393,050) warrants were granted, 43,505 warrants (2022: 59,035) were terminated or lapsed, no warrants (2022: 0) were exercised, and 237,789 warrants (2022: 212,702) were vested. Number of potential shares from outstanding warrants 2023 2022 As of January 1 1,225,778 891,763 Number of warrants cancelled/forfeited during the year (43,505 ) (59,035 ) Number of warrants granted during the year 455,500 393,050 As of December 31 1,637,773 1,225,778 The share-based compensation expense recognized in the consolidated statement of profit or loss is given below as is the cumulated amount per the consolidated statement of financial position: Thousands of $ 2023 2022 2021 Share-based compensation in consolidated statement of profit or loss 665 867 1,222 Cumulated Share-based compensation in equity 12,139 11,474 10,607 The Cumulated Share-based compensation amount is part of the Total Shareholders’ Equity on the Consolidated statement of financial position. This amount is presented on the Consolidated statement of financial position for both exercised and non-exercised warrants. In general, the warrants vest in cumulative tranches of 25% per year, provided that the beneficiary has provided at least one year of service. However, there are certain exceptions to this rule which are, if applicable, specified in the relevant stock option plans: ● The warrants granted to directors under the June 23, 2014 Stock Option Plan, the June 21, 2019 Stock Option Plan, the May 27, 2021 Stock Option Plan, the May 25, 2022, and the June 30, 2023 Stock Option Plan, all vest on the date of the annual meeting that takes place in the calendar year following the calendar year in which they were granted, provided that the mandate of the relevant director has not ended or been terminated. ● The warrants granted to beneficiaries who are not directors under the June 23, 2014 Stock Option Plan all vest in instalments of 25% per year, the first tranche of 25% vesting on the first anniversary date of the date of grant and the following tranches vesting on a quarterly basis. ● The warrants granted to beneficiaries who are not directors under the June 21, 2019 Stock Option Plan, the May 27, 2021 Stock Option Plan, the May 25, 2022, and the June 30, 2023 Stock Option Plan may adopt a manual or custom vesting procedure under certain conditions or a particular vesting period over 3 or 4 years. The table below presents the outstanding warrants and their exercise price at the end of each accounting year covered by the financial statements: Warrants Weighted Potential Weighted Granted in 2022 393,050 6.76 393,050 6.76 Outstanding at December 31, 2022 1,225,778 12.34 1,225,778 12.34 Granted in 2023 455,500 2.91 455,500 2.91 Outstanding at December 31, 2023 1,637,773 9.64 1,637,773 9.64 Exercisable at December 31, 2023 759,841 14.07 759,841 14.07 The following table provides an overview of the outstanding potential shares from warrants per personnel category at December 31, 2023 and 2022: Category 2023 2022 Executive Director 489,375 395,000 Non-Executive Directors 25,650 24,800 Management team (excluding the Executive Director) 517,912 408,300 Other employees, consultants, and former service providers 604,836 397,678 Total outstanding at December 31 1,637,773 1,225,778 The weighted average exercise price of all outstanding warrants (vested and non-vested warrants; assuming 1 warrant = 1 share) is €9.64 or $10.43 at December 31, 2023 (€12.34 or $13.25 at December 31, 2022; €15.28 or $17.27 at December 31, 2021). The weighted average remaining contractual life of all outstanding warrants at the end of 2023 is 7.11 years (2022: 7.31 years; 2021: 7.18 years). The fair value of each warrant is estimated on the date of grant using the Black-Scholes methodology with the following assumptions: Number of warrants granted Expected Expected Risk-free Expected duration (months) Dates to Belgian benef. to other benef. Exercise price (€) dividend Yield stock price volatility interest rate to Belgian benef. to other benef. 23-Jun-14 1,200 1,200 € 41.30 - 48.12 % 1.78 % 75.32 63.29 10-Dec-14 - 17,500 € 40.10 - 46.93 % 1.01 % 69.73 57.70 09-Feb-15 6,000 9,500 € 44.90 - 46.75 % 0.62 % 79.73 61.71 01-Apr-15 - 300 € 50.20 - 47.42 % 0.40 % 72.03 54.02 01-May-15 - 2,000 € 50.50 - 46.59 % 0.62 % 71.05 53.03 29-May-15 2,000 3,000 € 49.10 - 46.52 % 0.81 % 64.14 52.11 01-Jun-15 - 600 € 49.00 - 46.58 % 0.81 % 70.03 52.01 01-Jul-15 - 400 € 46.20 - 47.02 % 1.27 % 69.04 51.02 01-Aug-15 - 400 € 46.40 - 46.54 % 0.98 % 68.02 50.00 01-Sep-15 - 1,000 € 42.40 - 49.31 % 1.15 % 73.02 48.99 01-Oct-15 - 8,300 € 42.00 - 48.99 % 0.90 % 72.03 54.02 01-Nov-15 - 400 € 38.10 - 50.88 % 0.92 % 71.01 53.00 01-Dec-15 - 1,800 € 38.90 - 51.18 % 0.85 % 70.03 52.01 01-Jan-16 - 400 € 37.90 - 51.12 % 1.06 % 69.01 50.99 04-Feb-16 - 1,000 € 41.30 - 51.18 % 0.85 % 67.89 49.87 04-Feb-16 5,000 13,400 € 37.80 - 52.49 % 0.72 % 67.89 49.87 22-Apr-16 - 5,200 € 36.20 - 53.40 % 0.58 % 65.33 53.33 27-May-16 3,000 4,000 € 41.30 - 51.85 % 0.54 % 64.11 52.11 01-Jun-16 - 200 € 34.30 - 53.73 % 0.49 % 64.01 52.01 01-Aug-16 - 400 € 36.20 - 53.51 % 0.16 % 62.01 50.01 21-Oct-16 - 2,000 € 44.40 - 54.19 % 0.28 % 59.34 47.34 22-Jan-16 - 2,000 € 38.30 - 52.81 % 0.86 % 68.32 56.32 01-Dec-16 - 2,200 € 46.50 - 54.16 % 0.75 % 57.99 39.98 01-Jan-17 - 1,900 € 45.60 - 53.84 % 0.73 % 56.98 50.96 01-Mar-17 - 9,500 € 52.60 - 52.62 % 0.68 % 55.04 49.02 01-Apr-17 - 1,800 € 54.10 - 51.80 % 0.81 % 54.02 48.00 11-Apr-17 2,000 20,000 € 53.50 - 51.83 % 0.72 % 65.68 47.67 1-Jun-17 - 200 € 50.10 - 51.86 % 0.59 % 52.01 52.01 1-Jul-17 - 2,200 € 49.60 - 50.94 % 0.77 % 63.02 44.98 29-Jul-17 - 800 € 47.20 - 50.95 % 0.87 % 50.10 44.05 01-Sep-17 - 3,400 € 49.20 - 48.08 % 0.71 % 60.99 42.97 01-Oct-17 - 7,000 € 48.00 - 47.32 % 0.76 % 53.98 41.95 02-Nov-17 - 9,900 € 46.10 - 45.23 % 0.66 % 52.93 40.90 1-Dec-17 - 600 € 39.20 - 46.50 % 0.56 % 51.98 39.98 20-Jun-17 3,000 3,000 € 49.70 - 51.57 % 0.59 % 81.40 63.39 27-Jun-17 25,000 € 49.80 - 51.04 % 0.66 % 81.17 63.16 01-Apr-18 - 4,200 € 37.70 - 46.08 % 0.76 % 54.02 42.02 01-May-18 - 800 € 36.40 - 46.27 % 0.82 % 53.03 41.03 01-Jun-18 5,000 3,200 € 49.70 - 46.15 % 0.77 % 52.01 40.01 01-Aug-18 7,000 € 37.40 - 44.09 % 0.79 % 62.00 55.96 05-Dec-18 - 2,000 € 17.30 - 57.56 % 0.79 % 45.86 33.86 24-Jan-19 - 19,100 € 16.40 - 67.56 % 0.77 % 62.24 50.20 16-May-19 - 150,800 € 14.90 - 75.78 % 0.38 % 58.55 46.52 01-Nov-19 - 800 € 10.10 - 82.15 % 0.00 % 64.99 46.98 01-Dec-19 - 1,200 € 10.20 - 81.95 % 0.00 % 64.01 45.99 Number of warrants granted Expected Expected Risk-free Expected duration (months) Dates to Belgian benef. to other benef. Exercise price (€) dividend Yield stock price volatility interest rate to Belgian benef. to other benef. 01-Feb-20 - 200 € 9.80 - 80.26 % 0.00 % 61.97 49.67 01-Jun-20 - 600 € 8.50 - 86.64 % 0.00 % 57.99 45.99 01-Oct-20 - 200 € 8.00 - 85.20 % 0.00 % 53.95 35.97 15-Jul-20 - 22,500 € 8.00 - 85.89 % 0.00 % 56.51 38.53 01-Jul-19 6,000 2,000 € 12.80 - 78.70 % 0.07 % 69.01 51.02 24-Jul-19 - 98,000 € 12.40 - 78.64 % 0.00 % 68.25 50.27 15-Jul-20 - 159,800 € 8.00 - 85.89 % 0.00 % 56.52 38.53 30-Jul-20 2,000 - € 12.80 - 87.02 % 0.00 % 56.02 38.04 01-Oct-20 - 1,000 € 12.80 - 85.20 % 0.00 % 53.95 35.97 01-Mar-21 - 200 € 10.80 - 65.06 % 0.00 % 48.99 31.00 03-May-21 - 800 € 11.60 - 64.59 % 0.01 % 46.92 28.93 01-Jun-21 - 400 € 11.80 - 65.82 % 0.01 % 45.96 27.98 27-Jul-21 - 3,000 € 13.60 - 63.36 % 0.00 % 44.12 26.14 27-Jul-21 - 20,250 € 13.60 - 63.36 % 0.00 % 44.12 26.14 24-Nov-21 - 4,000 € 10.50 - 60.78 % 0.14 % 49.25 37.25 03-Jul-21 - 257,000 € 13.75 - 63.10 % 0.04 % 44.91 26.93 07-Jul-21 - 60,000 € 13.85 - 63.11 % 0.00 % 44.78 26.79 06-May-22 - 500 € 7.50 - 53.16 % 1.64 % 58.85 52.87 04-Aug-22 - 3,800 € 7.97 - 55.63 % 1.41 % 55.89 49.91 03-Aug-22 - 42,500 € 6.84 - 57.05 % 1.50 % 67.96 55.92 03-Aug-22 - 312,500 € 6.84 - 57.05 % 1.50 % 73.97 61.94 04-Aug-22 - 1,000 € 7.97 - 55.63 % 1.41 % 73.94 61.91 01-Oct-22 - 31,250 € 7.40 - 57.26 % 2.77 % 72.03 60.00 01-Dec-22 - 1,500 € 7.40 - 58.30 % 2.40 % 69.67 63.65 25-Mar-23 - 30,500 € 3.20 - 71.42 % 2.75 % 72.26 60.26 3-May-23 - 11,000 € 3.30 - 73.64 % 2.92 % 77.01 65.01 27-Apr-23 - 25,000 € 3.20 - 73.60 % 3.10 % 77.21 65.21 22-Jun-23 - 1,000 € 3.60 - 72.54 % 3.11 % 81.34 69.34 30-Jun-23 - 255,000 € 2.90 - 72.62 % 3.09 % 81.07 69.07 04-Jul-23 - 1,000 € 3.00 - 72.60 % 3.14 % 80.94 68.94 05-Sep-23 - 500 € 3.00 - 73.75 % 3.23 % 72.90 60.90 18-Sep-23 - 85,000 € 2.78 - 73.70 % 3.34 % 72.48 60.48 18-Sep-23 - 37,500 € 2.78 - 73.70 % 3.34 % 78.44 66.44 09-Nov-23 - 1,500 € 3.09 - 77.60 % 3.32 % 52.73 40.70 09-Nov-23 - 7,500 € 3.09 - 77.60 % 3.32 % 76.75 64.75 The above inputs for the Black-Scholes model have been determined based on the following: ● The dividend return is estimated by reference to the historical dividend payment of the Company. Currently, this is estimated to be zero as no dividends have been paid since inception. ● The expected volatility was determined using the average volatility of the stock over the last two years at the date of grant. ● On November 27, 2023 the Company announced its transition to a single listing on Nasdaq which repositioned the Company’s shares from the Euronext Brussels trading system to the Nasdaq trading system. Since there were no shares granted following this delisting date, the risk-free interest rate is based on the interest rate applicable for the 10-year Belgian government bond at the grant date.

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2023
Related Parties [Abstract]
Related parties	NOTE 25: Related parties Transactions between the Company and its employees, consultants or Directors are described below. There were no other related party transactions. Remuneration of key management personnel During the year ended December 31, 2023, the executive management team included four members: 1. Chief Executive Officer, Mr. Michael K. McGarrity 2. Executive Vice President of Corporate Development & General Counsel, Mr. Joseph Sollee 3. Chief Financial Officer, Mr. Ron Kalfus 4. Chief Commercial Officer, Mr. John Bellano Their combined remuneration package, including employer taxes, amounted to the following: Thousands of $ except per personnel, warrants & share amounts For The Years ended December 31 2023 2022 2021 Number of management members and Executive Directors 4 4 4 Short-term employee benefits 1,967 1,550 1,545 Post-employment benefits 48 54 52 Other employment costs 216 219 207 Total benefits 2,231 1,822 1,804 IFRS share-based compensation expense 909 863 982 Number of warrants offered 220,000 220,000 220,000 Cumulative outstanding warrants 1,007,287 808,800 588,800 Exercisable warrants 644,283 361,864 128,223 The following table sets forth the number of warrants that were exercised, granted and accepted in aggregate by the four members of the executive management team: 2023 2022 2021 Number of warrants exercised 0 0 0 Number of new warrants granted and accepted 220,000 220,000 220,000 Annualized IFRS cost for existing warrants $ 909,000 $ 863,000 $ 982,000 No loans, quasi-loans or other guarantees are outstanding with members of the executive management team. Remuneration of the Board The total remuneration of the Board of Directors (including the Executive Director) in 2023, 2022, and 2021 was $1,090,000, $876,000, and $863,000, respectively (excluding VAT, share-based compensation and reimbursement of expenses). No advances or credits have been granted to any member of the Board of Directors. None of the members of the Board of Directors have received any non-monetary remuneration other than warrants as disclosed above. Transactions with Non-Executive Directors Since 2012, the Non-Independent Directors do not receive a fee payment for attending and preparing for Board meetings or for assisting the Company with Board matters. They receive reimbursement for expenses directly related to the Board meetings, totaling less than $29,000 in 2023. The Independent Directors receive a fee for attending and preparing meetings of the Board of Directors and for assisting the Company with Board matters, and they receive reimbursement for expenses directly related to the Board meetings. In 2023, 2022, and 2021, fees and expense reimbursement in the amount of $337,000, $314,000, and $302,000, respectively, were paid to independent members of the Board of Directors. Warrants to subscribe to 1,000 new shares were granted to Jan Pensaert, acting through Valiance Advisors LLP, in July, 2023. No other warrants were granted to Non-Executive Directors in 2023. No warrants were exercised in 2023 by Non-Executive Directors.

Significant Agreements, Commitm

Significant Agreements, Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Significant Agreements, Commitments and Contingencies [Abstract]
Significant agreements, commitments and contingencies	NOTE 26: Significant agreements, commitments and contingencies Fair value of Other financial liabilities Other financial liabilities include the contingent consideration related to the acquisition of NovioGendix in 2015. The Company is contractually required to pay at maturity to the holder of the obligation the amount of maximum $2.2 million. Based on its judgement and estimates, management believes future milestones will be paid in 2024 or 2025. The fair value of this contingent consideration as of December 31, 2023, is estimated at $1.2 million (2022: $1.2 million) and was accounted for as other financial liabilities (current and non-current) as detailed in Note 16. The contingent consideration related to the acquisition of the GPS business from Exact Sciences in August 2022 (as detailed in Note 3), has been assessed at $50.5 million which has been accounted for under other non-current liabilities as further detailed in Note 3. The liability recognized reflects a probability-weighted estimate at the current net present value which is expected to become payable. Future fair value adjustments to this contingent consideration will be recognized in the statement of profit or loss. The value of the contingent liability for GPS is $62.6 million as of December 31, 2023 (2022: $52.9 million) and was accounted for as other non-current financial liabilities as detailed in Note 16. Collaborative research agreements and clinical research agreements The Company has entered into multiple agreements with universities, medical centers and external researchers for research and development work and for the validation of the Company’s technology and products. These agreements typically have durations of one to three years, and may include fixed fees to the collaborators in exchange for access and rights to the results of the work. In addition, MDxHealth collaborates on research and clinical development with leading academic and government cancer research institutes. These relationships provide the Company with additional resources and expertise for clinical marker validation as well as access to patient samples for testing. Intellectual property in-licensing agreements The Company has entered into numerous agreements with universities and companies for in-licensing intellectual property. These agreements typically require the Company to pay an up-front fee, annual maintenance fees and/or minimum annual royalty fees, legal fees related to the patents, and certain milestone and royalty fees if the patents are eventually used in a commercialized product. In addition, the Company must provide the licensor with periodic reports. Commercial and intellectual property sub-licensing agreements The Company has entered into multiple partnering and sub-licensing agreements. With regards to the Company’s developed tests, the Company has entered into a range of marketing and sales arrangements with commercial entities. These important relationships provide the Company with additional resources and infrastructure to expand the geographic reach and awareness of the Company’s solutions, primarily in relation to the Confirm mdx and Select mdx tests. In regard to intellectual property that MDxHealth has developed or improved, MDxHealth has sublicensed certain of its non-core technologies to commercial partners, several of whom have launched products that generate royalties and other fees. These sublicenses include an exclusive sublicense to Laboratory Corporation of America (LabCorp) for the MGMT test, which LabCorp began to commercialize in North America in 2008, and an exclusive sublicense to Vesica Health, Inc. for the Company’s patented AssureMDx test for the purpose of bladder cancer detection on a worldwide basis. Litigation As of the date of this document and as far as MDxHealth is aware, the Company is not involved in any material legal proceedings.

Subsidiaries

Subsidiaries	12 Months Ended
	Dec. 31, 2023
Subsidiaries [Abstract]
Subsidiaries	NOTE 27: Subsidiaries The Company has the following two wholly-owned direct subsidiaries: MDxHealth Inc. Address 15279 Alton Parkway – Suite 100 – Irvine, CA 92618 Incorporation Date April 14, 2003 MDxHealth B.V. Address Transistorweg 5, 6534 AT Nijmegen, The Netherlands Incorporation Date October 18, 2006 Incorporated into MDxHealth on September 18, 2015

Principal Audit Fees and Servic

Principal Audit Fees and Services	12 Months Ended
	Dec. 31, 2023
Principal Audit Fees And Services [Abstract]
Principal audit fees and services	NOTE 28: Principal audit fees and services During the past fiscal year, in addition to their usual activity, the statutory auditor performed additional activities on behalf of the Company mainly for the issuance of special reports related to warrant plans, grant report certification, for participation to the audit committees and for participation to special projects. The detail is presented in the table below: in thousands of $ in thousands of € For the years ended December 31 2023 2022 2021 2023 2022 2021 Audit fee for statutory and consolidated financials 408 239 182 378 226 155 Other audit fees - 191 183 - 180 156 Audit related and other services 40 42 17 37 39 14 Total 448 472 382 415 445 325

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of preparation and statement of compliance	2.1. Basis of preparation and statement of compliance MDxHealth’s consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) and interpretations issued by the IFRS Interpretation Committee (IFRS-IC) applicable to companies reported under IFRS. The financial statements comply with IFRS as issued by the International Accounting Standards Board (IASB), collectively “IFRS”. In addition the financial statements are also prepared in accordance with IFRS as adopted by the EU (“EU IFRS”). The principal accounting policies applied in the preparation of the consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. The functional and presentation currency is the U.S. Dollar ($) and all amounts are presented in thousands of U.S. Dollars, rounded to the nearest thousand, unless otherwise indicated. Reclassifications Certain prior period balances have been reclassified to conform to current period presentation of the Company’s consolidated financial statements and accompanying notes. Such reclassifications have no effect on previously reported results of operations, accumulated deficit, subtotals of operating, investing or financing cash flows or consolidated balance sheet totals.
Basis of consolidation	2.2. Basis of consolidation The consolidated financial statements incorporate the financial statements of MDxHealth SA (Belgium) and its wholly owned subsidiaries, including MDxHealth Inc. (United States), and MDxHealth BV (The Netherlands) for each fiscal year ending on December 31. Subsidiaries are all entities over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. The acquisition method of accounting is used to account for business combinations by the Company. All intercompany balances, profits and transactions are eliminated upon consolidation.
Going Concern	2.3. Going Concern The Company has experienced net losses and significant cash used in operating activities since its inception in 2003, and as of December 31, 2023, had an accumulated deficit of $331.4 million, a net loss of $43.1 million, and net cash used in operating activities of $21.5 million. Management expects the Company to continue to incur net losses and have significant cash outflows for at least the next twelve months. While these conditions, among others, could raise doubt about its ability to continue as a going concern, these consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of its assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company’s cost structure. As of December 31, 2023, the Company had cash and cash equivalents of $22.4 million. Taking into account the above financial situation and on the basis of the most recent business plan including the Company’s expected ability to access additional cash through debt, equity, or other means, the Company believes that it has sufficient cash to be able to continue its operations for at least the next twelve months from the date of issuance of these financial statements, and accordingly has prepared the consolidated financial statements assuming that it will continue as a going concern. This assessment is based on forecasts and projections within management’s most recent business plan as well as the Company’s expected ability to access additional cash through debt, equity or other means, for which at this moment a material uncertainty exists that casts substantial doubt on the Company’s ability to continue as a going concern. The Company also believes the going concern assumption is justified based on its ability to realize cost savings in case it will not be successful in raising additional cash through debt, equity or other means. Macroeconomic Factors The Company does not believe that the Ukraine war or the war in Israel/Gaza has an impact on the Company’s ability to continue as a going concern. There is no direct or indirect impact of these conflicts on the day-to-day business of the Company. The Company is not materially impacted by inflation, supply disruption or cyber-attacks due to the current geopolitical conflict. With regards to climate-related matters, the Company is not impacted in a material way by extreme weather conditions.
Use of estimates and judgments	2.4. Use of estimates and judgments Management makes certain critical accounting estimates and management judgments when applying the Company’s accounting policies, which affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are continuously evaluated based on historical experience and other factors, including expectations of future events, which are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions. Judgements: Financial Liabilities and Assets (Note 16) The warrant issued to Exact Sciences as well as the right held by MDxHealth to pay the earnout obligation either in cash or in shares, up to certain limits, were considered as embedded derivatives of the host financial (earnout) liability and not closely related to the host financial liability given the differences in risk and exposure: ● The fair value of the Company’s option to settle the earnout obligation in cash or through the issuance of additional shares of the Company was measured based on a Monte Carlo valuation model which takes into account several factors including the expected evolution in Company’s share price as well as the 7.5% ownership limit of the outstanding shares of MDxHealth, as described above. This valuation model is considered as level 3 input and was valued as a $0.8 million financial asset; and ● The fair value of the warrant held by Exact Sciences to acquire up to 1,000,000 of the Company’s shares at an exercise price of $5.265 per share, was measured based upon a Binomial tree valuation model which takes into account several factors including the expected evolution in the Company’s share price. This valuation model is considered as level 3 input and was valued at $2.2 million financial liability. Revenue recognition (Note 4): As further described in Note 2.7 (paragraph “Determining the Transaction Price”), the Company analyzes historical collection data on a quarterly basis and makes adjustments to its estimates. In accordance with IFRS 15, revenue is recognized where such a variable consideration is included in the transaction price only to the extent that it is highly probable that the amount of revenue recognized will not be subject to significant future reversals as a result of subsequent re-estimation. Going Concern (Note 2.3) Management needs to make significant judgements whether the Company will have sufficient liquidity to continue operations during the next twelve months. Refer to Note 2.3 for management assessment. Estimates: The areas where assumptions and estimation uncertainties in the financial statements have potentially the most significant effect in 2023, are listed below: Financial Liabilities and Assets (Note 16) Other financial assets and liabilities are accounted for at fair value through the statement of profit or loss and include the following: The fair value of the contingent consideration payable to Exact Sciences (for the GPS acquisition) and to NovioGendix, which are presented in the yearend statement of financial position under “other non-current financial liabilities” and “other current financial liabilities” are based on an estimated outcome of the conditional purchase price and contingent payments arising from contractual obligations (level 3 input). These were initially recognized as part of the purchase price and then subsequently measured for fair value. Any changes to fair value are recorded in the statement of profit or loss through either “other operating (expense) income”, “financial income” or “financial expense” depending on the underlying driver for the fair value adjustment. The fair value of the GPS contingent consideration is based on the estimated timing and amount of the earnout payments. This estimate is then discounted to its net present value, taking into account the expected time when the earnout would become payable in 2025, 2026, and 2027. This contingent consideration was initially recorded along with the purchase price allocation of this business combination as detailed in Note 3. In August 2023, the Company and Exact Sciences amended their existing GPS asset purchase agreement in consideration for an amendment fee of $250,000 in cash and 250,000 of the Company’s shares, a 5-year subscription right (warrant) to acquire up to 1,000,000 of the Company’s shares at an exercise price of $5.265 per share (representing a 50% premium to the market price of the shares as of August 18, 2023), and an increase in the potential aggregate earnout amount from $70 million to $82.5 million. At the option of MDxHealth, the earnout amounts can be settled in cash or through the issuance of additional shares of the Company (valued in function of a volume weighted average trading price of the Company's shares at the end of the relevant earnout period) to Exact Sciences, provided that the aggregate number of shares held by Exact Sciences shall not exceed more than 7.5% (increased from 5% in the initial agreement) of the outstanding shares of MDxHealth. The amendment resulted in a fair value adjustment to the contingent consideration liability of $9.7 million for the year ended December 31, 2023, of which 9.1 million was recorded in “financial expenses” and resulted from changes in the weighted-average cost of capital (WACC) as well as changes in the terms of the earnout following the GPS asset purchase agreement amendment in August 2023, while the remaining $0.6 million was recorded under “other operating (expense) income, net”. The contingent consideration liability is considered as a financial liability based on level 3 input and was valued at $62.6 million as of December 31, 2023, using a discount rate of 12.83%. The fair value of the contingent consideration related to NovioGendix is based on a risk-adjusted future cash flows of different scenarios discounted using an interest rate of 12.83%. The fair value of the liability for the year ended December 31, 2023, was valued at $1.2 million, of which $550,000 is considered to be current. The fair value of the derivative financial liabilities related to the Innovatus derivative call option (as detailed in Note 16) was performed using a binomial pricing model which takes into account several factors including the expected evolution in Company’s share price and are considered as level 3 input. The fair value of the liability for the year ended December 31, 2023, is estimated at $192,000. Impairment Testing (Notes 3, 10 and 11) The Company recorded Goodwill of $35.9 million as part of the GPS business combination in the prior year (detailed in Note 3), which is subject to annual impairment testing. The Company has performed an impairment test as of December 31, 2023, at the level of the entire company which is in line with the level at which management monitors its profitability. The Company’s cash-generating unit (CGU) is expected to benefit from the synergies of the business combination. The impairment testing is based on a discounted cash flow (DCF) model, with cash flows for the next five years derived from the internal budgets and a residual value that assumes a perpetual growth rate of 2%. The value-in-use is sensitive to the discount rate used for the DCF model as well as the expected future cash inflows and the growth rate used for extrapolation purposes. Key underlying estimates are considered to be the estimated cashflows and the weighted-average cost of capital, and are further described in Note 10. Share-Based Payments (Note 24) Management estimates the fair value of the equity-settled share-based payment transactions by using the Black-Scholes option valuation model: ● The dividend return is estimated by reference to the historical dividend payment of the Company; currently, this is estimated to be zero as no dividends have been paid since inception; ● The expected volatility was determined using the average volatility of the stock over the last two years at the date of grant; ● Risk-free interest rate is based on the interest rate applicable for the 10-year Belgian government bond at the grant date given all grants during 2023 were done at the moment the Company was still listed on Euronext.
New Standards, Interpretations and Amendments	2.5. New Standards, Interpretations and Amendments 2.5.1. New Standards, Interpretations and Amendments adopted by the Company The accounting policies have been consistently applied by the Company and are consistent with those used in previous years. The following amendments and interpretations issued by the IASB and IFRIC apply for the first time in 2023, but do not have a significant impact on the consolidated financial statements of the Group. ● IFRS 17 Insurance Contracts (issued on 18 May 2017); including Amendments to IFRS 17 (issued on 25 June 2020) ● Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (issued on 12 February 2021) ● Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2: Disclosure of Accounting policies (issued on 12 February 2021) ● Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction (issued on 7 May 2021) ● Amendments to IFRS 17 Insurance contracts: initial application of IFRS 17 and IFRS 9 – Comparative information (issued on 9 December 2021 ● Amendments to IAS 12 Income taxes: International Tax Reform – Pillar Two Model Rules (issued on 23 May 2023) This adoption has not had any material impact on the disclosures or on the amounts reported in these financial statements. 2.5.2. Standards and Interpretations issued but not yet effective in the current period Certain new accounting standards and amendments to standards have been published, but were not mandatory for the December 31, 2023, reporting period. No amendments to standards that are issued but not yet effective are considered to materially affect the Company’s accounting policies or any of the disclosures when applied for the first time. The following amendments have been issued, but are not mandatory for the financial year beginning January 1, 2023: ● Amendments to IAS 1 ‘Presentation of Financial Statements: Classification of Liabilities as current or non-current’ (effective January 1, 2024), affect only the presentation of liabilities in the statement of financial position — not the amount or timing of recognition of any asset, liability income or expenses, or the information that entities disclose about those items. The amendments: o clarify that the classification of liabilities as current or non-current should be based on rights that are in existence at the end of the reporting period and align the wording in all affected paragraphs to refer to the “right” to defer settlement by at least twelve months and make explicit that only rights in place “at the end of the reporting period” should affect the classification of a liability; o clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability; and make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services; and o clarify how conditions with which an entity must comply within 12 months after the reporting period, such as covenants, affect the corresponding liability’s classification. ● Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback (effective January 1, 2024). The amendments explain how an entity accounts for a sale and leaseback after the date of the transaction, specifically where some or all the lease payments are variable lease payments that do not depend on an index or rate. They state that, in subsequently measuring the lease liability, the seller-lessee determines ‘lease payments’ and ‘revised lease payments’ in a way that does not result in the seller-lessee recognizing any amount of the gain or loss that relates to the right of use it retains. Any gains and losses relating to the full or partial termination of a lease continue to be recognized when they occur as these relate to the right of use terminated and not the right of use retained. ● Amendments to IAS 7 ‘Statement of Cash Flows’ and IFRS 7 ‘Financial Instruments: Disclosures’1: Supplier Finance Arrangements, effective 1 January 2024 ● Amendments to IAS 21 ‘The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability’1, effective 1 January 2025 The Company is analyzing the impact, if any, on its consolidated financial statements in view of the application of the amendment of IAS 1.
Foreign currency translation	2.6. Foreign currency translation Functional and presentation currency Items included in the financial statements of each of the Company’s entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The Company’s functional and presentation currency is the U.S. dollar based on the continuing development of the commercial activities in the U.S. market. Foreign currency transactions are translated into the functional currency using the exchange rates at the date of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss. The results and financial positions of foreign operations that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● Assets and liabilities for each statement of financial position presented are translated at the closing rate at the date of that balance sheet. At December 31, 2023, the official exchange rate applied for assets and liabilities was €1 to $1.105 (2022: €1 to $1.066) quoted by the European Central Bank. ● Income and expenses for each statement of profit or loss and statement of comprehensive income are translated at average exchange rates. At December 31, 2023, the official exchange rate applied for income and expenses was €1 to $1.0813 (2022: €1 to $1.053) quoted by the European Central Bank. ● All resulting exchange differences are recognized in other comprehensive income.
Revenue recognition	2.7. Revenue recognition Performance obligations and timing of revenue recognition The majority of the Company’s revenue is derived from laboratory services with revenue recognized at a point in time when control of the services has transferred to the customer. This is generally when the test results are delivered to the customer. Minor other Company’s revenue is derived from license fees and royalties: ● License fees are recognized when the Company has fulfilled all conditions and obligations. If the Company has continuing performance obligations towards the fees, the fee will be recognized on a straight-line basis over the contractual performance period. ● Royalties are recognized as revenue once the amounts due can be reliably estimated based on the sale of the underlying products and services and when the collection of the royalties can be reasonably assured. License up-front (signature fees) and non-refundable fees for access to prior research results and databases are recognized when earned, if the Company has no continuing performance obligations and all conditions and obligations are fulfilled. If the Company has continuing performance obligations towards the fees, the fee will be recognized on a straight-line basis over the contractual performance period. Royalties are generated from the sales by third parties of products or services which incorporate the Company’s proprietary technology. Royalties are recognized as revenue once the amounts due can be reliably estimated based on the sale of the underlying products and services and when the collection of the royalties can be reasonably assured. Determining the transaction price A large portion of the Company’s revenues are derived from Medicare, which reimburses the Company for tests performed on its insured patients. Medicare has set a fixed price (via a Local Coverage Determination or “LCD”) for the Company’s Confirm mdx, Select mdx, and GPS tests. Therefore, the amount of revenue recognized from Medicare for these tests is determined by reference to the LCD pricing. For other patients insured by commercial insurance companies where there is no certainty of the amount that will be paid for services rendered, the Company uses historical collection data – on an individual payor basis – to estimate its future collection and corresponding revenues that should be recognized for each type of test. The Company analyzes historical collection data on a monthly basis and makes monthly adjustments to its estimates. In accordance with IFRS 15, revenue is recognized where such a variable consideration is included in the transaction price only to the extent that it is highly probable that the amount of revenue recognized will not be subject to significant future reversals as a result of subsequent re-estimation. When historical collection data is insufficient to estimate future collections, the Company defaults to cash basis, meaning that revenues will not be recognized until actual cash payment is received from the payor. Total revenue in any given year includes amounts related to tests performed in previous years that relate to: ● revenue from transactions in previous years that did not previously meet the revenue recognition criteria; ● differences between the revenue recognized in previous years and the actual amount received; and ● reversals of revenue relating to balances that are outstanding for more than 9 months.
Segment information	2.8. Segment information Information for the Company’s operating segments has been determined by reference to the information used by the chief operating decision maker (“CODM”) of the Company to review the performance of the Company and in making decisions on allocation of resources, the nature of the activities and the management structure and accountabilities. The Company’s CEO has been identified as the chief operating decision maker in accordance with his designated responsibility for the allocation of resources to operating segments and assessing their performance through periodic reporting. The CODM periodically reviews the Company’s performance based on information at a company level. The Company monitors the profitability of the group as a whole given revenues are generated from clinical laboratory service testing and does accordingly not distinguish different business segments.
intangible assets	2.9. intangible assets Initial measurement: Externally acquired Intangible assets are recognized on business combinations if they are separable from the acquired entity or give rise to other contractual/legal rights. The amounts ascribed to such intangibles are determined using appropriate valuation techniques. Intangible assets are recognized on the business combinations of NovioGendix in 2015 (Select mdx) and GPS in 2022 and include: ● Externally acquired intellectual property, including patents, technology and related IP; and ● Customers. All were valued through application of the relief from royalty method, except for the customers which were valued on the basis of multi-period excess earnings method. Externally acquired intangible assets also include patents and software licenses which are initially recognized at cost. Internally generated intangible assets (development costs) Development costs are capitalized when requirements for capitalization during the development phase have been met. In absence of meeting the requirements, these are expensed in the period in which they were incurred as research and development expenses. Internally generated intangible assets relate to Confirm mdx, Select mdx, Resolve mdx and GPS. Subsequent measurement Intangible assets are carried at their cost less any accumulated amortization and any accumulated impairment losses amortized on a straight-line basis over their estimated useful lives on the following basis: ● Patents & software: shorter of (a) 5 years; or (b) the software license period / patent life ● Intellectual property: 10-15 years ● Customers: 6.5 years ● Capitalized development costs: 5 years Amortization over the asset’s useful life shall begin when the asset is available for use. Amortization of intangible assets are presented as a separate line in the consolidated statement of profit or loss.
Property, plant and equipment	2.10. Property, plant and equipment Property, plant and equipment are stated at historical cost less accumulated depreciation and impairment. Repair and maintenance costs are charged to the income statement as incurred. Depreciation is charged to write off the cost or valuation of assets over their useful lives, using the straight-line method, on the following basis: ● Equipment: 5 years ● IT hardware and software: 3 years ● Furniture: 5 years ● Vehicles: 5 years ● Leasehold improvements: in line with the non-cancellable lease period of the related lease
Right-of-use assets and liabilities	2.11. Right-of-use assets and liabilities Right-of-use assets: The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Depreciation periods range between 3 and 6 years. Right-of-use assets are subject to impairment. Lease liabilities: At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date which is in the following ranges: ● Buildings: 10% and 12.75% ● Vehicles: 2.5% and 3.75% ● Materials: 9.75% and 12% After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.
Impairment of assets	2.12. Impairment of assets Goodwill and intangible assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. The Company monitors its Goodwill at consolidated Company level which is the level of the Company of cash-generating units (CGUs) benefiting from the synergies. Non-financial assets other than Goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.
Inventories	2.13. Inventories Inventories are initially recognized at cost, and subsequently at the lower of cost and net realizable value. Cost comprises merely purchase costs, as the inventory consists solely of raw materials. Raw materials are not ordinarily interchangeable, and they are as such accounted for using the specific identification of their individual cost. The Company does not account for work in progress and finished products.
Cash and cash equivalents	2.14. Cash and cash equivalents Cash and cash equivalents are carried on the consolidated statement of financial position at nominal value. For the purposes of the cash flow statements, cash and cash equivalents comprise cash on hand, deposits held on call with banks, other short-term highly liquid investments and bank overdrafts. Bank overdrafts, if any, are included in borrowings included in current liabilities.
Taxation	2.15. Taxation Current tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Deferred income tax is provided in full using the “balance sheet liability method”, on temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax liabilities are recognized for all taxable differences. Deferred tax assets are recognized for all deductible temporary differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.
Share Capital	2.16. Share Capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Financial Assets	2.17. Financial Assets The financial assets consist mainly of trade receivables and other current assets (deposits) as well as the Company’s option to settle the earnout obligation to Exact Sciences in cash or through the issuance of additional shares of the Company (refer to Note 3 for additional details on the Company’s earnout obligation to Exact Sciences). Trade receivables and other current assets (deposits) Classification and measurement on initial recognition The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Company’s business model for managing them. The company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. For both trade receivables that do not contain a significant financing component, and trade receivables for which the collection is expected in less than one year, the Company has applied the simplified approach to providing for expected credit losses (ECL) prescribed by IFRS 9, which requires the use of the lifetime expected loss provision for all trade receivables. Trade receivables do not carry any interest and are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less provision for impairment based on expected credit losses, where applicable. Subsequent measurement After initial recognition, trade receivables and some other current assets as listed in Note 14 are measured at amortized cost using the effective interest method, less provision for impairment based on expected credit losses. Option to settle the earnout obligation to Exact Sciences in cash or through the issuance of additional shares of the Company Classification and measurement on initial recognition At the option of MDxHealth, the earnout amounts to Exact Sciences can be settled in cash or through the issuance of additional shares of the Company (valued in function of a volume weighted average trading price of the Company's shares at the end of the relevant earnout period) to Exact Sciences, provided that the aggregate number of shares held by Exact Sciences shall not exceed more than 7.5% (increased from 5% in the initial agreement) of the outstanding shares of MDxHealth. This option is considered as an embedded derivative of the host financial (earnout) liability and not closely related to the host financial liability and is recognized at fair value through the statement of profit or loss at each closing date using the Monte Carlo valuation model, as further detailed in Note 3.
Financial Liabilities	2.18. Financial Liabilities The financial liabilities consist mainly of loans and borrowings, lease liabilities, trade and other payables and other financial liabilities that include derivative financial liabilities and contingent consideration related to business combinations. Measurement on initial recognition At initial recognition, financial liabilities are measured at fair value less transaction costs unless the financial liability is carried at fair value through the statement of profit or loss, in which case the transaction costs are immediately recognized in the statement of profit or loss. The best estimate of the fair value at initial recognition is usually the transaction price, represented by the fair value of the consideration given or received in exchange for the financial instrument. Any difference between the fair value estimated by the entity and the transaction price (“day one gain or loss”) is recognized: ● in the statement of profit or loss if the estimate is evidenced by a quoted price in an active market; and ● deferred as an adjustment to the carrying amount of the financial instrument in all other cases. The fair value of the contingent consideration payable at the date of acquisition is computed as the sum of the probability-weighted fair values of the purchase prices, as follows: ● GPS: ● NovioGendix The fair value of the derivative financial liabilities is determined as follows: ● Exact Sciences 5-Year Warrants: ● Innovatus Subsequent measurement After initial recognition, loans and borrowings, lease liabilities, trade and other payables, are measured at amortized cost using the effective interest method. Contingent considerations and derivative financial liabilities are measured at fair value and are reviewed at each reporting period, with any changes in fair value recorded in the statement of profit or loss in either operating results (e.g., for changes in internal forecasts and projections) or financial results (e.g., for changes in net present value), depending on the nature of the driver of the fair value adjustment.
Retirement benefit plans and employee savings plans	2.19. Retirement benefit plans and employee savings plans Payments to defined contribution employee savings plans are charged as an expense as they fall due. The Company does not offer nor operate any material defined benefit plans for its employees.
Share-based compensation plans for personnel, directors and business associates	2.20. Share-based compensation plans for personnel, directors and business associates The Company grants stock options in accordance with several share-based compensation plans in consideration for services performed by personnel, directors and business associates. The cost of the services rendered is measured at the fair value of the granted options and recognized as an expense in the statement of profit or loss. The corresponding credit is recorded directly into equity. The estimate of the number of options which will ultimately vest is revised at each reporting date. The change in estimate is recorded as an expense with a corresponding correction in equity. The received amount, less directly attributable transaction costs, will be recorded as share capital and share premium when the options are exercised.

Business Combination (Tables)

Business Combination (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of Contingent Liabilities in Business Combination Text Block [Abstract]
Schedule of Acquisition Consideration	The acquisition consideration was comprised of (in thousands of $): Cash 25,000 Stock 5,000 GPS Contingent consideration 50,483 Total acquisition consideration 80,483
Schedule of Fair Value of the Identifiable Assets	The fair value of the identifiable assets at the date of acquisition were: Thousands of $ Carrying Fair Fair Intangible assets IP / Brand - 36,550 36,550 Intangible assets Customer relationships - 8,007 8,007 Total identified assets - 44,557 44,557 Goodwill - 35,926 35,926 Acquisition price - - 80,483

Revenue and Cost of Sales (Tabl

Revenue and Cost of Sales (Tables)	12 Months Ended
	Dec. 31, 2023
Revenue and Cost of Sales [Abstract]
Schedule of Revenue	Thousands of $ 2023 2022 2021 Services 69,965 36,965 21,937 Royalties and other revenues 228 89 302 Total revenue 70,193 37,054 22,239
Schedule of Revenue from External Customers Broken Down by Location	The amount of its revenue from external customers broken down by location is shown in the table below: Thousands of $ 2023 2022 2021 United States of America 69,708 36,768 21,785 Europe 476 277 441 Rest of the world 9 9 13 Total segment revenue 70,193 37,054 22,239
Schedule of Cost of Sales	Thousands of $ 2023 2022 2021 Cost of sales 26,264 17,835 11,675 Total cost sales 26,264 17,835 11,675

Nature of Expenses (Tables)

Nature of Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Nature of Expenses [Abstract]
Schedule of Research and Development Expenses	Research and development expenses Thousands of $ Notes 2023 2022 2021 Personnel costs 6 3,693 2,453 1,949 Depreciation 12 428 212 276 Impairment 11 - 44 - Lab consumables 639 713 793 Patent expenses 83 430 577 External collaborator fees 199 783 1,020 Clinical validation 765 584 842 Other expenses 569 278 132 Total research and development expenses 6,376 5,497 5,589
Schedule of Selling and Marketing Expenses	Selling and Marketing expenses Thousands of $ Notes 2023 2022 2021 Personnel costs 6 27,952 19,070 13,402 Depreciation 12 888 750 504 Professional fees 710 1,259 523 Marketing expenses 5,075 2,843 1,761 Travel expenses 1,061 789 340 Offices & facilities expenses 459 356 436 Other expenses 770 637 486 Total selling and marketing expenses 36,915 25,704 17,452
Schedule of General and Administrative Expenses	General and administrative expenses Thousands of $ Notes 2023 2022 2021 Personnel costs 6 10,184 8,995 9,009 Depreciation 12 737 734 646 Professional fees 6,706 7,762 1,678 Public company expenses 2,701 4,025 1,108 Travel expenses 130 79 9 Offices & facilities expenses 1,266 1,142 845 Royalties to third parties 28 47 152 Board fees 366 394 314 Other expenses 892 130 154 Total general and administrative expenses 23,010 23,308 13,915
Schedule of Amortization of Intangible Assets	Amortization of intangible assets Thousands of $ 2023 2022 2021 Research and development 3,157 2,060 1,084 Selling and marketing 1,315 878 292 General and administrative 22 231 234 Total amortization of intangible assets 4,494 3,169 1,610

Personnel Costs (Tables)

Personnel Costs (Tables)	12 Months Ended
	Dec. 31, 2023
Personnel Costs [Abstract]
Schedule of Personnel Costs	Thousands of $ 2023 2022 2021 The number of employees at the end of the year was: Laboratory operations 79 67 42 R&D staff 31 19 14 S&M staff 106 101 71 G&A staff 84 71 64 Total number of employees 300 258 191 Their aggregate remuneration comprised: Wages and salaries 31,388 23,066 18,150 Social security costs 2,682 1,684 1,257 Pension costs 1,153 724 594 Health insurance expenses 5,058 3,167 2,324 Share-based compensation 665 867 1,222 Other costs 883 1,010 813 Total personnel costs 41,829 30,518 24,360

Other Operating (Expense) Inc_2

Other Operating (Expense) Income, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Other Operating (Expense) Income, Net [Abstract]
Schedule of Other Operating (Expense) Income, Net	Thousands of $ 2023 2022 2021 Grant subsidies – The Netherlands 62 5 382 Grant subsidies – USA - - 659 Fair value adjustments (588 ) 515 176 Other operating income 65 39 53 Other operating expenses - - (109 ) Total other operating (expense) income, net (461 ) 559 1,161

Financial Income and Expense (T

Financial Income and Expense (Tables)	12 Months Ended
	Dec. 31, 2023
Financial Income and Expense [Abstract]
Schedule of Financial Income and Expense, Net	Financial Income Thousands of $ 2023 2022 2021 Interest income 1,088 125 11 Innovatus derivative instrument 719 116 - Fair value of option to pay GPS earnout in shares 763 - - Financial income, net 2,570 241 11 Financial Expenses Thousands of $ 2023 2022 2021 Interest on Kreos loan - (660 ) (1,566 ) Interest on Innovatus loan (5,232 ) (1,615 ) - Interest on other loans and leases (350 ) (361 ) (309 ) Kreos settlement - (1,047 ) - Fair value adjustments GPS contingent consideration (9,105 ) (2,398 ) - NovioGendix contingent consideration (49 ) (197 ) (194 ) Kreos derivative instrument (135 ) - (96 ) Exact Sciences 5-year warrants (2,153 ) - - Other financial loss (190 ) (107 ) (7 ) GPS amendment: additional consideration payment in cash (250 ) - - GPS amendment: additional consideration payment in shares (878 ) - - Financial expenses, net (18,342 ) (6,385 ) (2,172 )

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax [Abstract]
Schedule of Tax Reconciliation and the Impact of the Unrecognized Deferred Tax Assets	The tax reconciliation and the impact of the unrecognized deferred tax assets is as follows: Thousands of $ Income Statement For the years ended December 31 2023 2022 2021 Loss for the year (43,100 ) (44,044 ) (29,002 ) Income tax expense (1 ) 0 0 Loss before income tax (43,099 ) (44,044 ) (29,002 ) Tax using the MDxHealth’s domestic tax rate 10,775 11,011 7,251 Effect of unused tax losses not recognized as deferred tax assets (10,775 ) (11,011 ) (7,251 )

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill [Abstract]
Schedule of Carrying Value of Goodwill	The changes in the carrying value of Goodwill at December 31, 2023, 2022, and 2021 can be presented as follows: Thousands of $ Goodwill At January 1, 2022 - Additions through business combination 35,926 Impairment - Currency translation adjustments - Carrying value at December 31, 2022 35,926 At January 1, 2023 35,926 Additions through business combination - Impairment - Currency translation adjustments - Carrying value at December 31, 2023 35,926
Schedule of Discount Rate	The assumptions used are as follows: Assumptions used December 31, Discount rate (post-tax) 12.83 % Terminal growth rate 2 %

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Intangible Assets [Abstract]
Schedule of Intangible Assets	Thousands of $ Patents Internally Externally Customers TOTAL Gross value At January 1, 2022 5,134 9,323 4,500 - 18,957 Additions 1,049 325 1,374 Additions through business combination (Note 3) 36,550 8,007 44,557 Currency translation adjustments Gross value at December 31, 2022 5,134 10,372 41,375 8,007 64,888 Accumulated amortization and impairment (4,910 ) (7,736 ) (2,863 ) - (15,509 ) Additions (224 ) (942 ) (1,490 ) (513 ) (3,169 ) Impairment (44 ) (44 ) Accumulated amortization and impairment at December 31, 2022 (5,134 ) (8,722 ) (4,353 ) (513 ) (18,722 ) Net value at December 31, 2022 0 1,650 37,022 7,494 46,166 Gross value At January 1, 2023 5,134 10,372 41,375 8,007 64,888 Additions 2,660 2,660 Gross value at December 31, 2023 5,134 13,032 41,375 8,007 67,548 Accumulated amortization and impairment (5,134 ) (8,722 ) (4,353 ) (513 ) (18,722 ) Additions (343 ) (2,919 ) (1,232 ) (4,494 ) Currency translation adjustments 5 5 Accumulated amortization and impairment at December 31, 2023 (5,134 ) (9,060 ) (7,272 ) (1,745 ) (23,211 ) Net value at December 31, 2023 0 3,972 34,103 6,262 44,337

Property, Plant and Equipment_2

Property, Plant and Equipment and Right of-Use Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of property, plant and equipment [text block] [Abstract]
Schedule of Additional Right of Use Assets	Thousands of $ Laboratory equipment Furniture IT Leasehold TOTAL Gross value At January 1, 2022 5,285 569 673 1,341 7,868 Additions 1,695 104 277 713 2,789 Disposals (258 ) (258 ) Exchange rate difference arising 88 (4 ) (5 ) 4 83 Gross value at December 31, 2022 7,068 669 687 2,058 10,482 Accumulated depreciation At January 1, 2022 (4,817 ) (315 ) (459 ) (606 ) (6,197 ) Additions (276 ) (72 ) (159 ) (166 ) (673 ) Disposals 258 258 Exchange rate difference arising (91 ) 7 3 2 (79 ) Accumulated depreciation at December 31, 2022 (5,184 ) (380 ) (357 ) (770 ) (6,691 ) Net value at December 31, 2022 1,884 289 330 1,288 3,791 Gross value At January 1, 2023 7,068 669 687 2,058 10,482 Additions 1,312 200 303 741 2,556 Disposals - - (111 ) - (111 ) Transfer from leases 498 - - - 498 Exchange rate difference arising (62 ) (2 ) (2 ) (2 ) (68 ) Gross value at December 31, 2023 8,816 867 877 2,797 13,357 Accumulated depreciation At January 1, 2023 (5,184 ) (380 ) (357 ) (770 ) (6,691 ) Additions (558 ) (102 ) (228 ) (500 ) (1,388 ) Disposals - - 108 - 108 Transfer from leases (498 ) - - - (498 ) Exchange rate difference arising 62 2 2 2 68 Accumulated depreciation at December 31, 2023 (6,178 ) (480 ) (475 ) (1,268 ) (8,401 ) Net value at December 31, 2023` 2,638 387 402 1,529 4,956
Schedule of Right-of-Use Assets	Thousands of $ buildings vehicles Equipment TOTAL Gross value Balance at January 1, 2022 5,130 218 897 6,245 Additions 1,435 58 334 1,827 Exchange rate differences (1 ) (1 ) Gross value at December 31, 2022 6,565 276 1,230 8,071 Accumulated depreciation Balance at January 1, 2022 (1,929 ) (129 ) (840 ) (2,898 ) Additions (945 ) (51 ) (71 ) (1,067 ) Exchange rate difference - - (3 ) (3 ) Accumulated depreciation on December 31, 2022 (2,874 ) (180 ) (914 ) (3,968 ) Net value at December 31, 2022 3,691 96 316 4,103 Gross value Balance at January 1, 2023 6,565 276 1,230 8,071 Additions 726 - 1,562 2,288 Disposals - (114 ) (325 ) (439 ) Transfer to tangible assets - - (498 ) (498 ) Gross value on December 31, 2023 7,291 162 1,970 9,423 Accumulated depreciation Balance at January 1, 2023 (2,874 ) (180 ) (914 ) (3,968 ) Additions (1,079 ) (34 ) (252 ) (1,365 ) Disposals - 70 325 395 Transfer to tangible assets - - 498 498 Exchange rate differences 7 - - 7 Accumulated depreciation on December 31, 2023 (3,946 ) (144 ) (343 ) (4,433 ) Net value at December 31, 2023 3,345 18 1,626 4,989
Schedule of Amounts Related to Leases are Recognized in Profit & Loss	The following amounts related to leases are recognized in the statement of profit or loss: Thousands of $ 2023 2022 2021 Depreciation expense 1,187 1,067 905 Interest expense on lease liabilities 284 314 229

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
Schedule of Inventories	Thousands of $ 2023 2022 Raw materials and consumables 2,779 2,327 Total Inventories $ 2,779 $ 2,327

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2023
Trade and other receivables [Abstract]
Schedule of Trade receivables	Thousands of $ 2023 2022 Trade receivables 11,088 9,357 Total trade receivables 11,088 9,357
Schedule of Total Accounts Receivable Balance	Considering the Company’s revenue recognition methodology further described in Note 2.7, total accounts receivable balance could be presented in relation with the claim date of each sample as follows: A/R by claim date Months Thousands of $ 1-3 4-6 7-12 Not due Total Confirm mdx 2,225 876 639 - 3,740 Select mdx 291 101 128 (8 ) 512 Resolve mdx 1,278 629 401 - 2,308 GPS 3,237 783 508 - 4,528 Total Trade Receivables 7,031 2,389 1,676 (8 ) 11,088 A/R by claim date Months Thousands of $ 1-3 4-6 7-12 Not due Total Confirm mdx 1,865 821 765 - 3,451 Select mdx 134 101 78 25 338 Resolve mdx 1,966 458 158 - 2,582 GPS 1,907 895 - - 2,802 Other 163 - - 21 184 Total Trade Receivables 6,035 2,275 1,001 46 9,357
Schedule of Prepaid Expenses and Other Current Assets	Thousands of $ 2023 2022 Prepayments 1,585 1,710 Deposits 110 101 Recoverable VAT 183 97 Grants to be received - 54 Other 36 - Total prepaid expenses and other current assets $ 1,914 $ 1,962

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	Thousands of $ 2023 2022 Cash and cash equivalents 22,380 15,503 Total cash and cash equivalents $ 22,380 $ 15,503

Loans, Borrowings, Leases obl_2

Loans, Borrowings, Leases obligations and Other Financial Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Abstract]
Schedule of Loans, Borrowings & Lease Liabilities	Loans, Borrowings & Lease liabilities Thousands of $ 2023 2022 Non-current loans and borrowings Loans 35,564 34,914 Lease liabilities (*) 3,578 3,091 Total non-current loans and borrowings $ 39,142 $ 38,005 Thousands of $ 2023 2022 Current loans and borrowings Loans 643 616 Lease liabilities (*) 1,480 1,172 Total current loans and borrowings $ 2,123 $ 1,788 (*) the evolution in the right of use assets is further disclosed in Note 12.
Schedule of Maturity of Loans And Borrowings	Maturity of loans and borrowings are as follows at the balance sheet date: Thousands of $ 2023 2022 Loans Within one year 643 630 Years two to five 35,564 38,439 Leases Within one year 1,900 1,551 Years two to five 3,955 2,330
Schedule of Other Financial Liabilities	Thousands of $ 2023 2022 Other financial liabilities Other non-current financial liabilities 63,259 53,537 Other current financial liabilities 2,895 2,327 Total other financial liabilities 66,154 55,864
Schedule of Cash and Non-Cash Movements of Loans and Borrowings	A reconciliation of cash and non-cash movements of loans and borrowings, lease liabilities and other financial liabilities is presented below: Thousands of $ Loans and Other financial For the years ended December 31 2023 2022 2023 2022 Beginning balance 35,530 12,092 55,864 2,427 Cash movements Loans and borrowings repaid 1 (637 ) (10,805 ) (1,022 ) Loans and borrowings received (Innovatus) 34,291 Non-cash movements GPS Contingent Consideration 50,483 Recognition of Innovatus embedded derivative convertible call option (1,026 ) 1,026 Kreos effective interest rate adjustment and extinguishment costs 1,328 Innovatus - effective interest rate adjustment 1,314 660 Foreign exchange rate impact / other (1,010 ) (4 ) (35 ) Fair value changes through profit and loss 11,316 1,963 Ending balance $ 36,207 $ 35,530 $ 66,154 $ 55,864 1 The amount includes interest paid on loans and borrowings
Schedule of Fair Value Adjustments Recognized	Fair value adjustments recognized during 2023 for other financial liabilities relate to: Thousands of $ 2023 Increase of NovioGendix contingent consideration 16 Increase of Kreos derivative financial instrument (“initial drawdown fee”) 135 Increase of GPS contingent consideration 9,730 Decrease of Innovatus embedded derivative convertible call option (718 ) Exact Sciences 5-Year Warrants 2,153 Total fair value adjustment 11,316
Schedule of Lease Liabilities	Thousands of $ Lease liabilities For the years ended December 31 2023 2022 Opening balance 4,263 3,464 Cash movements Repayment of lease liabilities (1,610 ) (1,358 ) Non-cash movements Interest accretion 355 314 New leases 2,050 1,843 Closing balance 5,058 4,263

Contractual Obligations (Tables

Contractual Obligations (Tables)	12 Months Ended
	Dec. 31, 2023
Contractual Obligations [Abstract]
Schedule of Contractual Obligations	Thousands of $ 2023 2022 Outstanding commitments for future minimum rent payments, which fall due as follows: Less than one year 90 156 Years 2-5 53 60 Total contractual obligations 143 216

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Dec. 31, 2023
Trade and Other Payables [Abstract]
Schedule of Trade Accounts Payable	Thousands of $ 2023 2022 Trade accounts payable 4,889 5,061 Accruals for invoices to be received 3,922 5,117 Total trade accounts payable 8,811 10,178
Schedule of Other Current Liabilities	Thousands of $ 2023 2022 Payroll 5,222 3,932 Other accruals 472 53 Total other current liabilities 5,694 3,985

Financial Instruments and Fai_2

Financial Instruments and Fair Value (Tables)	12 Months Ended
	Dec. 31, 2023
Financial Instruments and Fair Value [Abstract]
Schedule of Assets and Liabilities are Considered to have Carrying Amounts	All financial assets and liabilities are considered to have carrying amounts that do not materially differ from their fair value. Thousands of $ 2023 2022 Fair value hierarchy Assets At amortized cost Trade receivables 11,088 9,357 Cash and cash equivalents 22,380 15,503 Total financial assets 33,468 24,860 Liabilities At fair value: Other financial liabilities GPS contingent consideration 62,611 52,881 Level 3 Exact Sciences 5-Year Warrants 2,153 - Level 3 NovioGendix contingent consideration 1,198 1,182 Level 3 Innovatus derivative instrument 192 910 Level 3 Kreos derivative instrument - 891 Level 3 Subtotal financial liabilities at fair value 66,154 55,864 At amortized cost: Loans and borrowings 36,207 35,530 Level 2 Lease liabilities 5,058 4,263 Trade payables 8,811 10,178 Subtotal financial liabilities at amortized cost 50,076 49,971 Total financial liabilities 116,230 105,835
Schedule of Reconciliation of Cash and Non-Cash Movements	A reconciliation of cash and non-cash movements of level 3 financial liabilities is presented below: Thousands of $ Financial Derivative Instruments (Kreos and Innovatus) Contingent Consideration (NovioGendix and GPS) For the years ended December 31 2023 2022 2023 2022 Beginning balance 1,801 810 54,063 1,617 Cash movements Loans and borrowings repaid (1,022 ) (250 ) Non-cash movements GPS contingent consideration 50,483 Exact Sciences 5-year warrant 2,153 Innovatus embedded derivative convertible call option 1,026 Effective interest rate adjustment (4 ) Foreign exchange rate impact / other movements (35 ) Fair value changes through profit and loss (719 ) 9,996 1,963 Change to level 1 fair value hierarchy 136 Ending balance 192 1,801 65,962 54,063

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Loss Per Share [Abstract]
Schedule of Weighted Average Number of Shares Outstanding	Years ended December 31 2023 2022 2021 Loss for the year, in thousands of $ (43,100 ) (44,044 ) (29,002 ) Basic and diluted loss per share, in $ (1.66 ) (2.78 ) (2.38 ) Weighted average number of shares 2023 2022 2021 Weighted average number of shares for basic and diluted loss per share 25,910,696 15,865,817 12,193,574

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
	Dec. 31, 2023
Financial Risk Management [Abstract]
Schedule of Maturity Profiles of Financial Assets and Liabilities	For the years ended December 31, 2023 Thousands of $ Less than 1-2 3-5 Total Carrying Non derivatives Trade payables 8,811 - - 8,811 8,811 Loans 650 324 37,442 38,416 36,207 Lease liabilities 1,900 1,766 2,189 5,855 5,058 Total 11,361 2,090 39,631 53,082 50,076 For the years ended December 31, 2022 Thousands of $ Less than 1-2 3-5 Total Carrying Non derivatives Trade payables 10,178 - - 10,178 10,178 Loans 630 630 37,809 39,069 35,530 Lease liabilities 1,324 915 2,179 4,418 4,263 Total 12,132 1,545 39,988 53,665 49,971

Share Capital and Reserves (Tab

Share Capital and Reserves (Tables)	12 Months Ended
	Dec. 31, 2023
Share Capital and Reserves [Abstract ]
Schedule of Share Capital Number of Shares	At December 31, 2023 and 2022, the Company’s share capital was represented by the following number of shares, adjusted for the 1-for-10 reverse stock split that took place in November 2023. Only one class of shares (common shares) exists and they have no par value. For the Years ended December 31 2023 2022 Common shares 27,288,093 16,288,093 Total outstanding shares 27,288,093 16,288,093
Schedule of Share Capital and Issuance Premium Increased	Thousands of $ Thousands of € For the Years ended December 31 Share Issuance Share Issuance As of January 1, 2022 128,454 153,177 106,099 126,481 August 2022 – Issuance of 691,171 shares (*) 5,000 4,876 As of December 31, 2022 133,454 153,177 110,975 126,481 March 2023 – Issuance of 10,750,000 shares (*) 39,599 36,612 August 2023 – Issuance of 250,000 shares 878 812 As of December 31, 2023 173,931 153,177 148,398 126,481 (*) net of expenses
Schedule of Capital Stock and the Issuance Premium	The capital stock and the issuance premium amounted to the following: Thousands of $ Thousands of € For the Years ended December 31 2023 2022 2023 2022 Share Capital as per statutory accounts 192,297 148,419 164,303 123,539 Capital increase costs (18,366 ) (14,965 ) (15,905 ) (12,564 ) Share capital under IFRS 173,931 133,454 148,398 110,975 Issuance premium 153,177 153,177 126,481 126,481 Share capital and issuance premium 327,108 286,631 274,879 237,456

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payments [Abstract]
Schedule of Outstanding Warrants	Outstanding warrants 2023 2022 Warrants created 2,060,000 1,731,080 Warrants available for grant (208,250 ) (163,750 ) Warrants granted 1,851,750 1,567,330 Warrants terminated or lapsed (213,977 ) (283,840 ) Warrants exercised - (57,712 ) Total outstanding at December 31 1,637,773 1,225,778
Schedule of Potential Shares from Outstanding Warrants	Number of potential shares from outstanding warrants 2023 2022 As of January 1 1,225,778 891,763 Number of warrants cancelled/forfeited during the year (43,505 ) (59,035 ) Number of warrants granted during the year 455,500 393,050 As of December 31 1,637,773 1,225,778
Schedule of Share-Based Compensation Expense Recognized in the Statement of Comprehensive Income	The share-based compensation expense recognized in the consolidated statement of profit or loss is given below as is the cumulated amount per the consolidated statement of financial position: Thousands of $ 2023 2022 2021 Share-based compensation in consolidated statement of profit or loss 665 867 1,222 Cumulated Share-based compensation in equity 12,139 11,474 10,607
Schedule of Outstanding Warrants and their Exercise Price	The table below presents the outstanding warrants and their exercise price at the end of each accounting year covered by the financial statements: Warrants Weighted Potential Weighted Granted in 2022 393,050 6.76 393,050 6.76 Outstanding at December 31, 2022 1,225,778 12.34 1,225,778 12.34 Granted in 2023 455,500 2.91 455,500 2.91 Outstanding at December 31, 2023 1,637,773 9.64 1,637,773 9.64 Exercisable at December 31, 2023 759,841 14.07 759,841 14.07
Schedule of the Outstanding Potential Shares from Warrants	The following table provides an overview of the outstanding potential shares from warrants per personnel category at December 31, 2023 and 2022: Category 2023 2022 Executive Director 489,375 395,000 Non-Executive Directors 25,650 24,800 Management team (excluding the Executive Director) 517,912 408,300 Other employees, consultants, and former service providers 604,836 397,678 Total outstanding at December 31 1,637,773 1,225,778
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology	The fair value of each warrant is estimated on the date of grant using the Black-Scholes methodology with the following assumptions: Number of warrants granted Expected Expected Risk-free Expected duration (months) Dates to Belgian benef. to other benef. Exercise price (€) dividend Yield stock price volatility interest rate to Belgian benef. to other benef. 23-Jun-14 1,200 1,200 € 41.30 - 48.12 % 1.78 % 75.32 63.29 10-Dec-14 - 17,500 € 40.10 - 46.93 % 1.01 % 69.73 57.70 09-Feb-15 6,000 9,500 € 44.90 - 46.75 % 0.62 % 79.73 61.71 01-Apr-15 - 300 € 50.20 - 47.42 % 0.40 % 72.03 54.02 01-May-15 - 2,000 € 50.50 - 46.59 % 0.62 % 71.05 53.03 29-May-15 2,000 3,000 € 49.10 - 46.52 % 0.81 % 64.14 52.11 01-Jun-15 - 600 € 49.00 - 46.58 % 0.81 % 70.03 52.01 01-Jul-15 - 400 € 46.20 - 47.02 % 1.27 % 69.04 51.02 01-Aug-15 - 400 € 46.40 - 46.54 % 0.98 % 68.02 50.00 01-Sep-15 - 1,000 € 42.40 - 49.31 % 1.15 % 73.02 48.99 01-Oct-15 - 8,300 € 42.00 - 48.99 % 0.90 % 72.03 54.02 01-Nov-15 - 400 € 38.10 - 50.88 % 0.92 % 71.01 53.00 01-Dec-15 - 1,800 € 38.90 - 51.18 % 0.85 % 70.03 52.01 01-Jan-16 - 400 € 37.90 - 51.12 % 1.06 % 69.01 50.99 04-Feb-16 - 1,000 € 41.30 - 51.18 % 0.85 % 67.89 49.87 04-Feb-16 5,000 13,400 € 37.80 - 52.49 % 0.72 % 67.89 49.87 22-Apr-16 - 5,200 € 36.20 - 53.40 % 0.58 % 65.33 53.33 27-May-16 3,000 4,000 € 41.30 - 51.85 % 0.54 % 64.11 52.11 01-Jun-16 - 200 € 34.30 - 53.73 % 0.49 % 64.01 52.01 01-Aug-16 - 400 € 36.20 - 53.51 % 0.16 % 62.01 50.01 21-Oct-16 - 2,000 € 44.40 - 54.19 % 0.28 % 59.34 47.34 22-Jan-16 - 2,000 € 38.30 - 52.81 % 0.86 % 68.32 56.32 01-Dec-16 - 2,200 € 46.50 - 54.16 % 0.75 % 57.99 39.98 01-Jan-17 - 1,900 € 45.60 - 53.84 % 0.73 % 56.98 50.96 01-Mar-17 - 9,500 € 52.60 - 52.62 % 0.68 % 55.04 49.02 01-Apr-17 - 1,800 € 54.10 - 51.80 % 0.81 % 54.02 48.00 11-Apr-17 2,000 20,000 € 53.50 - 51.83 % 0.72 % 65.68 47.67 1-Jun-17 - 200 € 50.10 - 51.86 % 0.59 % 52.01 52.01 1-Jul-17 - 2,200 € 49.60 - 50.94 % 0.77 % 63.02 44.98 29-Jul-17 - 800 € 47.20 - 50.95 % 0.87 % 50.10 44.05 01-Sep-17 - 3,400 € 49.20 - 48.08 % 0.71 % 60.99 42.97 01-Oct-17 - 7,000 € 48.00 - 47.32 % 0.76 % 53.98 41.95 02-Nov-17 - 9,900 € 46.10 - 45.23 % 0.66 % 52.93 40.90 1-Dec-17 - 600 € 39.20 - 46.50 % 0.56 % 51.98 39.98 20-Jun-17 3,000 3,000 € 49.70 - 51.57 % 0.59 % 81.40 63.39 27-Jun-17 25,000 € 49.80 - 51.04 % 0.66 % 81.17 63.16 01-Apr-18 - 4,200 € 37.70 - 46.08 % 0.76 % 54.02 42.02 01-May-18 - 800 € 36.40 - 46.27 % 0.82 % 53.03 41.03 01-Jun-18 5,000 3,200 € 49.70 - 46.15 % 0.77 % 52.01 40.01 01-Aug-18 7,000 € 37.40 - 44.09 % 0.79 % 62.00 55.96 05-Dec-18 - 2,000 € 17.30 - 57.56 % 0.79 % 45.86 33.86 24-Jan-19 - 19,100 € 16.40 - 67.56 % 0.77 % 62.24 50.20 16-May-19 - 150,800 € 14.90 - 75.78 % 0.38 % 58.55 46.52 01-Nov-19 - 800 € 10.10 - 82.15 % 0.00 % 64.99 46.98 01-Dec-19 - 1,200 € 10.20 - 81.95 % 0.00 % 64.01 45.99 Number of warrants granted Expected Expected Risk-free Expected duration (months) Dates to Belgian benef. to other benef. Exercise price (€) dividend Yield stock price volatility interest rate to Belgian benef. to other benef. 01-Feb-20 - 200 € 9.80 - 80.26 % 0.00 % 61.97 49.67 01-Jun-20 - 600 € 8.50 - 86.64 % 0.00 % 57.99 45.99 01-Oct-20 - 200 € 8.00 - 85.20 % 0.00 % 53.95 35.97 15-Jul-20 - 22,500 € 8.00 - 85.89 % 0.00 % 56.51 38.53 01-Jul-19 6,000 2,000 € 12.80 - 78.70 % 0.07 % 69.01 51.02 24-Jul-19 - 98,000 € 12.40 - 78.64 % 0.00 % 68.25 50.27 15-Jul-20 - 159,800 € 8.00 - 85.89 % 0.00 % 56.52 38.53 30-Jul-20 2,000 - € 12.80 - 87.02 % 0.00 % 56.02 38.04 01-Oct-20 - 1,000 € 12.80 - 85.20 % 0.00 % 53.95 35.97 01-Mar-21 - 200 € 10.80 - 65.06 % 0.00 % 48.99 31.00 03-May-21 - 800 € 11.60 - 64.59 % 0.01 % 46.92 28.93 01-Jun-21 - 400 € 11.80 - 65.82 % 0.01 % 45.96 27.98 27-Jul-21 - 3,000 € 13.60 - 63.36 % 0.00 % 44.12 26.14 27-Jul-21 - 20,250 € 13.60 - 63.36 % 0.00 % 44.12 26.14 24-Nov-21 - 4,000 € 10.50 - 60.78 % 0.14 % 49.25 37.25 03-Jul-21 - 257,000 € 13.75 - 63.10 % 0.04 % 44.91 26.93 07-Jul-21 - 60,000 € 13.85 - 63.11 % 0.00 % 44.78 26.79 06-May-22 - 500 € 7.50 - 53.16 % 1.64 % 58.85 52.87 04-Aug-22 - 3,800 € 7.97 - 55.63 % 1.41 % 55.89 49.91 03-Aug-22 - 42,500 € 6.84 - 57.05 % 1.50 % 67.96 55.92 03-Aug-22 - 312,500 € 6.84 - 57.05 % 1.50 % 73.97 61.94 04-Aug-22 - 1,000 € 7.97 - 55.63 % 1.41 % 73.94 61.91 01-Oct-22 - 31,250 € 7.40 - 57.26 % 2.77 % 72.03 60.00 01-Dec-22 - 1,500 € 7.40 - 58.30 % 2.40 % 69.67 63.65 25-Mar-23 - 30,500 € 3.20 - 71.42 % 2.75 % 72.26 60.26 3-May-23 - 11,000 € 3.30 - 73.64 % 2.92 % 77.01 65.01 27-Apr-23 - 25,000 € 3.20 - 73.60 % 3.10 % 77.21 65.21 22-Jun-23 - 1,000 € 3.60 - 72.54 % 3.11 % 81.34 69.34 30-Jun-23 - 255,000 € 2.90 - 72.62 % 3.09 % 81.07 69.07 04-Jul-23 - 1,000 € 3.00 - 72.60 % 3.14 % 80.94 68.94 05-Sep-23 - 500 € 3.00 - 73.75 % 3.23 % 72.90 60.90 18-Sep-23 - 85,000 € 2.78 - 73.70 % 3.34 % 72.48 60.48 18-Sep-23 - 37,500 € 2.78 - 73.70 % 3.34 % 78.44 66.44 09-Nov-23 - 1,500 € 3.09 - 77.60 % 3.32 % 52.73 40.70 09-Nov-23 - 7,500 € 3.09 - 77.60 % 3.32 % 76.75 64.75

Related Parties (Tables)

Related Parties (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of related party [text block] [Abstract]
Schedule of Combined Remuneration Package, Including Employer Taxes	Their combined remuneration package, including employer taxes, amounted to the following: Thousands of $ except per personnel, warrants & share amounts For The Years ended December 31 2023 2022 2021 Number of management members and Executive Directors 4 4 4 Short-term employee benefits 1,967 1,550 1,545 Post-employment benefits 48 54 52 Other employment costs 216 219 207 Total benefits 2,231 1,822 1,804 IFRS share-based compensation expense 909 863 982 Number of warrants offered 220,000 220,000 220,000 Cumulative outstanding warrants 1,007,287 808,800 588,800 Exercisable warrants 644,283 361,864 128,223
Schedule of Warrants that were Exercised, Granted and Accepted in Aggregate by the Four Members	The following table sets forth the number of warrants that were exercised, granted and accepted in aggregate by the four members of the executive management team: 2023 2022 2021 Number of warrants exercised 0 0 0 Number of new warrants granted and accepted 220,000 220,000 220,000 Annualized IFRS cost for existing warrants $ 909,000 $ 863,000 $ 982,000

Subsidiaries (Tables)

Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2023
Subsidiaries [Abstract]
Schedule of Wholly-Owned Direct Subsidiaries	The Company has the following two wholly-owned direct subsidiaries: MDxHealth Inc. Address 15279 Alton Parkway – Suite 100 – Irvine, CA 92618 Incorporation Date April 14, 2003 MDxHealth B.V. Address Transistorweg 5, 6534 AT Nijmegen, The Netherlands Incorporation Date October 18, 2006 Incorporated into MDxHealth on September 18, 2015

Principal Audit Fees and Serv_2

Principal Audit Fees and Services (Tables)	12 Months Ended
	Dec. 31, 2023
Principal Audit Fees And Services [Abstract]
Schedule of Statutory Auditor Performed Additional Activities	The detail is presented in the table below: in thousands of $ in thousands of € For the years ended December 31 2023 2022 2021 2023 2022 2021 Audit fee for statutory and consolidated financials 408 239 182 378 226 155 Other audit fees - 191 183 - 180 156 Audit related and other services 40 42 17 37 39 14 Total 448 472 382 415 445 325

Status and Principal Activity (

Status and Principal Activity (Details)	Dec. 31, 2023 ft²	Nov. 27, 2023 shares	Nov. 13, 2023 shares	Nov. 04, 2021 shares
Status and Principal Activity [Abstract]
College of American Pathologists (in Square Feet) | ft²	13,448
Ordinary shares | shares		1	1	10

Summary of Material Accountin_2

Summary of Material Accounting Policies (Details)		12 Months Ended
	Aug. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2023 EUR (€) shares	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)
Summary of Material Accounting Policies [Line Items]
Accumulated deficit		$ 331,400,000
Net loss		43,100,000
Net cash used in operating activities		21,500,000
Cash and cash equivalents		$ 22,400,000
Outstanding ownership percentage		7.50%	7.50%
Financial asset		$ 800,000
Acquired shares (in Shares) | shares	1,000,000	1,000,000	1,000,000
Excerise price per share (in Dollars per share) | $ / shares	$ 5.265	$ 5.265
Estimated amount		$ 9,700,000
Amendment fee in cash	$ 250,000
Percentage of shares outstanding	50%
Exceed percentage	5%	5%	5%
Fair value adjustment expense		$ 9,100,000
Purchase agreement		$ 600,000
Discount rate		12.83%
Interest rate		12.83%
Estimated amount		$ 1,200,000
Amount Considered in current		550,000
Estimated value		192,000
Goodwill amount		$ 35,900,000
Impairment term		5 years	5 years
Perpetual growth rate		2%	2%
Interest rate		10 years	10 years
Assets and liabilities		$ 1.105	€ 1	$ 1.066	€ 1
Income and expenses		$ 1.0813	€ 1	$ 1.053	€ 1
Customers		6 years 6 months	6 years 6 months
Capitalized development costs		5 years	5 years
Trade receivables		1 year	1 year
Outstanding aggregate principal amount		15%	15%
IT hardware and software [Member]
Summary of Material Accounting Policies [Line Items]
Useful lives		3 years	3 years
Furniture [Member]
Summary of Material Accounting Policies [Line Items]
Useful lives		5 years	5 years
Vehicles [Member]
Summary of Material Accounting Policies [Line Items]
Useful lives		5 years	5 years
Level 3 of fair value hierarchy [member]
Summary of Material Accounting Policies [Line Items]
Estimated amount		$ 2,200,000
GPS asset purchase agreement [Member]
Summary of Material Accounting Policies [Line Items]
Estimated amount		$ 62,600,000
Initial agreement [Member]
Summary of Material Accounting Policies [Line Items]
Exceed percentage		7.50%	7.50%
Subsequent Event [Member]
Summary of Material Accounting Policies [Line Items]
Public offering	$ 250,000
Subscription period	5 years
Binomial tree valuation model [Member]
Summary of Material Accounting Policies [Line Items]
Acquired shares (in Shares) | shares		1,000,000	1,000,000
Bottom of Range [Member]
Summary of Material Accounting Policies [Line Items]
Aggregate earnout amount	$ 70,000,000
Intellectual property		10 years	10 years
Depreciation periods range		3 years	3 years
Percentage of buildings		10%	10%
Percentage of vehicles		2.50%	2.50%
Percentage of materials		9.75%	9.75%
Top of Range [Member]
Summary of Material Accounting Policies [Line Items]
Aggregate earnout amount	$ 82,500,000
Intellectual property		15 years	15 years
Depreciation periods range		6 years	6 years
Percentage of buildings		12.75%	12.75%
Percentage of vehicles		3.75%	3.75%
Percentage of materials		12%	12%
IT hardware and software [Member]
Summary of Material Accounting Policies [Line Items]
Useful lives		5 years	5 years
Exact Sciences [Member]
Summary of Material Accounting Policies [Line Items]
Exceed percentage	7.50%

Business Combination (Details)

Business Combination (Details) $ / shares in Units, € in Millions		12 Months Ended
	Aug. 23, 2023 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2023 EUR (€) shares	Dec. 31, 2022 USD ($)
Business Combination [Line Items]
Aggregate purchase price		$ 100,000,000
Cash paid		25,000,000
Settlement amount		$ 5,000,000
American depositary shares issued (in Shares) | shares		691,171	691,171
Price per share (in Dollars per share) | $ / shares		$ 7.23
Aggregate earn-out amount		$ 70,000,000
Outstanding shares percentage		5%	5%
Goodwill amount		$ 35,900,000
Business combination resulted in fair values at date of acquisition		$ 44,600,000
Royalty rate		9.56%	9.56%
Useful life		5 years	5 years
Discount rate used for valuation		14.95%	14.95%
Contingent consideration		$ 1,200,000		$ 52,900,000
Total acquisition-related costs				3,700,000
Revenue		70,200,000		37,100,000
Loan amount		$ 35,000,000
Debt facility amount (in Euro) | €			€ 9
Amendment fee	$ 250,000
Company shares (in Shares) | shares	250,000
Shares acquired (in Shares) | shares	1,000,000	1,000,000	1,000,000
Shares issued price per share (in Dollars per share) | $ / shares	$ 5.265
Premium market price percentage	50%
Bottom of Range [Member]
Business Combination [Line Items]
Aggregate earn-out amount	$ 70,000,000
Initial agreement		7.50%
Top of Range [Member]
Business Combination [Line Items]
Aggregate earn-out amount	$ 82,500,000
Initial agreement		5%
IP/Brand [Member]
Business Combination [Line Items]
Useful life		15 years	15 years
Customer relationships [Member]
Business Combination [Line Items]
Useful life		6 years 6 months	6 years 6 months
Business combination [Member]
Business Combination [Line Items]
Aggregate earn-out amount		$ 70,000,000
Revenue		$ 30,900,000		$ 9,300,000

Business Combination (Details)

Business Combination (Details) - Schedule of Acquisition Consideration $ in Thousands	Dec. 31, 2023 USD ($)
Schedule of Acquisition Consideration [Abstract]
Cash	$ 25,000
Stock	5,000
GPS Contingent consideration	50,483
Total acquisition consideration	$ 80,483

Business Combination (Details_2

Business Combination (Details) - Schedule of Fair Value of the Identifiable Assets $ in Thousands	Dec. 31, 2023 USD ($)
Schedule of Fair Value of the Identifiable Assets [Abstract]
Intangible assets IP / Brand, Carrying value at acquisition date
Intangible assets IP / Brand, Fair value adjustments	36,550
Intangible assets IP / Brand, Fair value at acquisition date	36,550
Intangible assets Customer relationships, Carrying value at acquisition date
Intangible assets Customer relationships, Fair value adjustments	8,007
Intangible assets Customer relationships, Fair value at acquisition date	8,007
Total identified assets, Carrying value at acquisition date
Total identified assets, Fair value adjustments	44,557
Total identified assets, Fair value at acquisition date	44,557
Goodwill, Carrying value at acquisition date
Goodwill, Fair value adjustments	35,926
Goodwill, Fair value at acquisition date	35,926
Acquisition price, Carrying value at acquisition date
Acquisition price, Fair value adjustments
Acquisition price, Fair value at acquisition date	$ 80,483

Revenue and Cost of Sales (Deta

Revenue and Cost of Sales (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue and Cost of Sales [Line Items]
Revenue (in Dollars)	$ 70.2	$ 37.1
Revenue percentage	89%		67%
Customer generating over	10%
Medicare represented generating of total revenues (in Dollars)	$ 27.7	$ 15.8	$ 8.5
Percentage of revenue from external customers	99.70%	99.80%	98.60%
Percentage of revenue	99%	99%	97%
Percentage of Intellectual Property Revenue	1%	1%	1.50%
Non-current assets percentage	91%	93%	38%
GPS [Member]
Revenue and Cost of Sales [Line Items]
Revenue (in Dollars)	$ 30.9		$ 22.2
Remaining revenue amount (in Dollars)		$ 9.3
ConfirmMDx [Member]
Revenue and Cost of Sales [Line Items]
Revenue (in Dollars)	24.8
Remaining revenue amount (in Dollars)		21.8
Resolve mdx [Member]
Revenue and Cost of Sales [Line Items]
Revenue (in Dollars)	$ 9.7	37.1
Remaining revenue amount (in Dollars)		$ 4.9
Europe [Member]
Revenue and Cost of Sales [Line Items]
Non-current assets percentage	9%	7%	62%

Revenue and Cost of Sales (De_2

Revenue and Cost of Sales (Details) - Schedule of Revenue - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Revenue [Line Items]
Total revenue	$ 70,193	$ 37,054	$ 22,239
Services [Member]
Schedule of Revenue [Line Items]
Total revenue	69,965	36,965	21,937
Royalties and other revenues [Member]
Schedule of Revenue [Line Items]
Total revenue	$ 228	$ 89	$ 302

Revenue and Cost of Sales (De_3

Revenue and Cost of Sales (Details) - Schedule of Revenue from External Customers Broken Down by Location - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Revenue from External Customers Broken Down by Location [Line Items]
Total segment revenue	$ 70,193	$ 37,054	$ 22,239
United States of America [Member]
Schedule of Revenue from External Customers Broken Down by Location [Line Items]
Total segment revenue	69,708	36,768	21,785
Europe [Member]
Schedule of Revenue from External Customers Broken Down by Location [Line Items]
Total segment revenue	476	277	441
Rest of the world [Member]
Schedule of Revenue from External Customers Broken Down by Location [Line Items]
Total segment revenue	$ 9	$ 9	$ 13

Revenue and Cost of Sales (De_4

Revenue and Cost of Sales (Details) - Schedule of Cost of Sales - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Cost of Sales [Abstract]
Cost of sales	$ 26,264	$ 17,835	$ 11,675
Total cost sales	$ 26,264	$ 17,835	$ 11,675

Nature of Expenses (Details)

Nature of Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Nature of Expenses [Line Items]
Expenses	$ 569	$ 278	$ 132
Percentage of research and development expenses	16%	2%
Selling expense	$ 11,200	$ 8,300
Percentage of selling and marketing expenses	44%	47%
Percentage of general and administrative expenses	1%	68%
One time expenses		$ 3,700
GPS acquisition [member]
Nature of Expenses [Line Items]
Expenses		5,700
Research and Development Expenses [Member]
Nature of Expenses [Line Items]
Expenses	$ 900	100
General and Administrative Expenses [Member]
Nature of Expenses [Line Items]
Expenses	300
Professional Fees [Member]
Nature of Expenses [Line Items]
Expenses	$ 1,200	$ 9,400

Nature of Expenses (Details) -

Nature of Expenses (Details) - Schedule of Research and Development Expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Research and Development Expenses [Abstract]
Personnel costs	$ 3,693	$ 2,453	$ 1,949
Depreciation and amortization	428	212	276
Impairment		44
Lab consumables	639	713	793
Patent expenses	83	430	577
External collaborator fees	199	783	1,020
Clinical validation	765	584	842
Other expenses	569	278	132
Total research and development expenses	$ 6,376	$ 5,497	$ 5,589

Nature of Expenses (Details) _2

Nature of Expenses (Details) - Schedule of Selling and Marketing Expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Selling and Marketing Expenses [Abstract ]
Personnel costs	$ 27,952	$ 19,070	$ 13,402
Depreciation and amortization	888	750	504
Professional fees	710	1,259	523
Marketing expenses	5,075	2,843	1,761
Travel expenses	1,061	789	340
Offices & facilities expenses	459	356	436
Other expenses	770	637	486
Total selling and marketing expenses	$ 36,915	$ 25,704	$ 17,452

Nature of Expenses (Details) _3

Nature of Expenses (Details) - Schedule of General and Administrative Expenses - General and Administrative Expenses [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of General and Administrative Expenses [Line Items]
Personnel costs	$ 10,184	$ 8,995	$ 9,009
Depreciation	737	734	646
Professional fees	6,706	7,762	1,678
Public company expenses	2,701	4,025	1,108
Travel expenses	130	79	9
Offices & facilities expenses	1,266	1,142	845
Royalties to third parties	28	47	152
Board fees	366	394	314
Other expenses	892	130	154
Total general and administrative expenses	$ 23,010	$ 23,308	$ 13,915

Nature of Expenses (Details) _4

Nature of Expenses (Details) - Schedule of Amortization of Intangible Assets - Amortization of Intangible Assets [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Amortization of Intangible Assets [Line Items]
Research and development	$ 3,157	$ 2,060	$ 1,084
Selling and marketing	1,315	878	292
General and administrative	22	231	234
Total amortization of intangible assets	$ 4,494	$ 3,169	$ 1,610

Personnel Costs (Details) - Sch

Personnel Costs (Details) - Schedule of Personnel Costs - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
The number of employees at the end of the year was:
Laboratory operations	$ 79	$ 67	$ 42
R&D staff	31	19	14
S&M staff	106	101	71
G&A staff	84	71	64
Total number of employees	300	258	191
Their aggregate remuneration comprised:
Wages and salaries	31,388	23,066	18,150
Social security costs	2,682	1,684	1,257
Pension costs	1,153	724	594
Health insurance expenses	5,058	3,167	2,324
Share-based compensation	665	867	1,222
Other costs	883	1,010	813
Total personnel costs	$ 41,829	$ 30,518	$ 24,360

Other Operating (Expense) Inc_3

Other Operating (Expense) Income, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other Operating (Expense) Income, Net [Line Items]
Other operating income	$ (461,000)	$ 559,000	$ 1,161,000
Fair Value Adjustments [Member]
Other Operating (Expense) Income, Net [Line Items]
Other operating income	588,000
NovioGendix [member]
Other Operating (Expense) Income, Net [Line Items]
Other operating income	$ 37,000	632,000
Kreos Drawdown [Member]
Other Operating (Expense) Income, Net [Line Items]
Other operating income		$ 117,000
Dutch Government [Member]
Other Operating (Expense) Income, Net [Line Items]
Other operating income			659,000
U.S. Department of Health and Humas Services [Member]
Other Operating (Expense) Income, Net [Line Items]
Other operating income			$ 382,000

Other Operating (Expense) Inc_4

Other Operating (Expense) Income, Net (Details) - Schedule of Other Operating (Expense) Income, Net - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Operating (Expense) Income, Net [Line Items]
Total other operating (expense) income, net	$ (461)	$ 559	$ 1,161
Grant subsidies – The Netherlands [Member]
Schedule of Other Operating (Expense) Income, Net [Line Items]
Total other operating (expense) income, net	62	5	382
Grant subsidies – USA [Member]
Schedule of Other Operating (Expense) Income, Net [Line Items]
Total other operating (expense) income, net			659
Fair value adjustments [Member]
Schedule of Other Operating (Expense) Income, Net [Line Items]
Total other operating (expense) income, net	(588)	515	176
Other operating income [Member]
Schedule of Other Operating (Expense) Income, Net [Line Items]
Total other operating (expense) income, net	65	39	53
Other operating expenses [Member]
Schedule of Other Operating (Expense) Income, Net [Line Items]
Total other operating (expense) income, net			$ (109)

Financial Income and Expense (D

Financial Income and Expense (Details) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Financial Income and Expense [Line Items]
Contingent consideration amount	$ 9.1
Interest charges	2.2
GPS [Member]
Financial Income and Expense [Line Items]
Interest charges	$ 5.2
Warrant reserve [member]
Financial Income and Expense [Line Items]
Warrant issued	5 years

Financial Income and Expense _2

Financial Income and Expense (Details) - Schedule of Financial Income and Expense, Net - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Financial Income and Expense, Net [Line Items]
Interest income	$ 1,088	$ 125	$ 11
Innovatus derivative instrument	719	116
Fair value of option to pay GPS earnout in shares	763
Financial income, net	2,570	241	11
Interest on Kreos loan		(660)	(1,566)
Interest on Innovatus loan	(5,232)	(1,615)
Interest on other loans and leases	(350)	(361)	(309)
Kreos settlement		(1,047)
Fair value adjustments
Other financial expenses	(190)	(107)	(7)
GPS amendment: additional consideration payment in cash	(250)
GPS amendment: additional consideration payment in shares	(878)
Financial expenses, net	(18,342)	(6,385)	(2,172)
GPS contingent consideration [Member]
Fair value adjustments
Fair value adjustments	(9,105)	(2,398)
NovioGendix contingent consideration [Member]
Fair value adjustments
Fair value adjustments	(49)	(197)	(194)
Kreos derivative instrument [Member]
Fair value adjustments
Fair value adjustments	(135)		(96)
Exact Sciences warrants [Member]
Fair value adjustments
Fair value adjustments	$ (2,153)

Financial Income and Expense _3

Financial Income and Expense (Details) - Schedule of Financial Income and Expense, Net (Parentheticals)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Financial Income and Expense, Net [Line Items]
Exact Sciences warrants	5 years	5 years	5 years

Income Tax (Details)

Income Tax (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax [Abstract]
Net tax loss	$ 308,700,000	$ 285,300,000	$ 258,500,000
Tax carry forward expiration period	2021 years
Tax credits	$ 0	$ 402,000	$ 372,000

Income Tax (Details) - Schedule

Income Tax (Details) - Schedule of Tax Reconciliation and the Impact of the Unrecognized Deferred Tax Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Tax Reconciliation and the Impact of the Unrecognized Deferred Tax Assets [Abstract ]
Loss for the year	$ (43,100)	$ (44,044)	$ (29,002)
Income tax expense	(1)	0	0
Loss before income tax	(43,099)	(44,044)	(29,002)
Tax using the MDxHealth’s domestic tax rate	10,775	11,011	7,251
Effect of unused tax losses not recognized as deferred tax assets	$ (10,775)	$ (11,011)	$ (7,251)

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Aug. 02, 2022
Goodwill [Line Items]
Good will	$ 35,926	$ 35,926	$ 35,900
Exceeds carrying value	$ 88,800
Discount rate, percentage	1%
Impairment amount	$ 18,900
Growth rate percentage	1%
Decrease in impairment amount	$ 13,600
Bottom of Range [Member]
Goodwill [Line Items]
Discount rate	7.28%
Top of Range [Member]
Goodwill [Line Items]
Discount rate	20.11%
December 31, 2028 [Member]
Goodwill [Line Items]
Term goodwill	5 years

Goodwill (Details) - Schedule o

Goodwill (Details) - Schedule of Carrying Value of Goodwill - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Carrying Value of Goodwill [Abstract]
Goodwill beginning balance	$ 35,926
Additions through business combination		35,926
Impairment
Currency translation adjustments
Carrying value at December 31	$ 35,926	$ 35,926

Goodwill (Details) - Schedule_2

Goodwill (Details) - Schedule of Discount Rate	12 Months Ended
	Dec. 31, 2023
Schedule of Discount Rate [Abstract]
Discount rate (post-tax)	12.83%
Terminal growth rate	2%

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets [Line Items]
Intangible asset (in Dollars)		$ 44,557,000
Estimated remaining amortization period	5 years
Cash generating unit (in Dollars)	$ 8,000,000
Capitalized development expenses (in Dollars)	$ 2,700,000	1,000,000	$ 0
GPS acquisition [member]
Intangible Assets [Line Items]
Intangible asset (in Dollars)		$ 36,600,000
NovioGendix IP [member]
Intangible Assets [Line Items]
Estimated remaining amortization period	1 year 7 months 6 days
GPS IP [member]
Intangible Assets [Line Items]
Estimated remaining amortization period	13 years 7 months 6 days
GPS Customer [member]
Intangible Assets [Line Items]
Estimated remaining amortization period	6 years 6 months
Confirm mdx [member]
Intangible Assets [Line Items]
Estimated remaining amortization period	2 months 12 days
Select mdx [member]
Intangible Assets [Line Items]
Estimated remaining amortization period	4 years
Resolve mdx [member]
Intangible Assets [Line Items]
Estimated remaining amortization period	3 years 3 months 18 days

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Gross value
Gross value Beginning Balance	$ 64,888	$ 18,957
Additions	2,660	1,374
Additions through business combination		44,557
Currency translation adjustments	5
Gross value Ending Balance	67,548	64,888
Accumulated amortization and impairment Beginning Balance	(18,722)	(15,509)
Additions	(4,494)	(3,169)
Impairment		(44)
Accumulated amortization and impairment Ending Balance	(23,211)	(18,722)
Net value	44,337	46,166
Patents and Software licenses [Member]
Gross value
Gross value Beginning Balance	5,134	5,134
Currency translation adjustments
Gross value Ending Balance	5,134	5,134
Accumulated amortization and impairment Beginning Balance	(5,134)	(4,910)
Additions		(224)
Accumulated amortization and impairment Ending Balance	(5,134)	(5,134)
Net value	0	0
Internally developed intangible assets [Member]
Gross value
Gross value Beginning Balance	10,372	9,323
Additions	2,660	1,049
Currency translation adjustments	5
Gross value Ending Balance	13,032	10,372
Accumulated amortization and impairment Beginning Balance	(8,722)	(7,736)
Additions	(343)	(942)
Impairment		(44)
Accumulated amortization and impairment Ending Balance	(9,060)	(8,722)
Net value	3,972	1,650
Externally acquired Intellectual property [Member]
Gross value
Gross value Beginning Balance	41,375	4,500
Additions		325
Additions through business combination		36,550
Currency translation adjustments
Gross value Ending Balance	41,375	41,375
Accumulated amortization and impairment Beginning Balance	(4,353)	(2,863)
Additions	(2,919)	(1,490)
Accumulated amortization and impairment Ending Balance	(7,272)	(4,353)
Net value	34,103	37,022
Customers [Member]
Gross value
Gross value Beginning Balance	8,007
Additions through business combination		8,007
Currency translation adjustments
Gross value Ending Balance	8,007	8,007
Accumulated amortization and impairment Beginning Balance	(513)
Additions	(1,232)	(513)
Accumulated amortization and impairment Ending Balance	(1,745)	(513)
Net value	$ 6,262	$ 7,494

Property, Plant and Equipment_3

Property, Plant and Equipment and Right of-Use Assets (Details)				12 Months Ended
	Nov. 30, 2022 ft²	Jun. 30, 2022 ft²	Dec. 31, 2019 ft²	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Property Plant and Equipment and Right of-Use Assets [Line Items]
Laboratory equipment				$ 1,300,000	$ 1,700,000
Leasehold improvements				741,000	$ 713,000
Property plant equipment (in Square Feet) (in Square Feet) | ft²	1,500	3,000
Office space (in Square Feet) | ft²			1,300
Additional right of use assets				$ 2,300,000

Property, Plant and Equipment_4

Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of Additional Right of Use Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Additional Right of Use Assets [Line Items]
Gross value beginning	$ 10,482	$ 7,868
Accumulated depreciation beginning	(6,691)	(6,197)
Net value	4,956	3,791
Additions,Gross value	2,556	2,789
Disposals,Gross value	(111)	(258)
Transfer from leases,Gross value	498
Exchange rate difference arising, Gross value	(68)	83
Gross value ending	13,357	10,482
Additions, Accumulated depreciation	(1,388)	(673)
Disposals, Accumulated depreciation	108	258
Transfer from leases, Accumulated depreciation	(498)
Exchange rate difference arising, Accumulated depreciation	68	(79)
Accumulated depreciation ending	(8,401)	(6,691)
Laboratory Equipment [Member]
Schedule of Additional Right of Use Assets [Line Items]
Gross value beginning	7,068	5,285
Accumulated depreciation beginning	(5,184)	(4,817)
Net value	2,638	1,884
Additions,Gross value	1,312	1,695
Transfer from leases,Gross value	498
Exchange rate difference arising, Gross value	(62)	88
Gross value ending	8,816	7,068
Additions, Accumulated depreciation	(558)	(276)
Disposals, Accumulated depreciation
Transfer from leases, Accumulated depreciation	(498)
Exchange rate difference arising, Accumulated depreciation	62	(91)
Accumulated depreciation ending	(6,178)	(5,184)
Furniture [Member]
Schedule of Additional Right of Use Assets [Line Items]
Gross value beginning	669	569
Accumulated depreciation beginning	(380)	(315)
Net value	387	289
Additions,Gross value	200	104
Disposals,Gross value
Transfer from leases,Gross value
Exchange rate difference arising, Gross value	(2)	(4)
Gross value ending	867	669
Additions, Accumulated depreciation	(102)	(72)
Disposals, Accumulated depreciation
Transfer from leases, Accumulated depreciation
Exchange rate difference arising, Accumulated depreciation	2	7
Accumulated depreciation ending	(480)	(380)
IT Equipment [Member]
Schedule of Additional Right of Use Assets [Line Items]
Gross value beginning	687	673
Accumulated depreciation beginning	(357)	(459)
Net value	402	330
Additions,Gross value	303	277
Disposals,Gross value	(111)	(258)
Transfer from leases,Gross value
Exchange rate difference arising, Gross value	(2)	(5)
Gross value ending	877	687
Additions, Accumulated depreciation	(228)	(159)
Disposals, Accumulated depreciation	108	258
Transfer from leases, Accumulated depreciation
Exchange rate difference arising, Accumulated depreciation	2	3
Accumulated depreciation ending	(475)	(357)
Leasehold improvements [Member]
Schedule of Additional Right of Use Assets [Line Items]
Gross value beginning	2,058	1,341
Accumulated depreciation beginning	(770)	(606)
Net value	1,529	1,288
Additions,Gross value	741	713
Disposals,Gross value
Transfer from leases,Gross value
Exchange rate difference arising, Gross value	(2)	4
Gross value ending	2,797	2,058
Additions, Accumulated depreciation	(500)	(166)
Disposals, Accumulated depreciation
Transfer from leases, Accumulated depreciation
Exchange rate difference arising, Accumulated depreciation	2	2
Accumulated depreciation ending	$ (1,268)	$ (770)

Property, Plant and Equipment_5

Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of Right-of-Use Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Gross value
Gross value Beginning	$ 8,071	$ 6,245
Gross value Additions	2,288	1,827
Gross value Disposals	(439)
Gross value Transfer to tangible assets	(498)
Gross value Exchange rate differences		(1)
Gross value Ending	9,423	8,071
Accumulated depreciation
Accumulated depreciation Beginning	(3,968)	(2,898)
Accumulated depreciation Additions	(1,365)	(1,067)
Accumulated depreciation Disposals	395
Accumulated depreciation Transfer to tangible assets	498
Accumulated depreciation Exchange rate difference	7	(3)
Accumulated depreciation Ending	(4,433)	(3,968)
Net value	4,989	4,103
Buildings [Member]
Gross value
Gross value Beginning	6,565	5,130
Gross value Additions	726	1,435
Gross value Disposals
Gross value Transfer to tangible assets
Gross value Exchange rate differences
Gross value Ending	7,291	6,565
Accumulated depreciation
Accumulated depreciation Beginning	(2,874)	(1,929)
Accumulated depreciation Additions	(1,079)	(945)
Accumulated depreciation Disposals
Accumulated depreciation Transfer to tangible assets
Accumulated depreciation Exchange rate difference	7
Accumulated depreciation Ending	(3,946)	(2,874)
Net value	3,345	3,691
Vehicles [Member]
Gross value
Gross value Beginning	276	218
Gross value Additions		58
Gross value Disposals	(114)
Gross value Transfer to tangible assets
Gross value Ending	162	276
Accumulated depreciation
Accumulated depreciation Beginning	(180)	(129)
Accumulated depreciation Additions	(34)	(51)
Accumulated depreciation Disposals	70
Accumulated depreciation Transfer to tangible assets
Accumulated depreciation Exchange rate difference
Accumulated depreciation Ending	(144)	(180)
Net value	18	96
Materials [Member]
Gross value
Gross value Beginning	1,230	897
Gross value Additions	1,562	334
Gross value Disposals	(325)
Gross value Transfer to tangible assets	(498)
Gross value Exchange rate differences		(1)
Gross value Ending	1,970	1,230
Accumulated depreciation
Accumulated depreciation Beginning	(914)	(840)
Accumulated depreciation Additions	(252)	(71)
Accumulated depreciation Disposals	325
Accumulated depreciation Transfer to tangible assets	498
Accumulated depreciation Exchange rate difference		(3)
Accumulated depreciation Ending	(343)	(914)
Net value	$ 1,626	$ 316

Property, Plant and Equipment_6

Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of Amounts Related to Leases are Recognized in Profit & Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Amounts Related to Leases are Recognized in Profit & Loss [Abstract]
Depreciation expense	$ 1,187	$ 1,067	$ 905
Interest expense on lease liabilities	$ 284	$ 314	$ 229

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Inventories [Abstract]
Inventories recognized as expense	$ 5.7	$ 3.6	$ 3.2

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Inventories [Abstract]
Raw materials and consumables	$ 2,779	$ 2,327
Total Inventories	$ 2,779	$ 2,327

Trade and Other Receivables (De

Trade and Other Receivables (Details) - Schedule of Trade Receivables - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Trade Receivables [Abstract]
Trade receivables	$ 11,088	$ 9,357
Total trade receivables	$ 11,088	$ 9,357

Trade and Other Receivables (_2

Trade and Other Receivables (Details) - Schedule of Total Accounts Receivable Balance - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	$ 11,088	$ 9,357
Months 1-3 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	7,031	6,035
Months 4-6 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	2,389	2,275
Months 7-12 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	1,676	1,001
Not due [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables		46
Confirm mdx [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	3,740	3,451
Confirm mdx [Member] | Months 1-3 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	2,225	1,865
Confirm mdx [Member] | Months 4-6 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	876	821
Confirm mdx [Member] | Months 7-12 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	639	765
Confirm mdx [Member] | Not due [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables
Select mdx [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	512	338
Select mdx [Member] | Months 1-3 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	291	134
Select mdx [Member] | Months 4-6 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	101	101
Select mdx [Member] | Months 7-12 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	128	78
Select mdx [Member] | Not due [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables		25
Resolve mdx [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	2,308	2,582
Resolve mdx [Member] | Months 1-3 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	1,278	1,966
Resolve mdx [Member] | Months 4-6 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	629	458
Resolve mdx [Member] | Months 7-12 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	401	158
Resolve mdx [Member] | Not due [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables
GPS [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	4,528	2,802
GPS [Member] | Months 1-3 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	3,237	1,907
GPS [Member] | Months 4-6 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	783	895
GPS [Member] | Months 7-12 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables	$ 508
GPS [Member] | Not due [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables
Other [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables		184
Other [Member] | Months 1-3 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables		163
Other [Member] | Months 4-6 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables
Other [Member] | Months 7-12 months [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables
Other [Member] | Not due [Member]
Schedule of Total Accounts Receivable Balance [Line Items]
Total Trade Receivables		$ 21

Trade and Other Receivables (_3

Trade and Other Receivables (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Prepayments	$ 1,585	$ 1,710
Deposits	110	101
Recoverable VAT	183	97
Grants to be received		54
Other	36
Total prepaid expenses and other current assets	$ 1,914	$ 1,962

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 22,380	$ 15,503
Total cash and cash equivalents	$ 22,380	$ 15,503

Loans, Borrowings, Leases obl_3

Loans, Borrowings, Leases obligations and Other Financial Liabilities (Details)				1 Months Ended									12 Months Ended
	Aug. 23, 2023 shares	Aug. 02, 2022 USD ($)	Apr. 20, 2020 USD ($)	Oct. 31, 2023 USD ($)	Oct. 31, 2023 EUR (€)	Jul. 31, 2023 USD ($)	Jul. 31, 2023 EUR (€)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 EUR (€)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Aug. 31, 2022 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2023 EUR (€) shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021	Aug. 02, 2022 EUR (€)
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Loan and security amount		$ 70,000,000
Debt facility amount (in Euro) | €																		€ 9,000,000
Drawn amount		35,000,000
Additional amount		$ 35,000,000
Loans accrue interest description														The loans accrue interest at a floating per annum rate equal to the sum of (a) the greater of (i) the prime rate published in The Wall Street Journal in the “Money Rates” section or (ii) 4.00%, plus (b) 4.25%, and require interest-only payments for the initial four years.	The loans accrue interest at a floating per annum rate equal to the sum of (a) the greater of (i) the prime rate published in The Wall Street Journal in the “Money Rates” section or (ii) 4.00%, plus (b) 4.25%, and require interest-only payments for the initial four years.
Percentage of outstanding principal amount														2.25%	2.25%
Loan price (in Dollars per share) | $ / shares														$ 11.21
Total loan														1%	1%
End-of-loan fee														5%	5%
Debt facility pecentage		62.85%												72.92%	72.92%	64.82%
Principal amount (in Euro) | €											€ 9,000,000
Total amount										$ 10,800,000
Convertible debt														$ (185,364)	€ 180,000
Financial liability																$ 891,000
Cash repayment								$ 1,000,000	€ 945,000
Percentage of initial drawdown fee								150%	150%
Initial drawdown fee (in Euro) | €									€ 630,000
Cash paid						$ 513,419	€ 472,500
Additional				$ (513,419)	€ 472,500
Small business administration			$ 2,316,000
Interest rate for the loan														12.83%
Outstanding amount														$ 1,000,000
Aggregate earn-out amount												$ 82,500,000
Earn-out payable														30,000,000
Other non-current financial liabilities														62,600,000
Financial asset														$ 800,000
Warrants term														5 years	5 years	5 years	5 years
Acquire shares (in Shares) | shares	1,000,000													1,000,000	1,000,000
Fair value of warrant														$ 1,000,000
Financial liability														66,154,000		$ 55,864,000
Fair value amount																891,000
Contingent consideration related to acquisition														1,200,000		$ 52,900,000
Contingent consideration amount														$ 9,100,000
August 2, 2025 [Member]
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Percentage of outstanding principal amount														15%	15%
Fixed rate														15%	15%
Purchased call options [member]
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Financial liability														$ 192,000
Kreos [Member]
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Convertible debt														(208,535)	€ 202,500
PPP Loans [Member]
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Interest rate for the loan			1%
MDxHealth [Member]
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Financial liability														$ 2,200,000
NovioGendix [Member]
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Interest rate for the loan														12.83%
Contingent consideration amount														$ 550,000
Term B Loan [Member]
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Drawn amount		$ 20,000,000
Term C Loan [Member]
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Drawn amount		$ 15,000,000
Forecast [Member]
Loans, Borrowings, Leases obligations and Other Financial Liabilities [Line Items]
Earn-out payable													$ 40,000,000

Loans, Borrowings, Leases obl_4

Loans, Borrowings, Leases obligations and Other Financial Liabilities (Details) - Schedule of Loans, Borrowings & Lease Liabilities - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Non-current loans and borrowings
Loans		$ 35,564	$ 34,914
Lease liabilities (*)	[1]	3,578	3,091
Total non-current loans and borrowings		39,142	38,005
Current loans and borrowings
Loans		643	616
Lease liabilities (*)		1,480	1,172
Total current loans and borrowings		$ 2,123	$ 1,788
[1] the evolution in the right of use assets is further disclosed in Note 12.

Loans, Borrowings, Leases obl_5

Loans, Borrowings, Leases obligations and Other Financial Liabilities (Details) - Schedule of Maturity of Loans And Borrowings - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Loans
Within one year	$ 643	$ 630
Years two to five	35,564	38,439
Leases
Within one year	1,900	1,551
Years two to five	$ 3,955	$ 2,330

Loans, Borrowings, Leases obl_6

Loans, Borrowings, Leases obligations and Other Financial Liabilities (Details) - Schedule of Other Financial Liabilities - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other financial liabilities
Other non-current financial liabilities	$ 63,259	$ 53,537
Other current financial liabilities	2,895	2,327
Total other financial liabilities	$ 66,154	$ 55,864

Loans, Borrowings, Leases obl_7

Loans, Borrowings, Leases obligations and Other Financial Liabilities (Details) - Schedule of Cash and Non-Cash Movements of Loans and Borrowings - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022
Loans and Borrowings [Member]
Schedule of Cash and Non-Cash Movements of Loans and Borrowings [Line Items]
Beginning balance	$ 35,530		$ 12,092
Cash movements
Loans and borrowings repaid1 (Kreos / PPP)	(637)	[1]	(10,805)
Loans and borrowings received (Innovatus)			34,291
Non-cash movements
Recognition of Innovatus embedded derivative convertible call option			(1,026)
Kreos effective interest rate adjustment and extinguishment costs			1,328
Innovatus - effective interest rate adjustment	1,314		660
Foreign exchange rate impact / other			(1,010)
Ending balance	36,207		35,530
Other Financial Liabilities [Member]
Schedule of Cash and Non-Cash Movements of Loans and Borrowings [Line Items]
Beginning balance	55,864		2,427
Cash movements
Loans and borrowings repaid1 (Kreos / PPP)	(1,022)
Non-cash movements
GPS Contingent Consideration			50,483
Recognition of Innovatus embedded derivative convertible call option			1,026
Foreign exchange rate impact / other	(4)		(35)
Fair value changes through profit and loss	11,316		1,963
Ending balance	$ 66,154		$ 55,864
[1] The amount includes interest paid on loans and borrowings

Loans, Borrowings, Leases obl_8

Loans, Borrowings, Leases obligations and Other Financial Liabilities (Details) - Schedule of Fair Value Adjustments Recognized $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Schedule of Fair Value Adjustments Recognized [Abstract]
Increase of NovioGendix contingent consideration	$ 16
Increase of Kreos derivative financial instrument (“initial drawdown fee”)	135
Increase of GPS contingent consideration	9,730
Decrease of Innovatus embedded derivative convertible call option	(718)
Exact Sciences 5-Year Warrants	2,153
Total fair value adjustment	$ 11,316

Loans, Borrowings, Leases obl_9

Loans, Borrowings, Leases obligations and Other Financial Liabilities (Details) - Schedule of Fair Value Adjustments Recognized (Parentheticals)	12 Months Ended
	Dec. 31, 2023
Schedule of Fair Value Adjustments Recognized [Abstract]
Exact Sciences Warrants	5 years

Loans, Borrowings, Leases ob_10

Loans, Borrowings, Leases obligations and Other Financial Liabilities (Details) - Schedule of Lease Liabilities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Lease Liabilities [Abstract]
Opening balance	$ 4,263	$ 3,464
Cash movements
Repayment of lease liabilities	(1,610)	(1,358)
Non-cash movements
Interest accretion	355	314
New leases	2,050	1,843
Closing balance	$ 5,058	$ 4,263

Contractual Obligations (Detail

Contractual Obligations (Details)	Dec. 31, 2023 USD ($)
Contractual Obligations [Abstract]
Equipment value	$ 5,000

Contractual Obligations (Deta_2

Contractual Obligations (Details) - Schedule of Contractual Obligations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Contractual Obligations [Abstract]
Less than one year	$ 90	$ 156
Years 2-5	53	60
Total contractual obligations	$ 143	$ 216

Trade and Other Payables (Detai

Trade and Other Payables (Details) - Schedule of Trade Accounts Payable - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Trade Accounts Payable [Abstract]
Trade accounts payable	$ 4,889	$ 5,061
Accruals for invoices to be received	3,922	5,117
Total trade accounts payable	$ 8,811	$ 10,178

Trade and Other Payables (Det_2

Trade and Other Payables (Details) - Schedule of Other Current Liabilities - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Other Current Liabilities [Abstract]
Payroll	$ 5,222	$ 3,932
Other accruals	472	53
Total other current liabilities	$ 5,694	$ 3,985

Financial Instruments and Fai_3

Financial Instruments and Fair Value (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Financial Instruments and Fair Value [Line Items]
Variable interest rate	4.25%
Weighted estimate, amount	$ 82,500,000
Fair-value adjustments total charges	10,000,000
Financial expense	9,400,000
Operating expense	$ (461,000)	$ 559,000	$ 1,161,000
Percentage of discount rate	12.83%
Percentage of volatility	72.99%
Liability	$ 66,154,000	$ 55,864,000
Warrants	5 years	5 years	5 years
Share price (in Dollars per share)	$ 3.94
Strike price (in Dollars per share)	$ 5.265
Financial liability	$ 2,200,000
Increase [Member]
Financial Instruments and Fair Value [Line Items]
Percentage of volatility	10%
Liability	$ 102,000
Decrease [Member]
Financial Instruments and Fair Value [Line Items]
Percentage of volatility	10%
Liability	$ 65,000
Innovatus Debt Facility [Member]
Financial Instruments and Fair Value [Line Items]
Variable interest rate	4%
GPS [Member]
Financial Instruments and Fair Value [Line Items]
Operating expense	$ 600,000
Novio Gendix [Member]
Financial Instruments and Fair Value [Line Items]
Fair-value adjustments total charges	16,000
Financial expense	53,000
Operating expense	$ 37,000	$ 632,000
Percentage of discount rate	12.83%
MDXHEALTH INC.[Member]
Financial Instruments and Fair Value [Line Items]
Fair value measurement	$ 192,000
Acquire shares	$ 1,000,000
MDxHealth [Member] | Increase [Member]
Financial Instruments and Fair Value [Line Items]
Percentage of volatility	10%
Liability	$ 253,000
MDxHealth [Member] | Decrease [Member]
Financial Instruments and Fair Value [Line Items]
Percentage of volatility	10%
Liability	$ 277,000
PPP Loans [Member]
Financial Instruments and Fair Value [Line Items]
Interest rate percentage	1%

Financial Instruments and Fai_4

Financial Instruments and Fair Value (Details) - Schedule of Assets and Liabilities are Considered to have Carrying Amounts - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
At amortized cost
Trade receivables	$ 11,088	$ 9,357
Cash and cash equivalents	22,380	15,503
Total financial assets	33,468	24,860
At fair value:
Subtotal financial liabilities at fair value	66,154	55,864
At amortized cost:
Lease liabilities	5,058	4,263
Trade payables	8,811	10,178
Subtotal financial liabilities at amortized cost	50,076	49,971
Total financial liabilities	116,230	105,835
Level 3 [Member]
At fair value:
GPS contingent consideration	62,611	52,881
Exact Sciences 5-Year Warrants	2,153
NovioGendix contingent consideration	1,198	1,182
Innovatus derivative instrument	192	910
Kreos derivative instrument		891
Level 2 [Member]
At amortized cost:
Loans and borrowings	$ 36,207	$ 35,530

Financial Instruments and Fai_5

Financial Instruments and Fair Value (Details) - Schedule of Assets and Liabilities are Considered to have Carrying Amounts (Parentheticals)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Assets and Liabilities are Considered to have Carrying Amounts [Abstract]
Exact Sciences Warrants	5 years	5 years

Financial Instruments and Fai_6

Financial Instruments and Fair Value (Details) - Schedule of Reconciliation of Cash and Non-Cash Movements - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Reconciliation of Cash and Non-Cash Movements [Abstract]
Financial Derivative Instrument,beginning balance	$ 1,801	$ 810
Contingent Liability,beginning balance	54,063	1,617
Financial Derivative Instrument, cash movements
Contingent Consideration, Cash movements
Financial Derivative Instrument, loans and borrowings repaid	(1,022)
Contingent Consideration, Loans and borrowings repaid	(250)
Financial Derivative Instrument, non-cash movements
Contingent Consideration, GPS Contingent Consideration		50,483
Contingent Consideration, Exact Sciences 5-year warrant	2,153
Financial Derivative Instrument, Innovatus embedded derivative convertible call option		1,026
Financial Derivative Instrument, Effective interest rate adjustment	(4)
Financial Derivative Instrument, Foreign exchange rate impact / other movements		(35)
Financial Derivative Instrument, fair value changes through profit and loss	(719)
Contingent Consideration, Fair value changes through profit and loss	9,996	1,963
Financial Derivative Instrument, Change to level 1 fair value hierarchy	136
Contingent Consideration, Non-cash movements
Financial Derivative Instrument, ending balance	192	1,801
Contingent Consideration, Ending balance	$ 65,962	$ 54,063

Financial Instruments and Fai_7

Financial Instruments and Fair Value (Details) - Schedule of Reconciliation of Cash and Non-Cash Movements (Parentheticals)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Reconciliation of Cash and Non-Cash Movements [Abstract]
Financial Derivative Instrument, Exact Sciences warrant	5 years	5 years
Contingent Consideration, Exact Sciences warrant	5 years	5 years

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of Weighted Average Number of Shares Outstanding - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Weighted Average Number of Shares Outstanding [Abstract]
Loss for the year	$ (43,100)	$ (44,044)	$ (29,002)
Basic and diluted loss per share	$ (1.66)	$ (2.78)	$ (2.38)
Weighted average number of shares for basic and diluted loss per share	25,910,696	15,865,817	12,193,574

Loss Per Share (Details) - Sc_2

Loss Per Share (Details) - Schedule of Weighted Average Number of Shares Outstanding (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Weighted Average Number of Shares Outstanding [Abstract]
Diluted loss per share	$ (1.66)	$ (2.78)	$ (2.38)
Weighted average number of shares for diluted loss per share	25,910,696	15,865,817	12,193,574

Financial Risk Management (Deta

Financial Risk Management (Details)	1 Months Ended	12 Months Ended
	Apr. 20, 2020 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 EUR (€)
Financial Risk Management [Line Items]
Total amount (in Dollars)			$ 35,000,000
Interest rate			4.25%
Increase prime rate			0.25%
Interest expense increase (in Dollars)		$ 9,400,000
Cash deposits (in Euro) | €				€ 357,000
Number of loan agreements		2
Number of leases		12
Aggregate earn out amount (in Dollars)		$ 70,000,000
Percentage of outstanding shares		7.50%
Credit risk [member]
Financial Risk Management [Line Items]
Customers		1,000		1,000
Trade accounts receivable (in Dollars)		$ 11,100,000
Cash and cash equivalents (in Dollars)		$ 22,400,000
Interest Risk [Member]
Financial Risk Management [Line Items]
Loan agreement term			60 months
Interest rate			4%
Interest expense increase (in Dollars)			$ 90,000
Interest Risk [Member] | Paycheck Protection Program [Member]
Financial Risk Management [Line Items]
Interest rate	1%
Loan amount (in Dollars)	$ 2,316,000
Currency Risk [Member]
Financial Risk Management [Line Items]
Exchange rate		10%
Liquidity risk [member]
Financial Risk Management [Line Items]
Aggregate earn out amount (in Dollars)		$ 82,500,000

Financial Risk Management (De_2

Financial Risk Management (Details) - Schedule of Maturity Profiles of Financial Assets and Liabilities - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Non derivatives
Trade payables	$ 8,811	$ 10,178
Loans	36,207	35,530
Lease liabilities	5,058	4,263
Total	50,076	49,971
Less than 1 year [Member]
Non derivatives
Trade payables	8,811	10,178
Loans	650	630
Lease liabilities	1,900	1,324
Total	11,361	12,132
Between 1 and 2 years [Member]
Non derivatives
Trade payables
Loans	324	630
Lease liabilities	1,766	915
Total	2,090	1,545
Between 3 and 5 years [Member]
Non derivatives
Trade payables
Loans	37,442	37,809
Lease liabilities	2,189	2,179
Total	39,631	39,988
Total contractual cash flows [Member]
Non derivatives
Trade payables	8,811	10,178
Loans	38,416	39,069
Lease liabilities	5,855	4,418
Total	$ 53,082	$ 53,665

Share Capital and Reserves (Det

Share Capital and Reserves (Details) $ / shares in Units, $ in Millions

12 Months Ended

Aug. 23, 2023 EUR (€) shares

Jul. 31, 2023 shares

Jul. 07, 2023

Jun. 30, 2023 EUR (€)

Mar. 31, 2023 USD ($) $ / shares shares

Aug. 11, 2022 EUR (€) shares

Aug. 02, 2022 USD ($) $ / shares shares

Dec. 31, 2023 EUR (€) shares

Dec. 31, 2023 $ / shares

Nov. 27, 2023 shares

Nov. 13, 2023 shares

Mar. 31, 2023 EUR (€) shares

Nov. 04, 2021 shares

Share Capital and Reserves [Line Items]

Depositary shares

691,171

Ordinary shares, per share (in Dollars per share) | $ / shares

$ 7.23

Share capital | $

$ 5

Depositary shares

1

1

10

Price per share (in Dollars per share) | $ / shares

$ 7.23

Gross proceeds (in Dollars) | $

$ 43

Commissions and offering expenses (in Dollars) | $

$ 3.4

Initial ]earnout payment term

3 years

Several occasion period

5 years

New shares

1,000

Description of shares outstanding

●a total of 2,060,000 subscription rights of the Company have been created, of which 1,851,750 subscription rights have been granted as of December 31, 2023, which entitles their holders (assuming all subscription rights are granted and exercised) to subscribe to a total of 1,637,773 new shares with voting rights (see Note 24 for further details). The remaining 208,250 subscription rights have not yet been granted and are currently still managed by the Company’s board of directors; ●under the loan and security agreement entered into by the Company and Innovatus Capital Partners in August 2022, Innovatus has the right to convert, prior to August 2, 2025, up to 15% of the outstanding principal amount of the loans (by means of a contribution in kind of the relevant payables due by the Company under the loans) into shares of the Company at a conversion price per share equal to $11.21 (see note 16 for further details).

Board of Directors [Member]

Share Capital and Reserves [Line Items]

New shares

250,000

Bottom of range [member]

Share Capital and Reserves [Line Items]

Share capital | €

€ 163,471,629.58

€ 118,662,067.69

€ 123,539,165.19

New ordinary shares

15,596,922

Issued and outstanding shares

27,038,093

16,288,093

Top of range [member]

Share Capital and Reserves [Line Items]

Share capital | €

€ 164,302,752.89

€ 123,539,165.19

€ 163,471,629.58

New ordinary shares

16,288,093

Issued and outstanding shares

27,288,093

27,038,093

Share Capital [Member]

Share Capital and Reserves [Line Items]

Depositary shares

10,750,000

Price per share (in Dollars per share) | $ / shares

$ 4

Aggregate amount (in Euro) | €

€ 163,471,629.58

€ 162,640,506.27

Share Capital and Reserves (D_2

Share Capital and Reserves (Details) - Schedule of Share Capital Number of Shares - Share Capital and Reserves [Member] - shares	Dec. 31, 2023	Dec. 31, 2022
Schedule of Share Capital Number of Shares [Line Items]
Common shares	27,288,093	16,288,093
Total outstanding shares	27,288,093	16,288,093

Share Capital and Reserves (D_3

Share Capital and Reserves (Details) - Schedule of Share Capital and Issuance Premium Increased € in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)
Schedule of Share Capital and Issuance Premium Increased [Line Items]
Share capital situation at beginning				$ 128,454	€ 106,099
Issuance premium situation at beginning				153,177	126,481
Share capital situation at ending		$ 173,931	€ 148,398	133,454	110,975
Issuance premium situation at ending		153,177	126,481	153,177	126,481
August 2022 [Member]
Schedule of Share Capital and Issuance Premium Increased [Line Items]
Share capital issuance shares	[1]			$ 5,000	€ 4,876
March 2023 [Member]
Schedule of Share Capital and Issuance Premium Increased [Line Items]
Share capital issuance shares	[1]	39,599	36,612
August 2023 [Member]
Schedule of Share Capital and Issuance Premium Increased [Line Items]
Share capital issuance shares	[1]	$ 878	€ 812
[1] net of expenses

Share Capital and Reserves (D_4

Share Capital and Reserves (Details) - Schedule of Share Capital and Issuance Premium Increased (Parentheticals) - shares		1 Months Ended
		Aug. 31, 2023	Mar. 31, 2023	Aug. 31, 2022
Schedule of Share Capital and Issuance Premium Increased [Line Items]
Share capital issuance of shares	[1]	250,000	10,750,000	691,171
Issuance premium issuance of shares	[1]	250,000	10,750,000	691,171
[1] net of expenses

Share Capital and Reserves (D_5

Share Capital and Reserves (Details) - Schedule of Capital Stock and the Issuance Premium € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)
Schedule of Capital Stock and the Issuance Premium [Abstract]
Share Capital as per statutory accounts	$ 192,297		$ 148,419		€ 164,303	€ 123,539
Capital increase costs	(18,366)		(14,965)		(15,905)	(12,564)
Share capital under IFRS	173,931		133,454		148,398	110,975
Issuance premium	153,177	€ 126,481	153,177	€ 126,481
Share capital and issuance premium	$ 327,108		$ 286,631		€ 274,879	€ 237,456

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefit Plans [Abstract]
Total cost	$ 1.2	$ 724,000

Share-Based Payments (Details)

Share-Based Payments (Details)		1 Months Ended						12 Months Ended
	Jun. 23, 2014	Jun. 30, 2023 USD ($)	May 25, 2022 USD ($)	May 27, 2021 USD ($)	Jun. 21, 2019 USD ($)	Jun. 19, 2017 USD ($)	Jun. 23, 2014 USD ($)	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2023 € / shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2022 € / shares shares	Dec. 31, 2021 $ / shares	Dec. 31, 2021 € / shares
Share-Based Payments [Abstract]
Warrant term								10 years
Stock option plans for grant to employees (in Dollars) | $				$ 360,000			$ 150,000
Stock option plans for grant to directors (in Dollars) | $			$ 500,000			$ 250,000
Stock option plans for grant to consultants (in Dollars) | $		$ 500,000			$ 300,000			$ 2,060,000
Warrants outstanding								1,637,773
Shares subscribe								1,637,773
Warrant granted								455,500		393,050	393,050
Warrant terminated or lapsed								43,505		59,035	59,035
Warrant exercised								0		0	0
Warrants vested								237,789		212,702	212,702
Cumulative tranches percentage								25%
Vest in instalments percentage	25%
Percentage of first tranche	25%
Non-vested price | (per share)								$ 10.43	€ 9.64	$ 13.25	€ 12.34	$ 17.27	€ 15.28
Contractual Life								7 years 1 month 9 days		7 years 3 months 21 days	7 years 3 months 21 days	7 years 2 months 4 days	7 years 2 months 4 days
Expected volatility term								2 years

Share-Based Payments (Details)

Share-Based Payments (Details) - Schedule of Outstanding Warrants - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Outstanding Warrants [Line Items]
Warrants created	$ 2,060,000	$ 1,731,080
Warrants available for grant	$ (208,250)	$ (163,750)
Warrants granted (in Shares)	1,851,750	1,567,330
Warrants terminated or lapsed	$ (213,977)	$ (283,840)
Warrants exercised (in Shares)		(57,712)
Total outstanding at December 31	$ 1,637,773	$ 1,225,778

Share-Based Payments (Details_2

Share-Based Payments (Details) - Schedule of Potential Shares from Outstanding Warrants - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Potential Shares from Outstanding Warrants [Abstract]
Beginning balance	1,225,778	891,763
Number of warrants cancelled/forfeited during the year	(43,505)	(59,035)
Number of warrants granted during the year	455,500	393,050
Ending balance	1,637,773	1,225,778

Share-Based Payments (Details_3

Share-Based Payments (Details) - Schedule of Share-Based Compensation Expense Recognized in the Statement of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Share-Based Compensation Expense Recognized in the Statement of Comprehensive Income [Abstract]
Share-based compensation in consolidated statement of profit or loss	$ 665	$ 867	$ 1,222
Cumulated Share-based compensation in equity	$ 12,139	$ 11,474	$ 10,607

Share-Based Payments (Details_4

Share-Based Payments (Details) - Schedule of Outstanding Warrants and their Exercise Price - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Outstanding Warrants and their Exercise Price [Abstract]
Warrants, Granted	455,500	393,050
Weighted average exercise price, Granted	$ 2.91	$ 6.76
Potential shares from exercise of warrants, Granted	455,500	393,050
Weighted average exercise price per potential share, Granted	$ 2.91	$ 6.76
Warrants , Outstanding ending	1,637,773
Weighted average exercise price, Outstanding ending	$ 9.64
Potential shares from exercise of warrants, Outstanding ending	1,637,773
Weighted average exercise price per potential share, Outstanding ending	$ 9.64
Warrants , Outstanding Exercisable	759,841
Weighted average exercise price, Outstanding Exercisable	$ 14.07
Potential shares from exercise of warrants, Outstanding Exercisable	759,841
Weighted average exercise price per potential share, Outstanding Exercisable	$ 14.07
Warrants , Outstanding beginning		1,225,778
Weighted average exercise price, Outstanding beginning		$ 12.34
Potential shares from exercise of warrants, Outstanding beginning		1,225,778
Weighted average exercise price per potential share, Outstanding beginning		$ 12.34

Share-Based Payments (Details_5

Share-Based Payments (Details) - Schedule of the Outstanding Potential Shares from Warrants - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of the Outstanding Potential Shares from Warrants [Abstract]
Executive Director	489,375	395,000
Non-Executive Directors	25,650	24,800
Management team (excluding the Executive Director)	517,912	408,300
Other employees, consultants, and former service providers	604,836	397,678
Total outstanding at December 31	1,637,773	1,225,778

Share-Based Payments (Details_6

Share-Based Payments (Details) - Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology	12 Months Ended
	Dec. 31, 2023 $ / shares shares
23-Jun-14 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	1,200
Number of warrants granted to other benef. (in Shares)	1,200
Exercise price (in Dollars per share) | $ / shares	$ 41.3
expected dividend Yield
Expected stock price volatility	48.12%
Risk-free interest rate	1.78%
Expected duration (months)to Belgian benef.	75.32%
Expected duration (months)to other benef.	63 months 8 days
10-Dec-14 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	17,500
Exercise price (in Dollars per share) | $ / shares	$ 40.1
expected dividend Yield
Expected stock price volatility	46.93%
Risk-free interest rate	1.01%
Expected duration (months)to Belgian benef.	69.73%
Expected duration (months)to other benef.	57 months 21 days
09-Feb-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	6,000
Number of warrants granted to other benef. (in Shares)	9,500
Exercise price (in Dollars per share) | $ / shares	$ 44.9
expected dividend Yield
Expected stock price volatility	46.75%
Risk-free interest rate	0.62%
Expected duration (months)to Belgian benef.	79.73%
Expected duration (months)to other benef.	61 months 21 days
01-Apr-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	300
Exercise price (in Dollars per share) | $ / shares	$ 50.2
expected dividend Yield
Expected stock price volatility	47.42%
Risk-free interest rate	0.40%
Expected duration (months)to Belgian benef.	72.03%
Expected duration (months)to other benef.	54 months
01-May-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	2,000
Exercise price (in Dollars per share) | $ / shares	$ 50.5
expected dividend Yield
Expected stock price volatility	46.59%
Risk-free interest rate	0.62%
Expected duration (months)to Belgian benef.	71.05%
Expected duration (months)to other benef.	53 months
29-May-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	2,000
Number of warrants granted to other benef. (in Shares)	3,000
Exercise price (in Dollars per share) | $ / shares	$ 49.1
expected dividend Yield
Expected stock price volatility	46.52%
Risk-free interest rate	0.81%
Expected duration (months)to Belgian benef.	64.14%
Expected duration (months)to other benef.	52 months 3 days
01-Jun-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	600
Exercise price (in Dollars per share) | $ / shares	$ 49
expected dividend Yield
Expected stock price volatility	46.58%
Risk-free interest rate	0.81%
Expected duration (months)to Belgian benef.	70.03%
Expected duration (months)to other benef.	52 months
01-Jul-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	400
Exercise price (in Dollars per share) | $ / shares	$ 46.2
expected dividend Yield
Expected stock price volatility	47.02%
Risk-free interest rate	1.27%
Expected duration (months)to Belgian benef.	69.04%
Expected duration (months)to other benef.	51 months
01-Aug-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	400
Exercise price (in Dollars per share) | $ / shares	$ 46.4
expected dividend Yield
Expected stock price volatility	46.54%
Risk-free interest rate	0.98%
Expected duration (months)to Belgian benef.	68.02%
Expected duration (months)to other benef.	50 months
01-Sep-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,000
Exercise price (in Dollars per share) | $ / shares	$ 42.4
expected dividend Yield
Expected stock price volatility	49.31%
Risk-free interest rate	1.15%
Expected duration (months)to Belgian benef.	73.02%
Expected duration (months)to other benef.	48 months 30 days
01-Oct-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	8,300
Exercise price (in Dollars per share) | $ / shares	$ 42
expected dividend Yield
Expected stock price volatility	48.99%
Risk-free interest rate	0.90%
Expected duration (months)to Belgian benef.	72.03%
Expected duration (months)to other benef.	54 months
01-Dec-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	400
Exercise price (in Dollars per share) | $ / shares	$ 38.1
expected dividend Yield
Expected stock price volatility	50.88%
Risk-free interest rate	0.92%
Expected duration (months)to Belgian benef.	71.01%
Expected duration (months)to other benef.	53 months
01-Dec-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,800
Exercise price (in Dollars per share) | $ / shares	$ 38.9
expected dividend Yield
Expected stock price volatility	51.18%
Risk-free interest rate	0.85%
Expected duration (months)to Belgian benef.	70.03%
Expected duration (months)to other benef.	52 months
01-Jan-16 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	400
Exercise price (in Dollars per share) | $ / shares	$ 37.9
expected dividend Yield
Expected stock price volatility	51.12%
Risk-free interest rate	1.06%
Expected duration (months)to Belgian benef.	69.01%
Expected duration (months)to other benef.	50 months 30 days
04-Feb-16 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,000
Exercise price (in Dollars per share) | $ / shares	$ 41.3
expected dividend Yield
Expected stock price volatility	51.18%
Risk-free interest rate	0.85%
Expected duration (months)to Belgian benef.	67.89%
Expected duration (months)to other benef.	49 months 26 days
04-Feb-16 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	5,000
Number of warrants granted to other benef. (in Shares)	13,400
Exercise price (in Dollars per share) | $ / shares	$ 37.8
expected dividend Yield
Expected stock price volatility	52.49%
Risk-free interest rate	0.72%
Expected duration (months)to Belgian benef.	67.89%
Expected duration (months)to other benef.	49 months 26 days
22-Apr-16 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	5,200
Exercise price (in Dollars per share) | $ / shares	$ 36.2
expected dividend Yield
Expected stock price volatility	53.40%
Risk-free interest rate	0.58%
Expected duration (months)to Belgian benef.	65.33%
Expected duration (months)to other benef.	53 months 10 days
27-May-16 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	3,000
Number of warrants granted to other benef. (in Shares)	4,000
Exercise price (in Dollars per share) | $ / shares	$ 41.3
expected dividend Yield
Expected stock price volatility	51.85%
Risk-free interest rate	0.54%
Expected duration (months)to Belgian benef.	64.11%
Expected duration (months)to other benef.	52 months 3 days
01-Dec-15 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	200
Exercise price (in Dollars per share) | $ / shares	$ 34.3
expected dividend Yield
Expected stock price volatility	53.73%
Risk-free interest rate	0.49%
Expected duration (months)to Belgian benef.	64.01%
Expected duration (months)to other benef.	52 months
01-Aug-16 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	400
Exercise price (in Dollars per share) | $ / shares	$ 36.2
expected dividend Yield
Expected stock price volatility	53.51%
Risk-free interest rate	0.16%
Expected duration (months)to Belgian benef.	62.01%
Expected duration (months)to other benef.	50 months
21-Oct-16 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	2,000
Exercise price (in Dollars per share) | $ / shares	$ 44.4
expected dividend Yield
Expected stock price volatility	54.19%
Risk-free interest rate	0.28%
Expected duration (months)to Belgian benef.	59.34%
Expected duration (months)to other benef.	47 months 10 days
22-Jan-16 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	2,000
Exercise price (in Dollars per share) | $ / shares	$ 38.3
expected dividend Yield
Expected stock price volatility	52.81%
Risk-free interest rate	0.86%
Expected duration (months)to Belgian benef.	68.32%
Expected duration (months)to other benef.	56 months 9 days
01-Dec-16 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	2,200
Exercise price (in Dollars per share) | $ / shares	$ 46.5
expected dividend Yield
Expected stock price volatility	54.16%
Risk-free interest rate	0.75%
Expected duration (months)to Belgian benef.	57.99%
Expected duration (months)to other benef.	39 months 29 days
01-Jan-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,900
Exercise price (in Dollars per share) | $ / shares	$ 45.6
expected dividend Yield
Expected stock price volatility	53.84%
Risk-free interest rate	0.73%
Expected duration (months)to Belgian benef.	56.98%
Expected duration (months)to other benef.	50 months 29 days
01-Mar-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	9,500
Exercise price (in Dollars per share) | $ / shares	$ 52.6
expected dividend Yield
Expected stock price volatility	52.62%
Risk-free interest rate	0.68%
Expected duration (months)to Belgian benef.	55.04%
Expected duration (months)to other benef.	49 months
01-Apr-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,800
Exercise price (in Dollars per share) | $ / shares	$ 54.1
expected dividend Yield
Expected stock price volatility	51.80%
Risk-free interest rate	0.81%
Expected duration (months)to Belgian benef.	54.02%
Expected duration (months)to other benef.	48 months
11-Apr-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	2,000
Number of warrants granted to other benef. (in Shares)	20,000
Exercise price (in Dollars per share) | $ / shares	$ 53.5
expected dividend Yield
Expected stock price volatility	51.83%
Risk-free interest rate	0.72%
Expected duration (months)to Belgian benef.	65.68%
Expected duration (months)to other benef.	47 months 20 days
1-Jun-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	200
Exercise price (in Dollars per share) | $ / shares	$ 50.1
expected dividend Yield
Expected stock price volatility	51.86%
Risk-free interest rate	0.59%
Expected duration (months)to Belgian benef.	52.01%
Expected duration (months)to other benef.	52 months
1-Jul-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	2,200
Exercise price (in Dollars per share) | $ / shares	$ 49.6
expected dividend Yield
Expected stock price volatility	50.94%
Risk-free interest rate	0.77%
Expected duration (months)to Belgian benef.	63.02%
Expected duration (months)to other benef.	44 months 29 days
29-Jul-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	800
Exercise price (in Dollars per share) | $ / shares	$ 47.2
expected dividend Yield
Expected stock price volatility	50.95%
Risk-free interest rate	0.87%
Expected duration (months)to Belgian benef.	50.10%
Expected duration (months)to other benef.	44 months 1 day
01-Sep-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	3,400
Exercise price (in Dollars per share) | $ / shares	$ 49.2
expected dividend Yield
Expected stock price volatility	48.08%
Risk-free interest rate	0.71%
Expected duration (months)to Belgian benef.	60.99%
Expected duration (months)to other benef.	42 months 29 days
01-Oct-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	7,000
Exercise price (in Dollars per share) | $ / shares	$ 48
expected dividend Yield
Expected stock price volatility	47.32%
Risk-free interest rate	0.76%
Expected duration (months)to Belgian benef.	53.98%
Expected duration (months)to other benef.	41 months 28 days
02-Nov-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	9,900
Exercise price (in Dollars per share) | $ / shares	$ 46.1
expected dividend Yield
Expected stock price volatility	45.23%
Risk-free interest rate	0.66%
Expected duration (months)to Belgian benef.	52.93%
Expected duration (months)to other benef.	40 months 27 days
1-Dec-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	600
Exercise price (in Dollars per share) | $ / shares	$ 39.2
expected dividend Yield
Expected stock price volatility	46.50%
Risk-free interest rate	0.56%
Expected duration (months)to Belgian benef.	51.98%
Expected duration (months)to other benef.	39 months 29 days
20-Jun-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	3,000
Number of warrants granted to other benef. (in Shares)	3,000
Exercise price (in Dollars per share) | $ / shares	$ 49.7
expected dividend Yield
Expected stock price volatility	51.57%
Risk-free interest rate	0.59%
Expected duration (months)to Belgian benef.	81.40%
Expected duration (months)to other benef.	63 months 11 days
27-Jun-17 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	25,000
Exercise price (in Dollars per share) | $ / shares	$ 49.8
expected dividend Yield
Expected stock price volatility	51.04%
Risk-free interest rate	0.66%
Expected duration (months)to Belgian benef.	81.17%
Expected duration (months)to other benef.	63 months 4 days
01-Apr-18 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	4,200
Exercise price (in Dollars per share) | $ / shares	$ 37.7
expected dividend Yield
Expected stock price volatility	46.08%
Risk-free interest rate	0.76%
Expected duration (months)to Belgian benef.	54.02%
Expected duration (months)to other benef.	42 months
01-May-18 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	800
Exercise price (in Dollars per share) | $ / shares	$ 36.4
expected dividend Yield
Expected stock price volatility	46.27%
Risk-free interest rate	0.82%
Expected duration (months)to Belgian benef.	53.03%
Expected duration (months)to other benef.	41 months
01-Jun-18 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	5,000
Number of warrants granted to other benef. (in Shares)	3,200
Exercise price (in Dollars per share) | $ / shares	$ 49.7
expected dividend Yield
Expected stock price volatility	46.15%
Risk-free interest rate	0.77%
Expected duration (months)to Belgian benef.	52.01%
Expected duration (months)to other benef.	40 months
01-Aug-18 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to other benef. (in Shares)	7,000
Exercise price (in Dollars per share) | $ / shares	$ 37.4
expected dividend Yield
Expected stock price volatility	44.09%
Risk-free interest rate	0.79%
Expected duration (months)to Belgian benef.	62%
Expected duration (months)to other benef.	55 months 29 days
05-Dec-18 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	2,000
Exercise price (in Dollars per share) | $ / shares	$ 17.3
expected dividend Yield
Expected stock price volatility	57.56%
Risk-free interest rate	0.79%
Expected duration (months)to Belgian benef.	45.86%
Expected duration (months)to other benef.	33 months 26 days
24-Jan-19 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	19,100
Exercise price (in Dollars per share) | $ / shares	$ 16.4
expected dividend Yield
Expected stock price volatility	67.56%
Risk-free interest rate	0.77%
Expected duration (months)to Belgian benef.	62.24%
Expected duration (months)to other benef.	50 months 6 days
16-May-19 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to other benef. (in Shares)	150,800
Exercise price (in Dollars per share) | $ / shares	$ 14.9
expected dividend Yield
Expected stock price volatility	75.78%
Risk-free interest rate	0.38%
Expected duration (months)to Belgian benef.	58.55%
Expected duration (months)to other benef.	46 months 15 days
01-Nov-19 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	800
Exercise price (in Dollars per share) | $ / shares	$ 10.1
expected dividend Yield
Expected stock price volatility	82.15%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	64.99%
Expected duration (months)to other benef.	46 months 29 days
01-Dec-19 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,200
Exercise price (in Dollars per share) | $ / shares	$ 10.2
expected dividend Yield
Expected stock price volatility	81.95%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	64.01%
Expected duration (months)to other benef.	45 months 30 days
01-Feb-20 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	200
Exercise price (in Dollars per share) | $ / shares	$ 9.8
expected dividend Yield
Expected stock price volatility	80.26%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	61.97%
Expected duration (months)to other benef.	49 months 20 days
01-Jun-20 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	600
Exercise price (in Dollars per share) | $ / shares	$ 8.5
expected dividend Yield
Expected stock price volatility	86.64%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	57.99%
Expected duration (months)to other benef.	45 months 30 days
01-Oct-20 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	200
Exercise price (in Dollars per share) | $ / shares	$ 8
expected dividend Yield
Expected stock price volatility	85.20%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	53.95%
Expected duration (months)to other benef.	35 months 29 days
15-Jul-20 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	22,500
Exercise price (in Dollars per share) | $ / shares	$ 8
expected dividend Yield
Expected stock price volatility	85.89%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	56.51%
Expected duration (months)to other benef.	38 months 16 days
01-Jul-19 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	6,000
Number of warrants granted to other benef. (in Shares)	2,000
Exercise price (in Dollars per share) | $ / shares	$ 12.8
expected dividend Yield
Expected stock price volatility	78.70%
Risk-free interest rate	0.07%
Expected duration (months)to Belgian benef.	69.01%
Expected duration (months)to other benef.	51 months
24-Jul-19 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	98,000
Exercise price (in Dollars per share) | $ / shares	$ 12.4
expected dividend Yield
Expected stock price volatility	78.64%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	68.25%
Expected duration (months)to other benef.	50 months 8 days
15-Jul-20 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	159,800
Exercise price (in Dollars per share) | $ / shares	$ 8
expected dividend Yield
Expected stock price volatility	85.89%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	56.52%
Expected duration (months)to other benef.	38 months 16 days
30-Jul-20 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)	2,000
Exercise price (in Dollars per share) | $ / shares	$ 12.8
expected dividend Yield
Expected stock price volatility	87.02%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	56.02%
Expected duration (months)to other benef.	38 months 1 day
01-Oct-20 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,000
Exercise price (in Dollars per share) | $ / shares	$ 12.8
Expected stock price volatility	85.20%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	53.95%
Expected duration (months)to other benef.	35 months 29 days
01-Mar-21 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	200
Exercise price (in Dollars per share) | $ / shares	$ 10.8
Expected stock price volatility	65.06%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	48.99%
Expected duration (months)to other benef.	31 months
03-May-21 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	800
Exercise price (in Dollars per share) | $ / shares	$ 11.6
expected dividend Yield
Expected stock price volatility	64.59%
Risk-free interest rate	0.01%
Expected duration (months)to Belgian benef.	46.92%
Expected duration (months)to other benef.	28 months 28 days
01-Jun-21 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	400
Exercise price (in Dollars per share) | $ / shares	$ 11.8
expected dividend Yield
Expected stock price volatility	65.82%
Risk-free interest rate	0.01%
Expected duration (months)to Belgian benef.	45.96%
Expected duration (months)to other benef.	27 months 29 days
27-Jul-21 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	3,000
Exercise price (in Dollars per share) | $ / shares	$ 13.6
expected dividend Yield
Expected stock price volatility	63.36%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	44.12%
Expected duration (months)to other benef.	26 months 4 days
27-Jul-21 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	20,250
Exercise price (in Dollars per share) | $ / shares	$ 13.6
expected dividend Yield
Expected stock price volatility	63.36%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	44.12%
Expected duration (months)to other benef.	26 months 4 days
24-Nov-21 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	4,000
Exercise price (in Dollars per share) | $ / shares	$ 10.5
expected dividend Yield
Expected stock price volatility	60.78%
Risk-free interest rate	0.14%
Expected duration (months)to Belgian benef.	49.25%
Expected duration (months)to other benef.	37 months 7 days
03-Jul-21 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	257,000
Exercise price (in Dollars per share) | $ / shares	$ 13.75
expected dividend Yield
Expected stock price volatility	63.10%
Risk-free interest rate	0.04%
Expected duration (months)to Belgian benef.	44.91%
Expected duration (months)to other benef.	26 months 28 days
07-Jul-21 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	60,000
Exercise price (in Dollars per share) | $ / shares	$ 13.85
expected dividend Yield
Expected stock price volatility	63.11%
Risk-free interest rate	0%
Expected duration (months)to Belgian benef.	44.78%
Expected duration (months)to other benef.	26 months 24 days
06-May-22 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	500
Exercise price (in Dollars per share) | $ / shares	$ 7.5
expected dividend Yield
Expected stock price volatility	53.16%
Risk-free interest rate	1.64%
Expected duration (months)to Belgian benef.	58.85%
Expected duration (months)to other benef.	52 months 26 days
04-Aug-22 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	3,800
Exercise price (in Dollars per share) | $ / shares	$ 7.97
expected dividend Yield
Expected stock price volatility	55.63%
Risk-free interest rate	1.41%
Expected duration (months)to Belgian benef.	55.89%
Expected duration (months)to other benef.	49 months 27 days
03-Aug-22 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	42,500
Exercise price (in Dollars per share) | $ / shares	$ 6.84
expected dividend Yield
Expected stock price volatility	57.05%
Risk-free interest rate	1.50%
Expected duration (months)to Belgian benef.	67.96%
Expected duration (months)to other benef.	55 months 28 days
03-Aug-22 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	312,500
Exercise price (in Dollars per share) | $ / shares	$ 6.84
expected dividend Yield
Expected stock price volatility	57.05%
Risk-free interest rate	1.50%
Expected duration (months)to Belgian benef.	73.97%
Expected duration (months)to other benef.	61 months 28 days
04-Aug-22 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,000
Exercise price (in Dollars per share) | $ / shares	$ 7.97
expected dividend Yield
Expected stock price volatility	55.63%
Risk-free interest rate	1.41%
Expected duration (months)to Belgian benef.	73.94%
Expected duration (months)to other benef.	61 months 27 days
01-Dec-22 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	31,250
Exercise price (in Dollars per share) | $ / shares	$ 7.4
expected dividend Yield
Expected stock price volatility	57.26%
Risk-free interest rate	2.77%
Expected duration (months)to Belgian benef.	72.03%
Expected duration (months)to other benef.	60 months
01-Dec-22 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,500
Exercise price (in Dollars per share) | $ / shares	$ 7.4
expected dividend Yield
Expected stock price volatility	58.30%
Risk-free interest rate	2.40%
Expected duration (months)to Belgian benef.	69.67%
Expected duration (months)to other benef.	63 months 19 days
25-Mar-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	30,500
Exercise price (in Dollars per share) | $ / shares	$ 3.2
expected dividend Yield
Expected stock price volatility	71.42%
Risk-free interest rate	2.75%
Expected duration (months)to Belgian benef.	72.26%
Expected duration (months)to other benef.	60 months 7 days
3-May-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	11,000
Exercise price (in Dollars per share) | $ / shares	$ 3.3
expected dividend Yield
Expected stock price volatility	73.64%
Risk-free interest rate	2.92%
Expected duration (months)to Belgian benef.	77.01%
Expected duration (months)to other benef.	65 months
27-Apr-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	25,000
Exercise price (in Dollars per share) | $ / shares	$ 3.2
expected dividend Yield
Expected stock price volatility	73.60%
Risk-free interest rate	3.10%
Expected duration (months)to Belgian benef.	77.21%
Expected duration (months)to other benef.	65 months 6 days
27-Apr-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,000
Exercise price (in Dollars per share) | $ / shares	$ 3.6
expected dividend Yield
Expected stock price volatility	72.54%
Risk-free interest rate	3.11%
Expected duration (months)to Belgian benef.	81.34%
Expected duration (months)to other benef.	69 months 10 days
30-Jun-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	255,000
Exercise price (in Dollars per share) | $ / shares	$ 2.9
expected dividend Yield
Expected stock price volatility	72.62%
Risk-free interest rate	3.09%
Expected duration (months)to Belgian benef.	81.07%
Expected duration (months)to other benef.	69 months 2 days
05-Sep-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,000
Exercise price (in Dollars per share) | $ / shares	$ 3
expected dividend Yield
Expected stock price volatility	72.60%
Risk-free interest rate	3.14%
Expected duration (months)to Belgian benef.	80.94%
Expected duration (months)to other benef.	68 months 28 days
05-Sep-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	500
Exercise price (in Dollars per share) | $ / shares	$ 3
expected dividend Yield
Expected stock price volatility	73.75%
Risk-free interest rate	3.23%
Expected duration (months)to Belgian benef.	72.90%
Expected duration (months)to other benef.	60 months 27 days
18-Sep-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	85,000
Exercise price (in Dollars per share) | $ / shares	$ 2.78
expected dividend Yield
Expected stock price volatility	73.70%
Risk-free interest rate	3.34%
Expected duration (months)to Belgian benef.	72.48%
Expected duration (months)to other benef.	60 months 14 days
18-Sep-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	37,500
Exercise price (in Dollars per share) | $ / shares	$ 2.78
expected dividend Yield
Expected stock price volatility	73.70%
Risk-free interest rate	3.34%
Expected duration (months)to Belgian benef.	78.44%
Expected duration (months)to other benef.	66 months 13 days
09-Nov-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	1,500
Exercise price (in Dollars per share) | $ / shares	$ 3.09
expected dividend Yield
Expected stock price volatility	77.60%
Risk-free interest rate	3.32%
Expected duration (months)to Belgian benef.	52.73%
Expected duration (months)to other benef.	40 months 21 days
09-Nov-23 [Member]
Schedule of Fair Value of Each Warrant is Estimated on the Date of Grant using the Black-Scholes Methodology [Line Items]
Number of warrants granted to Belgian benef. (in Shares)
Number of warrants granted to other benef. (in Shares)	7,500
Exercise price (in Dollars per share) | $ / shares	$ 3.09
expected dividend Yield
Expected stock price volatility	77.60%
Risk-free interest rate	3.32%
Expected duration (months)to Belgian benef.	76.75%
Expected duration (months)to other benef.	64 months 22 days

Related Parties (Details)

Related Parties (Details) - USD ($)		12 Months Ended
	Jul. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related Parties [Line Items]
Total remuneration		$ 1,090,000	$ 876,000	$ 863,000
Reimbursement expenses		29,000
Reimbursement for expenses		$ 337,000	$ 314,000	$ 302,000
New shares (in Shares)	1,000

Related Parties (Details) - Sch

Related Parties (Details) - Schedule of Combined Remuneration Package, Including Employer Taxes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Combined Remuneration Package, Including Employer Taxes [Abstract]
Number of management members and Executive Directors (in Shares)	4	4	4
Short-term employee benefits	$ 1,967	$ 1,550	$ 1,545
Post-employment benefits	48	54	52
Other employment costs	216	219	207
Total benefits	2,231	1,822	1,804
IFRS share-based compensation expense	$ 909	$ 863	$ 982
Number of warrants offered (in Shares)	220,000	220,000	220,000
Cumulative outstanding warrants (in Shares)	1,007,287	808,800	588,800
Exercisable warrants (in Shares)	644,283	361,864	128,223

Related Parties (Details) - S_2

Related Parties (Details) - Schedule of Warrants that were Exercised, Granted and Accepted in Aggregate by the Four Members - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Warrants that were Exercised, Granted and Accepted in Aggregate by the Four Members [Abstract]
Number of warrants exercised	0	0	0
Number of new warrants granted and accepted	220,000,000	220,000,000	220,000,000
Annualized IFRS cost for existing warrants (in Dollars)	$ 909,000	$ 863,000	$ 982,000

Significant Agreements, Commi_2

Significant Agreements, Commitments and Contingencies (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Aug. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Significant Agreements, Commitments and Contingencies [Line Items]
Maturity fee		$ 2.2
Fair value		1.2	$ 1.2
Contingent liability		9.7
Fair value of other financial liabilities [Member]
Significant Agreements, Commitments and Contingencies [Line Items]
Aggregate earn-out amount	$ 50.5
Contingent liability		$ 62.6	$ 52.9
Short-term contracts [Member]
Significant Agreements, Commitments and Contingencies [Line Items]
Agreement years		1 year
Long-term contracts [Member]
Significant Agreements, Commitments and Contingencies [Line Items]
Agreement years		3 years

Subsidiaries (Details) - Schedu

Subsidiaries (Details) - Schedule of Wholly-Owned Direct Subsidiaries	12 Months Ended
	Dec. 31, 2023
MDXHEALTH INC.[Member]
Schedule of Wholly-Owned Direct Subsidiaries [Line Items]
Address	15279 Alton Parkway – Suite 100 – Irvine, CA 92618
Incorporation Date	Apr. 14, 2003
MDXHEALTH B.V [Member]
Schedule of Wholly-Owned Direct Subsidiaries [Line Items]
Address	Transistorweg 5, 6534 AT Nijmegen, The Netherlands
Incorporation Date	Oct. 18, 2006
MDxHealth B.V.
Incorporated into MDxHealth on	Sep. 18, 2015

Principal Audit Fees and Serv_3

Principal Audit Fees and Services (Details) - Schedule of Statutory Auditor Performed Additional Activities € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)
Schedule of Statutory Auditor Performed Additional Activities [Abstract]
Audit fee for statutory and consolidated financials	$ 408	€ 378	$ 239	€ 226	$ 182	€ 155
Other audit fees			191	180	183	156
Audit related and other services	40	37	42	39	17	14
Total	$ 448	€ 415	$ 472	€ 445	$ 382	€ 325